{
    "64403ab057b1c7a31500004d_001": [
        {
            "text": "two",
            "probability": 0.9986900896262174,
            "start_logit": 5.806154727935791,
            "end_logit": 4.048570156097412
        },
        {
            "text": "two suprachoroidal injections of CLS-TA at 0 and 12 weeks",
            "probability": 0.0008305057027046923,
            "start_logit": 5.806154727935791,
            "end_logit": -3.0435948371887207
        },
        {
            "text": "two suprachoroidal injections",
            "probability": 0.0001924950935248105,
            "start_logit": 5.806154727935791,
            "end_logit": -4.505558967590332
        },
        {
            "text": "two suprachoroidal",
            "probability": 0.00015356673159612325,
            "start_logit": 5.806154727935791,
            "end_logit": -4.731494426727295
        },
        {
            "text": "two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks,",
            "probability": 5.521897405684418e-05,
            "start_logit": 5.806154727935791,
            "end_logit": -5.7543230056762695
        },
        {
            "text": "NCT02595398), a phase III trial with two",
            "probability": 2.6310143410497897e-05,
            "start_logit": -4.738090515136719,
            "end_logit": 4.048570156097412
        },
        {
            "text": "two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 1.9645670383568098e-05,
            "start_logit": 5.806154727935791,
            "end_logit": -6.7877726554870605
        },
        {
            "text": "two suprachoroidal injection",
            "probability": 1.3812756828540674e-05,
            "start_logit": 5.806154727935791,
            "end_logit": -7.1400370597839355
        },
        {
            "text": "two suprachoroidal injections of CLS-TA",
            "probability": 1.1370643542992816e-05,
            "start_logit": 5.806154727935791,
            "end_logit": -7.3345947265625
        },
        {
            "text": "ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two",
            "probability": 3.854455211524678e-06,
            "start_logit": -6.658815383911133,
            "end_logit": 4.048570156097412
        },
        {
            "text": "phase III trial with two",
            "probability": 2.8388423259752267e-06,
            "start_logit": -6.964648723602295,
            "end_logit": 4.048570156097412
        },
        {
            "text": "suprachoroidal injections of CLS-TA at 0 and 12 weeks",
            "probability": 1.462339945935604e-07,
            "start_logit": -2.8384273052215576,
            "end_logit": -3.0435948371887207
        },
        {
            "text": "suprachoroidal injections",
            "probability": 3.389420009293212e-08,
            "start_logit": -2.8384273052215576,
            "end_logit": -4.505558967590332
        },
        {
            "text": "NCT02595398",
            "probability": 3.291926797577701e-08,
            "start_logit": -4.738090515136719,
            "end_logit": -2.6350815296173096
        },
        {
            "text": "suprachoroidal",
            "probability": 2.703976206887441e-08,
            "start_logit": -2.8384273052215576,
            "end_logit": -4.731494426727295
        },
        {
            "text": "PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398",
            "probability": 1.9777798481022863e-08,
            "start_logit": -5.247588634490967,
            "end_logit": -2.6350815296173096
        },
        {
            "text": "suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks,",
            "probability": 9.722860574458619e-09,
            "start_logit": -2.8384273052215576,
            "end_logit": -5.7543230056762695
        },
        {
            "text": "0 and 12 weeks",
            "probability": 9.657154215467883e-09,
            "start_logit": -5.555936336517334,
            "end_logit": -3.0435948371887207
        },
        {
            "text": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398",
            "probability": 7.043942268463162e-09,
            "start_logit": -6.279980659484863,
            "end_logit": -2.6350815296173096
        },
        {
            "text": "NCT02595398), a phase III trial with two suprachoroidal injections",
            "probability": 5.071216355366559e-09,
            "start_logit": -4.738090515136719,
            "end_logit": -4.505558967590332
        }
    ],
    "6411b678201352f04a000036_001": [
        {
            "text": "acquired",
            "probability": 0.9968103525136065,
            "start_logit": 7.500129222869873,
            "end_logit": 5.877485752105713
        },
        {
            "text": "In contrast to the acquired",
            "probability": 0.002730119184560784,
            "start_logit": 1.5999139547348022,
            "end_logit": 5.877485752105713
        },
        {
            "text": "the acquired",
            "probability": 0.0002686370120481657,
            "start_logit": -0.7188255190849304,
            "end_logit": 5.877485752105713
        },
        {
            "text": "acquired form",
            "probability": 7.574299450681324e-05,
            "start_logit": 7.500129222869873,
            "end_logit": -3.6074841022491455
        },
        {
            "text": "acquired form of prosopagnosia we studied the congenital",
            "probability": 3.176319062322519e-05,
            "start_logit": 7.500129222869873,
            "end_logit": -4.476521968841553
        },
        {
            "text": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment.",
            "probability": 2.651459059719628e-05,
            "start_logit": 4.202502727508545,
            "end_logit": -1.3595083951950073
        },
        {
            "text": "acquired form of prosopagnosia",
            "probability": 2.3234901050119247e-05,
            "start_logit": 7.500129222869873,
            "end_logit": -4.789174556732178
        },
        {
            "text": "acquired form of prosopagnosia we studied the congenital form",
            "probability": 1.7142965116633207e-05,
            "start_logit": 7.500129222869873,
            "end_logit": -5.093242168426514
        },
        {
            "text": "contrast to the acquired",
            "probability": 5.7772570431480206e-06,
            "start_logit": -4.558257579803467,
            "end_logit": 5.877485752105713
        },
        {
            "text": "the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired",
            "probability": 2.5715980059941265e-06,
            "start_logit": -5.367659091949463,
            "end_logit": 5.877485752105713
        },
        {
            "text": "inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired",
            "probability": 2.1737345761496975e-06,
            "start_logit": -5.535739898681641,
            "end_logit": 5.877485752105713
        },
        {
            "text": "acquired form of prosopagnosia we",
            "probability": 2.1259047348761737e-06,
            "start_logit": 7.500129222869873,
            "end_logit": -7.180632591247559
        },
        {
            "text": "to the acquired",
            "probability": 1.5117392491046476e-06,
            "start_logit": -5.89892578125,
            "end_logit": 5.877485752105713
        },
        {
            "text": "is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired",
            "probability": 6.080268051615068e-07,
            "start_logit": -6.809722900390625,
            "end_logit": 5.877485752105713
        },
        {
            "text": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast",
            "probability": 5.759092703042633e-07,
            "start_logit": 4.202502727508545,
            "end_logit": -5.189008712768555
        },
        {
            "text": ". In contrast to the acquired",
            "probability": 5.602270867977969e-07,
            "start_logit": -6.891599655151367,
            "end_logit": 5.877485752105713
        },
        {
            "text": "In contrast to the acquired form",
            "probability": 2.0744909187358206e-07,
            "start_logit": 1.5999139547348022,
            "end_logit": -3.6074841022491455
        },
        {
            "text": "Prosopagnosia",
            "probability": 1.4137599099588607e-07,
            "start_logit": 4.202502727508545,
            "end_logit": -6.593535900115967
        },
        {
            "text": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In",
            "probability": 1.344335323842629e-07,
            "start_logit": 4.202502727508545,
            "end_logit": -6.6438889503479
        },
        {
            "text": "Prosopagnosia is the inability to recognize someone by the face alone",
            "probability": 1.0499250379242722e-07,
            "start_logit": 4.202502727508545,
            "end_logit": -6.8910698890686035
        }
    ],
    "6411b678201352f04a000036_002": [
        {
            "text": "autosomal dominant",
            "probability": 0.9433779186992856,
            "start_logit": 5.99090051651001,
            "end_logit": 4.081544399261475
        },
        {
            "text": "autosomal dominant mode of inheritance",
            "probability": 0.029329292307962957,
            "start_logit": 5.99090051651001,
            "end_logit": 0.6106641888618469
        },
        {
            "text": "Congenital",
            "probability": 0.013000127057529254,
            "start_logit": 5.857906341552734,
            "end_logit": -0.06996925920248032
        },
        {
            "text": "autosomal dominant mode of inheritance.",
            "probability": 0.007835756205321367,
            "start_logit": 5.99090051651001,
            "end_logit": -0.7092251777648926
        },
        {
            "text": "inherited in an autosomal dominant",
            "probability": 0.002560307377132861,
            "start_logit": 0.08156087249517441,
            "end_logit": 4.081544399261475
        },
        {
            "text": "There is evidence that it can be inherited in an autosomal dominant",
            "probability": 0.0013966232734820062,
            "start_logit": -0.524509072303772,
            "end_logit": 4.081544399261475
        },
        {
            "text": "an autosomal dominant",
            "probability": 0.0012111782328599564,
            "start_logit": -0.666972815990448,
            "end_logit": 4.081544399261475
        },
        {
            "text": "in an autosomal dominant",
            "probability": 0.0006902469011868004,
            "start_logit": -1.2292723655700684,
            "end_logit": 4.081544399261475
        },
        {
            "text": "auto",
            "probability": 9.184098886504608e-05,
            "start_logit": 5.99090051651001,
            "end_logit": -5.155619144439697
        },
        {
            "text": "Congenital prosopagnosia (cPA)",
            "probability": 8.199445022265346e-05,
            "start_logit": 5.857906341552734,
            "end_logit": -5.1360321044921875
        },
        {
            "text": "inherited in an autosomal dominant mode of inheritance",
            "probability": 7.959906838364343e-05,
            "start_logit": 0.08156087249517441,
            "end_logit": 0.6106641888618469
        },
        {
            "text": "autosomal dominant mode",
            "probability": 6.844678921694175e-05,
            "start_logit": 5.99090051651001,
            "end_logit": -5.449621200561523
        },
        {
            "text": "Congenital prosopagnosia",
            "probability": 5.911941574399017e-05,
            "start_logit": 5.857906341552734,
            "end_logit": -5.4631242752075195
        },
        {
            "text": "There is evidence that it can be inherited in an autosomal dominant mode of inheritance",
            "probability": 4.34205331926102e-05,
            "start_logit": -0.524509072303772,
            "end_logit": 0.6106641888618469
        },
        {
            "text": "an autosomal dominant mode of inheritance",
            "probability": 3.765511119612619e-05,
            "start_logit": -0.666972815990448,
            "end_logit": 0.6106641888618469
        },
        {
            "text": "Con",
            "probability": 3.640194484552352e-05,
            "start_logit": 5.857906341552734,
            "end_logit": -5.948061466217041
        },
        {
            "text": "evidence that it can be inherited in an autosomal dominant",
            "probability": 2.9678358808135394e-05,
            "start_logit": -4.375903606414795,
            "end_logit": 4.081544399261475
        },
        {
            "text": "it can be inherited in an autosomal dominant",
            "probability": 2.4749720895697913e-05,
            "start_logit": -4.557507514953613,
            "end_logit": 4.081544399261475
        },
        {
            "text": "Congenital prosopagnosia (cPA",
            "probability": 2.4184027103778268e-05,
            "start_logit": 5.857906341552734,
            "end_logit": -6.356991291046143
        },
        {
            "text": "in an autosomal dominant mode of inheritance",
            "probability": 2.1459536764954203e-05,
            "start_logit": -1.2292723655700684,
            "end_logit": 0.6106641888618469
        }
    ],
    "6411b678201352f04a000036_003": [
        {
            "text": "acquired",
            "probability": 0.9882625986264685,
            "start_logit": 8.4324369430542,
            "end_logit": 6.437922954559326
        },
        {
            "text": "acquired prosopagnosia",
            "probability": 0.009974789988252382,
            "start_logit": 8.4324369430542,
            "end_logit": 1.8420354127883911
        },
        {
            "text": "prosopagnosia",
            "probability": 0.0016003023691255763,
            "start_logit": 6.602568626403809,
            "end_logit": 1.8420354127883911
        },
        {
            "text": "acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal,",
            "probability": 5.927981723357937e-05,
            "start_logit": 8.4324369430542,
            "end_logit": -3.2835118770599365
        },
        {
            "text": "acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal",
            "probability": 5.7630616698598894e-05,
            "start_logit": 8.4324369430542,
            "end_logit": -3.3117268085479736
        },
        {
            "text": "acquired pro",
            "probability": 1.1146606939563017e-05,
            "start_logit": 8.4324369430542,
            "end_logit": -4.95464563369751
        },
        {
            "text": "prosopagnosia following a large unilateral right-hemispheric lesion in frontal,",
            "probability": 9.510539276712033e-06,
            "start_logit": 6.602568626403809,
            "end_logit": -3.2835118770599365
        },
        {
            "text": "prosopagnosia following a large unilateral right-hemispheric lesion in frontal",
            "probability": 9.245950295249694e-06,
            "start_logit": 6.602568626403809,
            "end_logit": -3.3117268085479736
        },
        {
            "text": "Here we report a follow-up examination on M.T., suffering from acquired",
            "probability": 6.736973832373558e-06,
            "start_logit": -3.463655948638916,
            "end_logit": 6.437922954559326
        },
        {
            "text": "M.T., suffering from acquired",
            "probability": 2.149884634937954e-06,
            "start_logit": -4.6058526039123535,
            "end_logit": 6.437922954559326
        },
        {
            "text": "pro",
            "probability": 1.7883024619167497e-06,
            "start_logit": 6.602568626403809,
            "end_logit": -4.95464563369751
        },
        {
            "text": "report a follow-up examination on M.T., suffering from acquired",
            "probability": 1.2032039611726573e-06,
            "start_logit": -5.186278820037842,
            "end_logit": 6.437922954559326
        },
        {
            "text": "acquired prosopagnosia following a large unilateral right-hemispheric lesion",
            "probability": 1.193017676525035e-06,
            "start_logit": 8.4324369430542,
            "end_logit": -7.189294815063477
        },
        {
            "text": "we report a follow-up examination on M.T., suffering from acquired",
            "probability": 1.1823666712494815e-06,
            "start_logit": -5.20374870300293,
            "end_logit": 6.437922954559326
        },
        {
            "text": "a follow-up examination on M.T., suffering from acquired",
            "probability": 3.675858872442385e-07,
            "start_logit": -6.37206506729126,
            "end_logit": 6.437922954559326
        },
        {
            "text": "from acquired",
            "probability": 2.2282138545427986e-07,
            "start_logit": -6.87265157699585,
            "end_logit": 6.437922954559326
        },
        {
            "text": "suffering from acquired",
            "probability": 2.1332730436382448e-07,
            "start_logit": -6.916194438934326,
            "end_logit": 6.437922954559326
        },
        {
            "text": "prosopagnosia following a large unilateral right-hemispheric lesion",
            "probability": 1.9140142463151755e-07,
            "start_logit": 6.602568626403809,
            "end_logit": -7.189294815063477
        },
        {
            "text": "follow-up examination on M.T., suffering from acquired",
            "probability": 1.7860245120131032e-07,
            "start_logit": -7.093859672546387,
            "end_logit": 6.437922954559326
        },
        {
            "text": "Here we report a follow-up examination on M.T., suffering from acquired prosopagnosia",
            "probability": 6.799801917797504e-08,
            "start_logit": -3.463655948638916,
            "end_logit": 1.8420354127883911
        }
    ],
    "643bc8f957b1c7a31500002b_001": [
        {
            "text": "A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins.",
            "probability": 0.7842300894000955,
            "start_logit": 3.55157470703125,
            "end_logit": 1.189780354499817
        },
        {
            "text": "A promoter is a short region of DNA (100-1,000 bp)",
            "probability": 0.06412931487221799,
            "start_logit": 3.55157470703125,
            "end_logit": -1.3140205144882202
        },
        {
            "text": "directly upstream or at the 5' end of the transcription initiation site.",
            "probability": 0.049121716058631894,
            "start_logit": 0.7822028398513794,
            "end_logit": 1.188750982284546
        },
        {
            "text": "5' end of the transcription initiation site.",
            "probability": 0.04199570239690768,
            "start_logit": 0.625468909740448,
            "end_logit": 1.188750982284546
        },
        {
            "text": "A promoter is a short region of DNA (100-1,000 bp",
            "probability": 0.025064025311437664,
            "start_logit": 3.55157470703125,
            "end_logit": -2.253488540649414
        },
        {
            "text": "upstream or at the 5' end of the transcription initiation site.",
            "probability": 0.006227639058027926,
            "start_logit": -1.2831010818481445,
            "end_logit": 1.188750982284546
        },
        {
            "text": "directly upstream or at the 5' end of the transcription initiation site",
            "probability": 0.0036257690965957336,
            "start_logit": 0.7822028398513794,
            "end_logit": -1.4174838066101074
        },
        {
            "text": "100-1,000 bp) where transcription of a gene by RNA polymerase begins.",
            "probability": 0.0031306350382851716,
            "start_logit": -1.9718918800354004,
            "end_logit": 1.189780354499817
        },
        {
            "text": "5' end of the transcription initiation site",
            "probability": 0.003099784212725652,
            "start_logit": 0.625468909740448,
            "end_logit": -1.4174838066101074
        },
        {
            "text": "It is typically located directly upstream or at the 5' end of the transcription initiation site.",
            "probability": 0.0027100045448319385,
            "start_logit": -2.1151480674743652,
            "end_logit": 1.188750982284546
        },
        {
            "text": "A promoter",
            "probability": 0.002590162560890331,
            "start_logit": 3.55157470703125,
            "end_logit": -4.5232014656066895
        },
        {
            "text": "promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins.",
            "probability": 0.0023421923090487387,
            "start_logit": -2.262040376663208,
            "end_logit": 1.189780354499817
        },
        {
            "text": "at the 5' end of the transcription initiation site.",
            "probability": 0.0020050678882808527,
            "start_logit": -2.4164204597473145,
            "end_logit": 1.188750982284546
        },
        {
            "text": "short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins.",
            "probability": 0.0019659922152327263,
            "start_logit": -2.4371306896209717,
            "end_logit": 1.189780354499817
        },
        {
            "text": "directly upstream",
            "probability": 0.0017073658258254009,
            "start_logit": 0.7822028398513794,
            "end_logit": -2.1705985069274902
        },
        {
            "text": "a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins.",
            "probability": 0.0016368065396747216,
            "start_logit": -2.6203806400299072,
            "end_logit": 1.189780354499817
        },
        {
            "text": "1,000 bp) where transcription of a gene by RNA polymerase begins.",
            "probability": 0.0013811718238322655,
            "start_logit": -2.7901954650878906,
            "end_logit": 1.189780354499817
        },
        {
            "text": "the 5' end of the transcription initiation site.",
            "probability": 0.0013601126407930828,
            "start_logit": -2.8045308589935303,
            "end_logit": 1.188750982284546
        },
        {
            "text": "A promoter is a short region",
            "probability": 0.0010699063135095625,
            "start_logit": 3.55157470703125,
            "end_logit": -5.407351016998291
        },
        {
            "text": "A promoter is a short region of DNA",
            "probability": 0.000606541893155335,
            "start_logit": 3.55157470703125,
            "end_logit": -5.974903583526611
        }
    ],
    "643bc8f957b1c7a31500002b_002": [
        {
            "text": "Promoters",
            "probability": 0.7862742181116614,
            "start_logit": 8.523046493530273,
            "end_logit": 3.7760519981384277
        },
        {
            "text": "Promoters mark the start of every transcript and are an important class of regulatory elements.",
            "probability": 0.2043685966707581,
            "start_logit": 8.523046493530273,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "Promoters mark the start of every transcript and are an important class of regulatory elements",
            "probability": 0.0059198806028321355,
            "start_logit": 8.523046493530273,
            "end_logit": -1.112937331199646
        },
        {
            "text": "Promote",
            "probability": 0.0019327369699172804,
            "start_logit": 8.523046493530273,
            "end_logit": -2.232316493988037
        },
        {
            "text": "Pro",
            "probability": 0.0010642956511154682,
            "start_logit": 8.523046493530273,
            "end_logit": -2.8289403915405273
        },
        {
            "text": "Promoters mark the start of every transcript",
            "probability": 0.0002550951240608755,
            "start_logit": 8.523046493530273,
            "end_logit": -4.2573723793029785
        },
        {
            "text": "Promoters mark the start of every transcript and",
            "probability": 0.00013381811914276958,
            "start_logit": 8.523046493530273,
            "end_logit": -4.902527332305908
        },
        {
            "text": "Promoters mark",
            "probability": 1.934095763322598e-05,
            "start_logit": 8.523046493530273,
            "end_logit": -6.8367838859558105
        },
        {
            "text": "Promoters mark the start",
            "probability": 1.2775256207184392e-05,
            "start_logit": 8.523046493530273,
            "end_logit": -7.251498699188232
        },
        {
            "text": "Promoters mark the start of every",
            "probability": 8.844993353175238e-06,
            "start_logit": 8.523046493530273,
            "end_logit": -7.619157314300537
        },
        {
            "text": "Promoters mark the start of every transcript and are an important class",
            "probability": 8.369656568176325e-06,
            "start_logit": 8.523046493530273,
            "end_logit": -7.67439603805542
        },
        {
            "text": "mark the start of every transcript and are an important class of regulatory elements.",
            "probability": 6.860674903198706e-07,
            "start_logit": -4.081413269042969,
            "end_logit": 2.4286715984344482
        },
        {
            "text": ".",
            "probability": 4.137465062477996e-07,
            "start_logit": -4.5871357917785645,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "the start of every transcript and are an important class of regulatory elements.",
            "probability": 4.113514629793574e-07,
            "start_logit": -4.5929412841796875,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "start of every transcript and are an important class of regulatory elements.",
            "probability": 1.260273471126679e-07,
            "start_logit": -5.775890350341797,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "regulatory elements.",
            "probability": 9.09719883935797e-08,
            "start_logit": -6.101837635040283,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "are an important class of regulatory elements.",
            "probability": 8.632741647060717e-08,
            "start_logit": -6.154242038726807,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "important class of regulatory elements.",
            "probability": 7.574184455381548e-08,
            "start_logit": -6.285058498382568,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "an important class of regulatory elements.",
            "probability": 6.937839950156906e-08,
            "start_logit": -6.372813701629639,
            "end_logit": 2.4286715984344482
        },
        {
            "text": "transcript and are an important class of regulatory elements.",
            "probability": 6.827429491523993e-08,
            "start_logit": -6.388855934143066,
            "end_logit": 2.4286715984344482
        }
    ],
    "64403be357b1c7a31500004e_001": [
        {
            "text": "24 weeks",
            "probability": 0.9976610552408306,
            "start_logit": 9.177952766418457,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "24",
            "probability": 0.0013434660597469476,
            "start_logit": 9.177952766418457,
            "end_logit": 1.2820287942886353
        },
        {
            "text": "0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 0.0006670978328691759,
            "start_logit": 1.867720603942871,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "12 weeks with follow up lasting 24 weeks",
            "probability": 0.00029657013689515885,
            "start_logit": 1.057067632675171,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "weeks",
            "probability": 1.3719758076264751e-05,
            "start_logit": -2.0163791179656982,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness,",
            "probability": 6.381903338863121e-06,
            "start_logit": 9.177952766418457,
            "end_logit": -4.0675129890441895
        },
        {
            "text": "0 and 12 weeks",
            "probability": 2.9579052997171806e-06,
            "start_logit": 1.867720603942871,
            "end_logit": 2.473734140396118
        },
        {
            "text": "24 weeks,",
            "probability": 2.5626254022643254e-06,
            "start_logit": 9.177952766418457,
            "end_logit": -4.979947090148926
        },
        {
            "text": "12 weeks",
            "probability": 1.314989101204399e-06,
            "start_logit": 1.057067632675171,
            "end_logit": 2.473734140396118
        },
        {
            "text": "two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 9.15471020629761e-07,
            "start_logit": -4.723532676696777,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "0 and 12 weeks with follow up lasting 24",
            "probability": 8.983244282038609e-07,
            "start_logit": 1.867720603942871,
            "end_logit": 1.2820287942886353
        },
        {
            "text": "at 0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 6.095767118118863e-07,
            "start_logit": -5.13020658493042,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 5.4761071231e-07,
            "start_logit": -5.2374067306518555,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 4.4704573640301305e-07,
            "start_logit": -5.440310478210449,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "12 weeks with follow up lasting 24",
            "probability": 3.9936600828522107e-07,
            "start_logit": 1.057067632675171,
            "end_logit": 1.2820287942886353
        },
        {
            "text": "weeks with follow up lasting 24 weeks",
            "probability": 3.700237964025417e-07,
            "start_logit": -5.629404067993164,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness",
            "probability": 3.125236604670642e-07,
            "start_logit": 9.177952766418457,
            "end_logit": -7.084054470062256
        },
        {
            "text": "follow up lasting 24 weeks",
            "probability": 1.466811927501732e-07,
            "start_logit": -6.5547099113464355,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "and 12 weeks with follow up lasting 24 weeks",
            "probability": 1.1409758866640436e-07,
            "start_logit": -6.805917263031006,
            "end_logit": 7.8921895027160645
        },
        {
            "text": "phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
            "probability": 1.1282758394424915e-07,
            "start_logit": -6.817110538482666,
            "end_logit": 7.8921895027160645
        }
    ],
    "6440396957b1c7a31500004b_001": [
        {
            "text": "Suprachoroidal",
            "probability": 0.8873111422936777,
            "start_logit": 4.967072010040283,
            "end_logit": -0.2621316611766815
        },
        {
            "text": "Suprachoroidal (SC)",
            "probability": 0.024369265312659098,
            "start_logit": 4.967072010040283,
            "end_logit": -3.8570046424865723
        },
        {
            "text": "Microinjector",
            "probability": 0.020439061429999423,
            "start_logit": 0.1839582473039627,
            "end_logit": 0.7502342462539673
        },
        {
            "text": "suprachoroidal space (SCS\u00ae)",
            "probability": 0.012462735703395523,
            "start_logit": 1.7316762208938599,
            "end_logit": -1.2921885251998901
        },
        {
            "text": "Suprachoroidal (SC) delivery",
            "probability": 0.00987540408719638,
            "start_logit": 4.967072010040283,
            "end_logit": -4.760280132293701
        },
        {
            "text": "SCS Microinjector",
            "probability": 0.00915469860025502,
            "start_logit": -0.6192223429679871,
            "end_logit": 0.7502342462539673
        },
        {
            "text": "suprachoroidal space",
            "probability": 0.008512558095094842,
            "start_logit": 1.7316762208938599,
            "end_logit": -1.6733890771865845
        },
        {
            "text": "Microinjector\u00ae. Suprachoroidal",
            "probability": 0.007426702405076667,
            "start_logit": 0.1839582473039627,
            "end_logit": -0.2621316611766815
        },
        {
            "text": "Suprachoroidal (SC) delivery facilitates targeting, compartmentalization, and durability of small molecule suspensions,",
            "probability": 0.00420385649013192,
            "start_logit": 4.967072010040283,
            "end_logit": -5.614325046539307
        },
        {
            "text": "SCS Microinjector\u00ae. Suprachoroidal",
            "probability": 0.0033264356264654502,
            "start_logit": -0.6192223429679871,
            "end_logit": -0.2621316611766815
        },
        {
            "text": "Su",
            "probability": 0.0030811997966496466,
            "start_logit": 4.967072010040283,
            "end_logit": -5.925008296966553
        },
        {
            "text": "suprachoroidal space (SCS",
            "probability": 0.002407514905590165,
            "start_logit": 1.7316762208938599,
            "end_logit": -2.9363365173339844
        },
        {
            "text": "suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA",
            "probability": 0.0020081316661943785,
            "start_logit": 1.7316762208938599,
            "end_logit": -3.1177268028259277
        },
        {
            "text": "suprachoroidal space (SCS\u00ae",
            "probability": 0.0016116352167823208,
            "start_logit": 1.7316762208938599,
            "end_logit": -3.3376822471618652
        },
        {
            "text": "microneedle-based device, the SCS Microinjector",
            "probability": 0.0010836136905177736,
            "start_logit": -2.753188133239746,
            "end_logit": 0.7502342462539673
        },
        {
            "text": "Microinjector\u00ae.",
            "probability": 0.000846858346011505,
            "start_logit": 0.1839582473039627,
            "end_logit": -2.4334354400634766
        },
        {
            "text": "SCS\u00ae)",
            "probability": 0.0006951558137459761,
            "start_logit": -1.1546860933303833,
            "end_logit": -1.2921885251998901
        },
        {
            "text": "the SCS Microinjector",
            "probability": 0.0004109808690100204,
            "start_logit": -3.722698211669922,
            "end_logit": 0.7502342462539673
        },
        {
            "text": "microneedle-based device, the SCS Microinjector\u00ae. Suprachoroidal",
            "probability": 0.00039374001732439524,
            "start_logit": -2.753188133239746,
            "end_logit": -0.2621316611766815
        },
        {
            "text": "SCS Microinjector\u00ae.",
            "probability": 0.00037930963422159574,
            "start_logit": -0.6192223429679871,
            "end_logit": -2.4334354400634766
        }
    ],
    "6440396957b1c7a31500004b_002": [
        {
            "text": "Suprachoroidal",
            "probability": 0.8793205639425237,
            "start_logit": 10.049869537353516,
            "end_logit": 8.32517147064209
        },
        {
            "text": "Suprachoroidal delivery",
            "probability": 0.1196490716073969,
            "start_logit": 10.049869537353516,
            "end_logit": 6.33058500289917
        },
        {
            "text": "Su",
            "probability": 0.0006611768216106363,
            "start_logit": 10.049869537353516,
            "end_logit": 1.1322879791259766
        },
        {
            "text": "Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions.",
            "probability": 0.0002718946898323427,
            "start_logit": 10.049869537353516,
            "end_logit": 0.24368149042129517
        },
        {
            "text": "Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions",
            "probability": 4.7907519925196274e-05,
            "start_logit": 10.049869537353516,
            "end_logit": -1.49246084690094
        },
        {
            "text": "Supra",
            "probability": 4.48617448556464e-05,
            "start_logit": 10.049869537353516,
            "end_logit": -1.55814790725708
        },
        {
            "text": "Suprachoroidal delivery enables",
            "probability": 2.1906048101915757e-06,
            "start_logit": 10.049869537353516,
            "end_logit": -4.5775556564331055
        },
        {
            "text": "Suprachoroid",
            "probability": 9.882180640559304e-07,
            "start_logit": 10.049869537353516,
            "end_logit": -5.373585224151611
        },
        {
            "text": "delivery",
            "probability": 5.072631644486763e-07,
            "start_logit": -2.321174144744873,
            "end_logit": 6.33058500289917
        },
        {
            "text": "Suprachoroidal delivery enables targeting, localization and durability of small molecule",
            "probability": 2.9282655964309205e-07,
            "start_logit": 10.049869537353516,
            "end_logit": -6.589908123016357
        },
        {
            "text": "Suprachoroidal delivery enables targeting, localization and durability of small molecule suspension",
            "probability": 1.450737550255522e-07,
            "start_logit": 10.049869537353516,
            "end_logit": -7.292246341705322
        },
        {
            "text": "Suprachoroidal delivery enables targeting, localization",
            "probability": 1.4363199487490507e-07,
            "start_logit": 10.049869537353516,
            "end_logit": -7.302234172821045
        },
        {
            "text": "Suprachoroidal delivery enables targeting, localization and durability",
            "probability": 1.3936367142863054e-07,
            "start_logit": 10.049869537353516,
            "end_logit": -7.332401752471924
        },
        {
            "text": "Suprachoroidal delivery enables targeting,",
            "probability": 1.1412441664654758e-07,
            "start_logit": 10.049869537353516,
            "end_logit": -7.532199382781982
        },
        {
            "text": "delivery enables targeting, localization and durability of small molecule suspensions.",
            "probability": 1.1527223647309848e-09,
            "start_logit": -2.321174144744873,
            "end_logit": 0.24368149042129517
        },
        {
            "text": "enables targeting, localization and durability of small molecule suspensions.",
            "probability": 9.498272150728441e-10,
            "start_logit": -2.5147757530212402,
            "end_logit": 0.24368149042129517
        },
        {
            "text": "delivery enables targeting, localization and durability of small molecule suspensions",
            "probability": 2.0310830524355445e-10,
            "start_logit": -2.321174144744873,
            "end_logit": -1.49246084690094
        },
        {
            "text": "enables targeting, localization and durability of small molecule suspensions",
            "probability": 1.673584219671772e-10,
            "start_logit": -2.5147757530212402,
            "end_logit": -1.49246084690094
        },
        {
            "text": "small molecule suspensions.",
            "probability": 5.073528759305214e-11,
            "start_logit": -5.44443416595459,
            "end_logit": 0.24368149042129517
        },
        {
            "text": ".",
            "probability": 4.366763787799045e-11,
            "start_logit": -5.594448566436768,
            "end_logit": 0.24368149042129517
        }
    ],
    "6431708a57b1c7a315000017_001": [
        {
            "text": "T1AM",
            "probability": 0.8341838030722304,
            "start_logit": 5.9323954582214355,
            "end_logit": 2.2552573680877686
        },
        {
            "text": "cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP) expression. A",
            "probability": 0.06557806677238145,
            "start_logit": 5.0371809005737305,
            "end_logit": 0.6072594523429871
        },
        {
            "text": "T1AM on cardiomyocytes",
            "probability": 0.05755880075973569,
            "start_logit": 5.9323954582214355,
            "end_logit": -0.41838935017585754
        },
        {
            "text": "cardiomyocytes",
            "probability": 0.023513917726936694,
            "start_logit": 5.0371809005737305,
            "end_logit": -0.41838935017585754
        },
        {
            "text": "cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP) expression.",
            "probability": 0.015426495709960691,
            "start_logit": 5.0371809005737305,
            "end_logit": -0.8398953080177307
        },
        {
            "text": "A",
            "probability": 0.0009050076092947285,
            "start_logit": 0.7541276812553406,
            "end_logit": 0.6072594523429871
        },
        {
            "text": "T1",
            "probability": 0.0007424796715817272,
            "start_logit": 5.9323954582214355,
            "end_logit": -4.768956184387207
        },
        {
            "text": "T1AM on cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide",
            "probability": 0.00047260074235175146,
            "start_logit": 5.9323954582214355,
            "end_logit": -5.220700740814209
        },
        {
            "text": "T",
            "probability": 0.0004111896483837002,
            "start_logit": 5.9323954582214355,
            "end_logit": -5.359897136688232
        },
        {
            "text": "T1AM on cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP",
            "probability": 0.00024705200445349475,
            "start_logit": 5.9323954582214355,
            "end_logit": -5.8693528175354
        },
        {
            "text": "T1AM on card",
            "probability": 0.00023376342281301488,
            "start_logit": 5.9323954582214355,
            "end_logit": -5.924642086029053
        },
        {
            "text": "cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide",
            "probability": 0.0001930668260399545,
            "start_logit": 5.0371809005737305,
            "end_logit": -5.220700740814209
        },
        {
            "text": "T1AM on cardiomy",
            "probability": 0.00013162868713322758,
            "start_logit": 5.9323954582214355,
            "end_logit": -6.498966693878174
        },
        {
            "text": "cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP",
            "probability": 0.00010092566958167023,
            "start_logit": 5.0371809005737305,
            "end_logit": -5.8693528175354
        },
        {
            "text": "card",
            "probability": 9.549701903166596e-05,
            "start_logit": 5.0371809005737305,
            "end_logit": -5.924642086029053
        },
        {
            "text": "We explored the direct impact of T1AM",
            "probability": 5.454062516527332e-05,
            "start_logit": -3.7028677463531494,
            "end_logit": 2.2552573680877686
        },
        {
            "text": "cardiomy",
            "probability": 5.377294312776117e-05,
            "start_logit": 5.0371809005737305,
            "end_logit": -6.498966693878174
        },
        {
            "text": "cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP) expression",
            "probability": 4.787300894059368e-05,
            "start_logit": 5.0371809005737305,
            "end_logit": -6.615185260772705
        },
        {
            "text": "cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP)",
            "probability": 3.3901558671470596e-05,
            "start_logit": 5.0371809005737305,
            "end_logit": -6.960276126861572
        },
        {
            "text": "NP) expression. A",
            "probability": 1.5616522185267616e-05,
            "start_logit": -3.3054862022399902,
            "end_logit": 0.6072594523429871
        }
    ],
    "6431708a57b1c7a315000017_002": [
        {
            "text": "miR-145",
            "probability": 0.9891987609773555,
            "start_logit": 2.430081367492676,
            "end_logit": 6.157501697540283
        },
        {
            "text": "145",
            "probability": 0.008000987108924846,
            "start_logit": -2.387248992919922,
            "end_logit": 6.157501697540283
        },
        {
            "text": "cardiomyocytes, after up-regulating the expression of miR-145",
            "probability": 0.0017113023431099736,
            "start_logit": -3.9295592308044434,
            "end_logit": 6.157501697540283
        },
        {
            "text": "B-type natriuretic peptide (BNP) induced by PE decreased.",
            "probability": 0.000415452950160494,
            "start_logit": 2.885291576385498,
            "end_logit": -2.0729897022247314
        },
        {
            "text": "In hypertrophic cardiomyocytes, after up-regulating the expression of miR-145",
            "probability": 0.0002599790401545124,
            "start_logit": -5.813968181610107,
            "end_logit": 6.157501697540283
        },
        {
            "text": "hypertrophic cardiomyocytes, after up-regulating the expression of miR-145",
            "probability": 0.00020779517839891992,
            "start_logit": -6.038016319274902,
            "end_logit": 6.157501697540283
        },
        {
            "text": "up-regulating the expression of miR-145",
            "probability": 7.678500666599479e-05,
            "start_logit": -7.033559799194336,
            "end_logit": 6.157501697540283
        },
        {
            "text": "after up-regulating the expression of miR-145",
            "probability": 7.42033784442724e-05,
            "start_logit": -7.0677595138549805,
            "end_logit": 6.157501697540283
        },
        {
            "text": "miR-145, the relative messenger ribonucleic acid (mRNA) and protein expressions of atrial natriuretic peptide",
            "probability": 1.635093489667666e-05,
            "start_logit": 2.430081367492676,
            "end_logit": -4.852863788604736
        },
        {
            "text": "B-type natriuretic peptide",
            "probability": 1.2306567278699255e-05,
            "start_logit": 2.885291576385498,
            "end_logit": -5.592226028442383
        },
        {
            "text": "B",
            "probability": 7.659028228269557e-06,
            "start_logit": 2.885291576385498,
            "end_logit": -6.066473960876465
        },
        {
            "text": "mi",
            "probability": 5.110456750185844e-06,
            "start_logit": 2.430081367492676,
            "end_logit": -6.015860080718994
        },
        {
            "text": "B-type natriuretic peptide (BNP) induced by PE",
            "probability": 4.688661735587846e-06,
            "start_logit": 2.885291576385498,
            "end_logit": -6.557211875915527
        },
        {
            "text": "miR-145,",
            "probability": 2.22810305912991e-06,
            "start_logit": 2.430081367492676,
            "end_logit": -6.845998287200928
        },
        {
            "text": "B-type",
            "probability": 2.1335291134727046e-06,
            "start_logit": 2.885291576385498,
            "end_logit": -7.344581604003906
        },
        {
            "text": "B-type natriuretic peptide (BNP",
            "probability": 1.9774737992647398e-06,
            "start_logit": 2.885291576385498,
            "end_logit": -7.420538902282715
        },
        {
            "text": "miR-145, the relative messenger ribonucleic acid",
            "probability": 1.726338416708184e-06,
            "start_logit": 2.430081367492676,
            "end_logit": -7.101146221160889
        },
        {
            "text": "atrial natriuretic peptide",
            "probability": 2.721904423918707e-07,
            "start_logit": -1.665457010269165,
            "end_logit": -4.852863788604736
        },
        {
            "text": "PE decreased.",
            "probability": 1.484809594796048e-07,
            "start_logit": -5.0513763427734375,
            "end_logit": -2.0729897022247314
        },
        {
            "text": "145, the relative messenger ribonucleic acid (mRNA) and protein expressions of atrial natriuretic peptide",
            "probability": 1.3225210593462735e-07,
            "start_logit": -2.387248992919922,
            "end_logit": -4.852863788604736
        }
    ],
    "6431708a57b1c7a315000017_003": [
        {
            "text": "cardiomyocytes",
            "probability": 0.9853509316638251,
            "start_logit": 2.7741847038269043,
            "end_logit": 2.8715403079986572
        },
        {
            "text": "cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP).",
            "probability": 0.007463972956319079,
            "start_logit": 2.7741847038269043,
            "end_logit": -2.0113697052001953
        },
        {
            "text": "Stretching of cultured cardiomyocytes",
            "probability": 0.003952474498647781,
            "start_logit": -2.744471311569214,
            "end_logit": 2.8715403079986572
        },
        {
            "text": "brain natriuretic peptide (BNP).",
            "probability": 0.0014823613728468766,
            "start_logit": 1.1577332019805908,
            "end_logit": -2.0113697052001953
        },
        {
            "text": "cardiomyocytes up-regulates the expression of brain natriuretic peptide",
            "probability": 0.0009711386457327237,
            "start_logit": 2.7741847038269043,
            "end_logit": -4.050743579864502
        },
        {
            "text": "brain natriuretic peptide",
            "probability": 0.00019287026152663836,
            "start_logit": 1.1577332019805908,
            "end_logit": -4.050743579864502
        },
        {
            "text": "cultured cardiomyocytes",
            "probability": 0.00012693215626909238,
            "start_logit": -6.182915687561035,
            "end_logit": 2.8715403079986572
        },
        {
            "text": "cardiomy",
            "probability": 0.00012021555114057269,
            "start_logit": 2.7741847038269043,
            "end_logit": -6.139926433563232
        },
        {
            "text": "cardiomyocytes up-regulates the expression of brain",
            "probability": 7.969630287216862e-05,
            "start_logit": 2.7741847038269043,
            "end_logit": -6.550989627838135
        },
        {
            "text": "card",
            "probability": 5.6610721524914836e-05,
            "start_logit": 2.7741847038269043,
            "end_logit": -6.893014430999756
        },
        {
            "text": "cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP)",
            "probability": 3.289137844280567e-05,
            "start_logit": 2.7741847038269043,
            "end_logit": -7.436002254486084
        },
        {
            "text": "cardio",
            "probability": 3.1544675972220854e-05,
            "start_logit": 2.7741847038269043,
            "end_logit": -7.477807998657227
        },
        {
            "text": "cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP",
            "probability": 3.133651220811679e-05,
            "start_logit": 2.7741847038269043,
            "end_logit": -7.484428882598877
        },
        {
            "text": "Stretching of cultured cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP).",
            "probability": 2.9939752245053784e-05,
            "start_logit": -2.744471311569214,
            "end_logit": -2.0113697052001953
        },
        {
            "text": "cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP). Intracellular calcium",
            "probability": 2.785625719262057e-05,
            "start_logit": 2.7741847038269043,
            "end_logit": -7.6021552085876465
        },
        {
            "text": "brain",
            "probability": 1.5827860259915714e-05,
            "start_logit": 1.1577332019805908,
            "end_logit": -6.550989627838135
        },
        {
            "text": "brain natriuretic peptide (BNP). Intracellular calcium-elevating agents",
            "probability": 1.5111319577558857e-05,
            "start_logit": 1.1577332019805908,
            "end_logit": -6.597317218780518
        },
        {
            "text": "brain natriuretic peptide (BNP)",
            "probability": 6.532299780377079e-06,
            "start_logit": 1.1577332019805908,
            "end_logit": -7.436002254486084
        },
        {
            "text": "brain natriuretic peptide (BNP",
            "probability": 6.223499941506369e-06,
            "start_logit": 1.1577332019805908,
            "end_logit": -7.484428882598877
        },
        {
            "text": "brain natriuretic peptide (BNP). Intracellular calcium",
            "probability": 5.5323136747795395e-06,
            "start_logit": 1.1577332019805908,
            "end_logit": -7.6021552085876465
        }
    ],
    "640f8641201352f04a00002c_001": [
        {
            "text": "trabeculotomy",
            "probability": 0.7834705791163179,
            "start_logit": -0.7945951819419861,
            "end_logit": -2.69368839263916
        },
        {
            "text": "trab",
            "probability": 0.06154741954034232,
            "start_logit": -3.3385207653045654,
            "end_logit": -2.69368839263916
        },
        {
            "text": "This retrospective case series included patients with PCG who underwent trab",
            "probability": 0.03820147813186549,
            "start_logit": -3.8154544830322266,
            "end_logit": -2.69368839263916
        },
        {
            "text": "trabeculotomy using an illuminated microcatheter with the intent of catheterizing the full circumference",
            "probability": 0.028824868604531977,
            "start_logit": -0.7945951819419861,
            "end_logit": -5.996183395385742
        },
        {
            "text": "trabeculotomy using an illuminated microcatheter",
            "probability": 0.02213561885613231,
            "start_logit": -0.7945951819419861,
            "end_logit": -6.2602338790893555
        },
        {
            "text": "This retrospective case series",
            "probability": 0.014414512461805161,
            "start_logit": -3.8154544830322266,
            "end_logit": -3.6683270931243896
        },
        {
            "text": "PCG who underwent trab",
            "probability": 0.010185977185308608,
            "start_logit": -5.137316703796387,
            "end_logit": -2.69368839263916
        },
        {
            "text": "This retrospective case series included patients with PCG who underwent trabeculotomy",
            "probability": 0.008635712048577264,
            "start_logit": -3.8154544830322266,
            "end_logit": -4.180656433105469
        },
        {
            "text": "retrospective case series included patients with PCG who underwent trab",
            "probability": 0.006344313778366393,
            "start_logit": -5.610769748687744,
            "end_logit": -2.69368839263916
        },
        {
            "text": "trabeculotomy using an illuminated microcatheter with the intent of catheterizing",
            "probability": 0.006006836313746822,
            "start_logit": -0.7945951819419861,
            "end_logit": -7.564523696899414
        },
        {
            "text": "trabeculotomy using an illuminated microcatheter with the intent of catheterizing the full circumference of",
            "probability": 0.005402941671251574,
            "start_logit": -0.7945951819419861,
            "end_logit": -7.670478343963623
        },
        {
            "text": "retrospective case series",
            "probability": 0.002393891401379625,
            "start_logit": -5.610769748687744,
            "end_logit": -3.6683270931243896
        },
        {
            "text": "the full circumference of Schlemm's canal in a single procedure",
            "probability": 0.0023640253814847002,
            "start_logit": -3.9257850646972656,
            "end_logit": -5.365866184234619
        },
        {
            "text": "PCG who underwent trabeculotomy",
            "probability": 0.002302611579637512,
            "start_logit": -5.137316703796387,
            "end_logit": -4.180656433105469
        },
        {
            "text": "This retrospective case series included patients with PCG",
            "probability": 0.0020265764892667365,
            "start_logit": -3.8154544830322266,
            "end_logit": -5.630214691162109
        },
        {
            "text": "retrospective case series included patients with PCG who underwent trabeculotomy",
            "probability": 0.0014341766239168812,
            "start_logit": -5.610769748687744,
            "end_logit": -4.180656433105469
        },
        {
            "text": "This retrospective",
            "probability": 0.0013445592345874362,
            "start_logit": -3.8154544830322266,
            "end_logit": -6.040496349334717
        },
        {
            "text": "the full circumference",
            "probability": 0.001258661210847611,
            "start_logit": -3.9257850646972656,
            "end_logit": -5.996183395385742
        },
        {
            "text": "This retrospective case series included patients with PCG who underwent trabeculotomy using an illuminated microcatheter",
            "probability": 0.0010793173122360525,
            "start_logit": -3.8154544830322266,
            "end_logit": -6.2602338790893555
        },
        {
            "text": "This",
            "probability": 0.0006259230583975456,
            "start_logit": -3.8154544830322266,
            "end_logit": -6.805090427398682
        }
    ],
    "640f8641201352f04a00002c_002": [
        {
            "text": "P",
            "probability": 0.809197211696602,
            "start_logit": -3.815234899520874,
            "end_logit": -1.371559977531433
        },
        {
            "text": "Paired comparisons, randomized design, baseline-controlled study.P",
            "probability": 0.02745670799893234,
            "start_logit": -7.198667049407959,
            "end_logit": -1.371559977531433
        },
        {
            "text": "MIGS) devices on outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P",
            "probability": 0.025930925829464636,
            "start_logit": -7.255841255187988,
            "end_logit": -1.371559977531433
        },
        {
            "text": "outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P",
            "probability": 0.025289577124377193,
            "start_logit": -7.280885219573975,
            "end_logit": -1.371559977531433
        },
        {
            "text": "DESIGN: Paired comparisons, randomized design, baseline-controlled study.P",
            "probability": 0.02415455369557313,
            "start_logit": -7.3268046379089355,
            "end_logit": -1.371559977531433
        },
        {
            "text": "baseline-controlled study.P",
            "probability": 0.021457285567135404,
            "start_logit": -7.445213317871094,
            "end_logit": -1.371559977531433
        },
        {
            "text": "glaucoma surgery (MIGS) devices on outflow facility.DESIGN:",
            "probability": 0.020709014305465415,
            "start_logit": -5.131686210632324,
            "end_logit": -3.7205822467803955
        },
        {
            "text": "randomized design, baseline-controlled study.P",
            "probability": 0.018727250041321978,
            "start_logit": -7.581297874450684,
            "end_logit": -1.371559977531433
        },
        {
            "text": "3 Schlemm's canal (SC) microinvasive glaucoma surgery (MIGS) devices on outflow facility.",
            "probability": 0.0047547291400188135,
            "start_logit": -6.603115558624268,
            "end_logit": -3.7205822467803955
        },
        {
            "text": "microinvasive glaucoma surgery (MIGS) devices on outflow facility.",
            "probability": 0.004280437876404221,
            "start_logit": -6.708199977874756,
            "end_logit": -3.7205822467803955
        },
        {
            "text": "Schlemm's canal (SC) microinvasive glaucoma surgery (MIGS) devices on outflow facility.",
            "probability": 0.0033409396532144736,
            "start_logit": -6.956003189086914,
            "end_logit": -3.7205822467803955
        },
        {
            "text": "MIGS) devices on outflow facility.",
            "probability": 0.0024754297928428785,
            "start_logit": -7.255841255187988,
            "end_logit": -3.7205822467803955
        },
        {
            "text": "outflow facility.",
            "probability": 0.0024142050721130577,
            "start_logit": -7.280885219573975,
            "end_logit": -3.7205822467803955
        },
        {
            "text": "glaucoma surgery (MIGS) devices on outflow facility.",
            "probability": 0.002082357120888674,
            "start_logit": -7.428754806518555,
            "end_logit": -3.7205822467803955
        },
        {
            "text": "glaucoma surgery (MIGS)",
            "probability": 0.0019188709714048906,
            "start_logit": -5.131686210632324,
            "end_logit": -6.099414348602295
        },
        {
            "text": "glaucoma",
            "probability": 0.001900909238113297,
            "start_logit": -5.131686210632324,
            "end_logit": -6.108819007873535
        },
        {
            "text": "To study the effect of 3 Schlemm's canal (SC) microinvasive glaucoma surgery (MIGS)",
            "probability": 0.0010651100931733729,
            "start_logit": -5.7203450202941895,
            "end_logit": -6.099414348602295
        },
        {
            "text": "To study the effect of 3 Schlemm's canal (SC) microinvasive glau",
            "probability": 0.0010551400515682523,
            "start_logit": -5.7203450202941895,
            "end_logit": -6.108819007873535
        },
        {
            "text": "glaucoma surgery (MIGS) devices",
            "probability": 0.0010487511061547925,
            "start_logit": -5.131686210632324,
            "end_logit": -6.703551292419434
        },
        {
            "text": "To study the effect of 3 Schlemm's canal (SC)",
            "probability": 0.0007405936252313154,
            "start_logit": -5.7203450202941895,
            "end_logit": -6.462795734405518
        }
    ],
    "640f8641201352f04a00002c_003": [
        {
            "text": "3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices.",
            "probability": 0.24339435545114643,
            "start_logit": -5.408080101013184,
            "end_logit": -1.660887598991394
        },
        {
            "text": "Glaucoma Surgery Devices.",
            "probability": 0.2407474929169371,
            "start_logit": -5.4190144538879395,
            "end_logit": -1.660887598991394
        },
        {
            "text": "Microinvasive Glaucoma Surgery Devices.",
            "probability": 0.19440431736698924,
            "start_logit": -5.6328229904174805,
            "end_logit": -1.660887598991394
        },
        {
            "text": "Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices.",
            "probability": 0.11969457678391801,
            "start_logit": -6.117819786071777,
            "end_logit": -1.660887598991394
        },
        {
            "text": "Schlemm's Canal Microinvasive Glaucoma Surgery Devices.",
            "probability": 0.03340110528854882,
            "start_logit": -7.394174098968506,
            "end_logit": -1.660887598991394
        },
        {
            "text": "3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
            "probability": 0.03294928918571306,
            "start_logit": -5.408080101013184,
            "end_logit": -3.6606009006500244
        },
        {
            "text": "Glaucoma Surgery Devices",
            "probability": 0.032590972580905854,
            "start_logit": -5.4190144538879395,
            "end_logit": -3.6606009006500244
        },
        {
            "text": "Microinvasive Glaucoma Surgery Devices",
            "probability": 0.026317307400178236,
            "start_logit": -5.6328229904174805,
            "end_logit": -3.6606009006500244
        },
        {
            "text": "of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices.",
            "probability": 0.0244910259214337,
            "start_logit": -7.704456329345703,
            "end_logit": -1.660887598991394
        },
        {
            "text": "Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
            "probability": 0.016203544314348128,
            "start_logit": -6.117819786071777,
            "end_logit": -3.6606009006500244
        },
        {
            "text": "'s Canal Microinvasive Glaucoma Surgery Devices.",
            "probability": 0.015312038159487812,
            "start_logit": -8.174123764038086,
            "end_logit": -1.660887598991394
        },
        {
            "text": "Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
            "probability": 0.004521644206723369,
            "start_logit": -7.394174098968506,
            "end_logit": -3.6606009006500244
        },
        {
            "text": "of 3 Schlemm's Canal Microinvasive Glaucoma Surgery Devices",
            "probability": 0.003315450327697042,
            "start_logit": -7.704456329345703,
            "end_logit": -3.6606009006500244
        },
        {
            "text": "3 Schlemm's Canal Microinvasive Glau",
            "probability": 0.002209894970955642,
            "start_logit": -5.408080101013184,
            "end_logit": -6.362625598907471
        },
        {
            "text": "Glau",
            "probability": 0.002185862826938505,
            "start_logit": -5.4190144538879395,
            "end_logit": -6.362625598907471
        },
        {
            "text": "'s Canal Microinvasive Glaucoma Surgery Devices",
            "probability": 0.0020728532196421607,
            "start_logit": -8.174123764038086,
            "end_logit": -3.6606009006500244
        },
        {
            "text": "Glaucoma",
            "probability": 0.0019175434762111468,
            "start_logit": -5.549980163574219,
            "end_logit": -6.362625598907471
        },
        {
            "text": "Microinvasive Glau",
            "probability": 0.001765090741258398,
            "start_logit": -5.6328229904174805,
            "end_logit": -6.362625598907471
        },
        {
            "text": "3",
            "probability": 0.0014188699571751006,
            "start_logit": -5.408080101013184,
            "end_logit": -6.8057098388671875
        },
        {
            "text": "Outflow Facility Effects of 3 Schlemm's Canal Microinvasive Glau",
            "probability": 0.00108676490379226,
            "start_logit": -6.117819786071777,
            "end_logit": -6.362625598907471
        }
    ],
    "640f8641201352f04a00002c_004": [
        {
            "text": "eyes",
            "probability": 0.999393168539312,
            "start_logit": 4.01638126373291,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "glaucoma surgery was reported in eyes",
            "probability": 0.00019593691335776056,
            "start_logit": -4.5207295417785645,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "eyes treated with excisional LOT",
            "probability": 0.0001837171431089584,
            "start_logit": 4.01638126373291,
            "end_logit": -5.894811630249023
        },
        {
            "text": "blood reflux from Schlemm's canal (SC) after long-standing glaucoma surgery was reported in eyes",
            "probability": 6.097595693610571e-05,
            "start_logit": -5.688042640686035,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "Previously, blood reflux from Schlemm's canal (SC) after long-standing glaucoma surgery was reported in eyes",
            "probability": 5.441487899433409e-05,
            "start_logit": -5.801884651184082,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "in eyes",
            "probability": 4.3058686540942945e-05,
            "start_logit": -6.035958290100098,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "Schlemm's canal (SC) after long-standing glaucoma surgery was reported in eyes",
            "probability": 1.8273685445594343e-05,
            "start_logit": -6.893060207366943,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "eyes treated with excision",
            "probability": 1.732796911333079e-05,
            "start_logit": 4.01638126373291,
            "end_logit": -8.255887031555176
        },
        {
            "text": "long-standing glaucoma surgery was reported in eyes",
            "probability": 1.3610714220554283e-05,
            "start_logit": -7.187664985656738,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "(SC) after long-standing glaucoma surgery was reported in eyes",
            "probability": 9.813120330536992e-06,
            "start_logit": -7.514801979064941,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "after long-standing glaucoma surgery was reported in eyes",
            "probability": 9.577867903835378e-06,
            "start_logit": -7.539067268371582,
            "end_logit": 2.7066946029663086
        },
        {
            "text": "glaucoma surgery was reported in eyes treated with excisional LOT",
            "probability": 3.601882730926362e-08,
            "start_logit": -4.5207295417785645,
            "end_logit": -5.894811630249023
        },
        {
            "text": "glaucoma",
            "probability": 2.7706430117129087e-08,
            "start_logit": -4.5207295417785645,
            "end_logit": -6.157188892364502
        },
        {
            "text": "blood reflux",
            "probability": 1.2313134738009122e-08,
            "start_logit": -5.688042640686035,
            "end_logit": -5.800873756408691
        },
        {
            "text": "Previously, blood reflux",
            "probability": 1.0988228319430607e-08,
            "start_logit": -5.801884651184082,
            "end_logit": -5.800873756408691
        },
        {
            "text": "blood reflux from Schlemm's canal (SC) after long-standing glau",
            "probability": 8.622296129522916e-09,
            "start_logit": -5.688042640686035,
            "end_logit": -6.157188892364502
        },
        {
            "text": "in eyes treated with excisional LOT",
            "probability": 7.91542220454454e-09,
            "start_logit": -6.035958290100098,
            "end_logit": -5.894811630249023
        },
        {
            "text": "Previously, blood reflux from Schlemm's canal (SC) after long-standing glau",
            "probability": 7.694527878142873e-09,
            "start_logit": -5.801884651184082,
            "end_logit": -6.157188892364502
        },
        {
            "text": "glau",
            "probability": 7.421271268551809e-09,
            "start_logit": -5.838043689727783,
            "end_logit": -6.157188892364502
        },
        {
            "text": "glaucoma surgery",
            "probability": 5.844598484611002e-09,
            "start_logit": -4.5207295417785645,
            "end_logit": -7.7133355140686035
        }
    ],
    "640f8641201352f04a00002c_005": [
        {
            "text": "subscleral",
            "probability": 0.996242120532214,
            "start_logit": 5.90726375579834,
            "end_logit": 6.2377705574035645
        },
        {
            "text": "subscle",
            "probability": 0.003320995626051533,
            "start_logit": 5.90726375579834,
            "end_logit": 0.5340448617935181
        },
        {
            "text": "subscleral removing of the external wall",
            "probability": 0.0003407237150759618,
            "start_logit": 5.90726375579834,
            "end_logit": -1.7429031133651733
        },
        {
            "text": "subscleral removing of the external wall of Schlemm's canal with subsequent laser trabeculopuncture",
            "probability": 4.754221239063556e-05,
            "start_logit": 5.90726375579834,
            "end_logit": -3.7123570442199707
        },
        {
            "text": "sub",
            "probability": 2.2070861727934635e-05,
            "start_logit": 5.90726375579834,
            "end_logit": -4.479716777801514
        },
        {
            "text": "to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral",
            "probability": 9.71618621565419e-06,
            "start_logit": -5.630688667297363,
            "end_logit": 6.2377705574035645
        },
        {
            "text": "hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral",
            "probability": 5.449054765006262e-06,
            "start_logit": -6.209039688110352,
            "end_logit": 6.2377705574035645
        },
        {
            "text": "minimally invasive (type 1) and basic (type 2) subscleral",
            "probability": 4.850415277517261e-06,
            "start_logit": -6.325417518615723,
            "end_logit": 6.2377705574035645
        },
        {
            "text": "subscleral removing",
            "probability": 2.0620693479528485e-06,
            "start_logit": 5.90726375579834,
            "end_logit": -6.850265026092529
        },
        {
            "text": "the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral",
            "probability": 2.012598367372358e-06,
            "start_logit": -7.205055236816406,
            "end_logit": 6.2377705574035645
        },
        {
            "text": "subscleral removing of the external wall of Schlemm's canal with subsequent laser trabeculopunc",
            "probability": 1.093991808044107e-06,
            "start_logit": 5.90726375579834,
            "end_logit": -7.484141826629639
        },
        {
            "text": "subscleral removing of",
            "probability": 9.883439485697524e-07,
            "start_logit": 5.90726375579834,
            "end_logit": -7.585699558258057
        },
        {
            "text": "AIM: to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscle",
            "probability": 2.3018734853324354e-07,
            "start_logit": -3.6696178913116455,
            "end_logit": 0.5340448617935181
        },
        {
            "text": "external wall",
            "probability": 4.6555884076189806e-08,
            "start_logit": -2.990910053253174,
            "end_logit": -1.7429031133651733
        },
        {
            "text": "to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscle",
            "probability": 3.238912635700628e-08,
            "start_logit": -5.630688667297363,
            "end_logit": 0.5340448617935181
        },
        {
            "text": "hypotensive effect of minimally invasive (type 1) and basic (type 2) subscle",
            "probability": 1.8164547219739754e-08,
            "start_logit": -6.209039688110352,
            "end_logit": 0.5340448617935181
        },
        {
            "text": "external wall of Schlemm's canal with subsequent laser trabeculopuncture in patients with open-angle glaucoma",
            "probability": 1.7721808725288643e-08,
            "start_logit": -2.990910053253174,
            "end_logit": -2.7087604999542236
        },
        {
            "text": "minimally invasive (type 1) and basic (type 2) subscle",
            "probability": 1.61689689576295e-08,
            "start_logit": -6.325417518615723,
            "end_logit": 0.5340448617935181
        },
        {
            "text": "the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscle",
            "probability": 6.7090421467739295e-09,
            "start_logit": -7.205055236816406,
            "end_logit": 0.5340448617935181
        },
        {
            "text": "external wall of Schlemm's canal with subsequent laser trabeculopuncture",
            "probability": 6.496083574019994e-09,
            "start_logit": -2.990910053253174,
            "end_logit": -3.7123570442199707
        }
    ],
    "644009c557b1c7a315000041_001": [
        {
            "text": "autosomal recessive",
            "probability": 0.9996168202025265,
            "start_logit": 8.692391395568848,
            "end_logit": 9.249492645263672
        },
        {
            "text": "recessive",
            "probability": 0.00013679616430245425,
            "start_logit": -0.20424394309520721,
            "end_logit": 9.249492645263672
        },
        {
            "text": "autosomal recess",
            "probability": 0.00010338449226646179,
            "start_logit": 8.692391395568848,
            "end_logit": 0.07282031327486038
        },
        {
            "text": "auto",
            "probability": 9.244223414778305e-05,
            "start_logit": 8.692391395568848,
            "end_logit": -0.03905070573091507
        },
        {
            "text": "Friedreich's Ataxia (FRDA) is an autosomal recessive",
            "probability": 4.0448783825286865e-05,
            "start_logit": -1.4226993322372437,
            "end_logit": 9.249492645263672
        },
        {
            "text": "autosomal re",
            "probability": 3.5529765592894065e-06,
            "start_logit": 8.692391395568848,
            "end_logit": -3.29784893989563
        },
        {
            "text": "autosomal recessive neurodegenerative disorder,",
            "probability": 2.019911391461383e-06,
            "start_logit": 8.692391395568848,
            "end_logit": -3.8625810146331787
        },
        {
            "text": "FRDA) is an autosomal recessive",
            "probability": 1.4243564819862583e-06,
            "start_logit": -4.769015789031982,
            "end_logit": 9.249492645263672
        },
        {
            "text": "an autosomal recessive",
            "probability": 9.126845854646636e-07,
            "start_logit": -5.2141008377075195,
            "end_logit": 9.249492645263672
        },
        {
            "text": "autosomal",
            "probability": 7.07035086417319e-07,
            "start_logit": 8.692391395568848,
            "end_logit": -4.912309646606445
        },
        {
            "text": "autoso",
            "probability": 5.003300452395794e-07,
            "start_logit": 8.692391395568848,
            "end_logit": -5.258121967315674
        },
        {
            "text": "(FRDA) is an autosomal recessive",
            "probability": 3.72881853746474e-07,
            "start_logit": -6.109229564666748,
            "end_logit": 9.249492645263672
        },
        {
            "text": "autosomal recessive neurodegenerative disorder",
            "probability": 1.8429044029026702e-07,
            "start_logit": 8.692391395568848,
            "end_logit": -6.2568769454956055
        },
        {
            "text": "Ataxia (FRDA) is an autosomal recessive",
            "probability": 9.404047988403919e-08,
            "start_logit": -7.4867658615112305,
            "end_logit": 9.249492645263672
        },
        {
            "text": "autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia",
            "probability": 9.088818723366464e-08,
            "start_logit": 8.692391395568848,
            "end_logit": -6.963759899139404
        },
        {
            "text": "autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG), cerebellar dentate nuclei",
            "probability": 8.911741629830523e-08,
            "start_logit": 8.692391395568848,
            "end_logit": -6.983435153961182
        },
        {
            "text": "autosomal recessive neurodegenerative",
            "probability": 6.434043103218857e-08,
            "start_logit": 8.692391395568848,
            "end_logit": -7.309201717376709
        },
        {
            "text": "autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG)",
            "probability": 4.862435766738082e-08,
            "start_logit": 8.692391395568848,
            "end_logit": -7.5892653465271
        },
        {
            "text": "autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG",
            "probability": 4.2462235352126994e-08,
            "start_logit": 8.692391395568848,
            "end_logit": -7.7247748374938965
        },
        {
            "text": "Friedreich's Ataxia (FRDA) is an autosomal recess",
            "probability": 4.183379965260998e-09,
            "start_logit": -1.4226993322372437,
            "end_logit": 0.07282031327486038
        }
    ],
    "64371a4257b1c7a315000029_001": [
        {
            "text": "operons",
            "probability": 0.4743473402249003,
            "start_logit": 8.871572494506836,
            "end_logit": 9.183433532714844
        },
        {
            "text": "polycistronic messages (operons",
            "probability": 0.2629664533917399,
            "start_logit": 8.281659126281738,
            "end_logit": 9.183433532714844
        },
        {
            "text": "operons)",
            "probability": 0.1479279454359871,
            "start_logit": 8.871572494506836,
            "end_logit": 8.018218994140625
        },
        {
            "text": "polycistronic messages (operons)",
            "probability": 0.08200760048614336,
            "start_logit": 8.281659126281738,
            "end_logit": 8.018218994140625
        },
        {
            "text": "polycistronic messages",
            "probability": 0.017300417545852518,
            "start_logit": 8.281659126281738,
            "end_logit": 6.462137699127197
        },
        {
            "text": "Prokaryotes evolved polycistronic messages (operons",
            "probability": 0.004393644318060761,
            "start_logit": 4.189791679382324,
            "end_logit": 9.183433532714844
        },
        {
            "text": "operon",
            "probability": 0.0043361976261943585,
            "start_logit": 8.871572494506836,
            "end_logit": 4.488491535186768
        },
        {
            "text": "polycistronic messages (operon",
            "probability": 0.0024038808996491444,
            "start_logit": 8.281659126281738,
            "end_logit": 4.488491535186768
        },
        {
            "text": "(operons",
            "probability": 0.0017169967269098974,
            "start_logit": 3.250209331512451,
            "end_logit": 9.183433532714844
        },
        {
            "text": "Prokaryotes evolved polycistronic messages (operons)",
            "probability": 0.0013701832430199198,
            "start_logit": 4.189791679382324,
            "end_logit": 8.018218994140625
        },
        {
            "text": "(operons)",
            "probability": 0.0005354553016185812,
            "start_logit": 3.250209331512451,
            "end_logit": 8.018218994140625
        },
        {
            "text": "Prokaryotes evolved polycistronic messages",
            "probability": 0.0002890554299607907,
            "start_logit": 4.189791679382324,
            "end_logit": 6.462137699127197
        },
        {
            "text": "cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages (operons",
            "probability": 0.00016899671862970737,
            "start_logit": 0.9317566752433777,
            "end_logit": 9.183433532714844
        },
        {
            "text": "operons) to confer expression from a single promoter to efficiently cotranslate proteins functioning on the same pathway.",
            "probability": 9.605912427115288e-05,
            "start_logit": 8.871572494506836,
            "end_logit": 0.6787022948265076
        },
        {
            "text": "cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages (operons)",
            "probability": 5.270259839649018e-05,
            "start_logit": 0.9317566752433777,
            "end_logit": 8.018218994140625
        },
        {
            "text": "Prokaryotes evolved polycistronic messages (operon",
            "probability": 4.01640495196716e-05,
            "start_logit": 4.189791679382324,
            "end_logit": 4.488491535186768
        },
        {
            "text": "(operon",
            "probability": 1.5695749717665124e-05,
            "start_logit": 3.250209331512451,
            "end_logit": 4.488491535186768
        },
        {
            "text": "op",
            "probability": 1.13390520293206e-05,
            "start_logit": 8.871572494506836,
            "end_logit": -1.458008885383606
        },
        {
            "text": "cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages",
            "probability": 1.1118200661958379e-05,
            "start_logit": 0.9317566752433777,
            "end_logit": 6.462137699127197
        },
        {
            "text": "evolved polycistronic messages (operons",
            "probability": 8.753876737648082e-06,
            "start_logit": -2.028625965118408,
            "end_logit": 9.183433532714844
        }
    ],
    "64371a4257b1c7a315000029_002": [
        {
            "text": "operons",
            "probability": 0.9898131565961229,
            "start_logit": 7.535892486572266,
            "end_logit": 6.370467662811279
        },
        {
            "text": "operon",
            "probability": 0.0036165520285133014,
            "start_logit": 7.535892486572266,
            "end_logit": 0.7584725618362427
        },
        {
            "text": "operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription",
            "probability": 0.002589637445713444,
            "start_logit": 7.535892486572266,
            "end_logit": 0.42446935176849365
        },
        {
            "text": "operons is a fundamental element of how genetic information is organized in prokaryotes.",
            "probability": 0.001705266689874305,
            "start_logit": 7.535892486572266,
            "end_logit": 0.006672983057796955
        },
        {
            "text": "operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription.",
            "probability": 0.001692158091451039,
            "start_logit": 7.535892486572266,
            "end_logit": -0.0010438403114676476
        },
        {
            "text": "The arrangement of functionally-related genes in operons",
            "probability": 0.00045665159267875517,
            "start_logit": -0.14545826613903046,
            "end_logit": 6.370467662811279
        },
        {
            "text": "op",
            "probability": 5.941275787585675e-05,
            "start_logit": 7.535892486572266,
            "end_logit": -3.350294828414917
        },
        {
            "text": "in operons",
            "probability": 2.959644203466073e-05,
            "start_logit": -2.8817248344421387,
            "end_logit": 6.370467662811279
        },
        {
            "text": "operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression",
            "probability": 2.41009165515307e-05,
            "start_logit": 7.535892486572266,
            "end_logit": -4.252553939819336
        },
        {
            "text": "arrangement of functionally-related genes in operons",
            "probability": 3.2614648600737465e-06,
            "start_logit": -5.087202548980713,
            "end_logit": 6.370467662811279
        },
        {
            "text": "functionally-related genes in operons",
            "probability": 1.7805974741842647e-06,
            "start_logit": -5.692430019378662,
            "end_logit": 6.370467662811279
        },
        {
            "text": "The arrangement of functionally-related genes in operon",
            "probability": 1.6685010022553692e-06,
            "start_logit": -0.14545826613903046,
            "end_logit": 0.7584725618362427
        },
        {
            "text": "operons is a fundamental element of how genetic information",
            "probability": 1.3532700704531657e-06,
            "start_logit": 7.535892486572266,
            "end_logit": -7.132279872894287
        },
        {
            "text": "operons is a fundamental element of how genetic information is organized in prokaryotes",
            "probability": 1.2962439168993409e-06,
            "start_logit": 7.535892486572266,
            "end_logit": -7.175333023071289
        },
        {
            "text": "co-transcription",
            "probability": 1.2256870293525426e-06,
            "start_logit": -0.11987914890050888,
            "end_logit": 0.42446935176849365
        },
        {
            "text": "operons is a fundamental element of how genetic information is organized",
            "probability": 1.1084702798955992e-06,
            "start_logit": 7.535892486572266,
            "end_logit": -7.331822872161865
        },
        {
            "text": "co-transcription.",
            "probability": 8.009060217053243e-07,
            "start_logit": -0.11987914890050888,
            "end_logit": -0.0010438403114676476
        },
        {
            "text": "The arrangement of functionally-related genes in operons is a fundamental element of how genetic information is organized in prokaryotes.",
            "probability": 7.867270147742351e-07,
            "start_logit": -0.14545826613903046,
            "end_logit": 0.006672983057796955
        },
        {
            "text": "in operon",
            "probability": 1.0813866411446716e-07,
            "start_logit": -2.8817248344421387,
            "end_logit": 0.7584725618362427
        },
        {
            "text": "in operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription",
            "probability": 7.743285087906564e-08,
            "start_logit": -2.8817248344421387,
            "end_logit": 0.42446935176849365
        }
    ],
    "64371a4257b1c7a315000029_003": [
        {
            "text": "Clustering of functionally related genes in operons",
            "probability": 0.7114261264568054,
            "start_logit": 7.877361297607422,
            "end_logit": 6.533306121826172
        },
        {
            "text": "operons",
            "probability": 0.26236617011518865,
            "start_logit": 6.879830837249756,
            "end_logit": 6.533306121826172
        },
        {
            "text": "Clustering of functionally related genes in operon",
            "probability": 0.015629086541921525,
            "start_logit": 7.877361297607422,
            "end_logit": 2.7151682376861572
        },
        {
            "text": "operon",
            "probability": 0.005763836083480911,
            "start_logit": 6.879830837249756,
            "end_logit": 2.7151682376861572
        },
        {
            "text": "Clustering of functionally related genes in operons allows for coregulated gene expression in prokaryotes.",
            "probability": 0.0031832052993350105,
            "start_logit": 7.877361297607422,
            "end_logit": 1.1239231824874878
        },
        {
            "text": "operons allows for coregulated gene expression in prokaryotes.",
            "probability": 0.0011739312797470153,
            "start_logit": 6.879830837249756,
            "end_logit": 1.1239231824874878
        },
        {
            "text": "Clustering of functionally related genes in operons allows for coregulated gene expression",
            "probability": 0.0001604518291912327,
            "start_logit": 7.877361297607422,
            "end_logit": -1.8637269735336304
        },
        {
            "text": "Clustering",
            "probability": 6.264897195455102e-05,
            "start_logit": 7.877361297607422,
            "end_logit": -2.804173469543457
        },
        {
            "text": "operons allows for coregulated gene expression",
            "probability": 5.9172878739414827e-05,
            "start_logit": 6.879830837249756,
            "end_logit": -1.8637269735336304
        },
        {
            "text": "C",
            "probability": 5.218090898486391e-05,
            "start_logit": 7.877361297607422,
            "end_logit": -2.987004041671753
        },
        {
            "text": "in operons",
            "probability": 4.295099655449753e-05,
            "start_logit": -1.8376057147979736,
            "end_logit": 6.533306121826172
        },
        {
            "text": "Cluster",
            "probability": 3.5604494303538205e-05,
            "start_logit": 7.877361297607422,
            "end_logit": -3.369248867034912
        },
        {
            "text": "Clustering of functionally related genes in op",
            "probability": 2.2774703472297564e-05,
            "start_logit": 7.877361297607422,
            "end_logit": -3.816070318222046
        },
        {
            "text": "op",
            "probability": 8.399061411049533e-06,
            "start_logit": 6.879830837249756,
            "end_logit": -3.816070318222046
        },
        {
            "text": "Clustering of functionally related genes in operons allows",
            "probability": 4.0860947754640215e-06,
            "start_logit": 7.877361297607422,
            "end_logit": -5.534131050109863
        },
        {
            "text": "coregulated gene expression in prokaryotes.",
            "probability": 2.4923780403216765e-06,
            "start_logit": 0.7249546647071838,
            "end_logit": 1.1239231824874878
        },
        {
            "text": "Clustering of functionally related genes in",
            "probability": 1.9869180673577105e-06,
            "start_logit": 7.877361297607422,
            "end_logit": -6.255136013031006
        },
        {
            "text": "Clustering of functionally related genes in operons allows for coregulated gene expression in prokaryotes",
            "probability": 1.9406968169363405e-06,
            "start_logit": 7.877361297607422,
            "end_logit": -6.2786736488342285
        },
        {
            "text": "operons allows",
            "probability": 1.5069070379878258e-06,
            "start_logit": 6.879830837249756,
            "end_logit": -5.534131050109863
        },
        {
            "text": "functionally related genes in operons",
            "probability": 1.4473841721186906e-06,
            "start_logit": -5.227907657623291,
            "end_logit": 6.533306121826172
        }
    ],
    "6440377c57b1c7a315000049_001": [
        {
            "text": "triamcinolone acetonide",
            "probability": 0.6361403415798683,
            "start_logit": 6.249919891357422,
            "end_logit": 7.1080145835876465
        },
        {
            "text": "triamcinolone",
            "probability": 0.35979825971621565,
            "start_logit": 6.249919891357422,
            "end_logit": 6.5381388664245605
        },
        {
            "text": "acetonide",
            "probability": 0.0030187900123452645,
            "start_logit": 0.8993567824363708,
            "end_logit": 7.1080145835876465
        },
        {
            "text": "CLS-TA, a triamcinolone acetonide",
            "probability": 0.0006350571212262369,
            "start_logit": -0.6595396399497986,
            "end_logit": 7.1080145835876465
        },
        {
            "text": "CLS-TA, a triamcinolone",
            "probability": 0.00035918559491153137,
            "start_logit": -0.6595396399497986,
            "end_logit": 6.5381388664245605
        },
        {
            "text": "triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE",
            "probability": 2.0386751008946954e-05,
            "start_logit": 6.249919891357422,
            "end_logit": -3.240274667739868
        },
        {
            "text": "triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae",
            "probability": 9.931999983839754e-06,
            "start_logit": 6.249919891357422,
            "end_logit": -3.959398031234741
        },
        {
            "text": "triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae),",
            "probability": 5.2272329689552845e-06,
            "start_logit": 6.249919891357422,
            "end_logit": -4.601277828216553
        },
        {
            "text": "a triamcinolone acetonide",
            "probability": 2.540011290498683e-06,
            "start_logit": -6.18108606338501,
            "end_logit": 7.1080145835876465
        },
        {
            "text": "t",
            "probability": 2.0161467290511066e-06,
            "start_logit": 6.249919891357422,
            "end_logit": -5.553971767425537
        },
        {
            "text": "a triamcinolone",
            "probability": 1.4366195354177592e-06,
            "start_logit": -6.18108606338501,
            "end_logit": 6.5381388664245605
        },
        {
            "text": "2021 FDA approval of CLS-TA, a triamcinolone acetonide",
            "probability": 1.4122273743120425e-06,
            "start_logit": -6.7680864334106445,
            "end_logit": 7.1080145835876465
        },
        {
            "text": "tria",
            "probability": 9.69074303320583e-07,
            "start_logit": 6.249919891357422,
            "end_logit": -6.286573886871338
        },
        {
            "text": "the 2021 FDA approval of CLS-TA, a triamcinolone acetonide",
            "probability": 8.520293766372316e-07,
            "start_logit": -7.273388862609863,
            "end_logit": 7.1080145835876465
        },
        {
            "text": "2021 FDA approval of CLS-TA, a triamcinolone",
            "probability": 7.987497701201498e-07,
            "start_logit": -6.7680864334106445,
            "end_logit": 6.5381388664245605
        },
        {
            "text": "triamcinolone ace",
            "probability": 7.131968062955627e-07,
            "start_logit": 6.249919891357422,
            "end_logit": -6.593157768249512
        },
        {
            "text": "SCS\u00ae) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone",
            "probability": 6.398419319671451e-07,
            "start_logit": -6.989912986755371,
            "end_logit": 6.5381388664245605
        },
        {
            "text": "triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE\u00ae)",
            "probability": 4.859205417871222e-07,
            "start_logit": 6.249919891357422,
            "end_logit": -6.976870059967041
        },
        {
            "text": "the 2021 FDA approval of CLS-TA, a triamcinolone",
            "probability": 4.819041757040951e-07,
            "start_logit": -7.273388862609863,
            "end_logit": 6.5381388664245605
        },
        {
            "text": "triamcin",
            "probability": 4.742696359924873e-07,
            "start_logit": 6.249919891357422,
            "end_logit": -7.001139163970947
        }
    ],
    "6441057657b1c7a315000052_001": [
        {
            "text": "FLACC",
            "probability": 0.8461884993297555,
            "start_logit": 8.806351661682129,
            "end_logit": 9.902244567871094
        },
        {
            "text": "Face, leg, activity, cry, and consolability (FLACC",
            "probability": 0.14649842992556625,
            "start_logit": 7.052624225616455,
            "end_logit": 9.902244567871094
        },
        {
            "text": "FLACC)",
            "probability": 0.005967153913123371,
            "start_logit": 8.806351661682129,
            "end_logit": 4.94777250289917
        },
        {
            "text": "Face, leg, activity, cry, and consolability (FLACC)",
            "probability": 0.0010330779490493993,
            "start_logit": 7.052624225616455,
            "end_logit": 4.94777250289917
        },
        {
            "text": "(FLACC",
            "probability": 9.099136324271822e-05,
            "start_logit": -0.3313811719417572,
            "end_logit": 9.902244567871094
        },
        {
            "text": "Face, leg, activity, cry, and consolability",
            "probability": 7.460978599422923e-05,
            "start_logit": 7.052624225616455,
            "end_logit": 2.319746255874634
        },
        {
            "text": "(FLACC)",
            "probability": 6.851513155557056e-05,
            "start_logit": -0.6150911450386047,
            "end_logit": 9.902244567871094
        },
        {
            "text": "FLACC) scores for postoperative pain were also assessed.",
            "probability": 3.3255585714596086e-05,
            "start_logit": 8.806351661682129,
            "end_logit": -0.24203011393547058
        },
        {
            "text": "FL",
            "probability": 1.570255289452481e-05,
            "start_logit": 8.806351661682129,
            "end_logit": -0.9924295544624329
        },
        {
            "text": "FLACC) scores",
            "probability": 1.231928230629072e-05,
            "start_logit": 8.806351661682129,
            "end_logit": -1.2350871562957764
        },
        {
            "text": "Face, leg, activity, cry, and consolability (FLACC) scores for postoperative pain were also assessed.",
            "probability": 5.7574536847313795e-06,
            "start_logit": 7.052624225616455,
            "end_logit": -0.24203011393547058
        },
        {
            "text": "Face, leg, activity, cry, and consolability (FL",
            "probability": 2.7185424366948127e-06,
            "start_logit": 7.052624225616455,
            "end_logit": -0.9924295544624329
        },
        {
            "text": "Face",
            "probability": 2.582483191896146e-06,
            "start_logit": 7.052624225616455,
            "end_logit": -1.0437740087509155
        },
        {
            "text": "Face, leg, activity, cry, and consolability (FLACC) scores",
            "probability": 2.132805535777076e-06,
            "start_logit": 7.052624225616455,
            "end_logit": -1.2350871562957764
        },
        {
            "text": "Face, leg, activity, cry, and consolability (",
            "probability": 1.3036464415009098e-06,
            "start_logit": 7.052624225616455,
            "end_logit": -1.7273601293563843
        },
        {
            "text": "FLACC) scores for postoperative pain",
            "probability": 1.2358749746665245e-06,
            "start_logit": 8.806351661682129,
            "end_logit": -3.5344736576080322
        },
        {
            "text": "FLAC",
            "probability": 9.873659470421974e-07,
            "start_logit": 8.806351661682129,
            "end_logit": -3.758967399597168
        },
        {
            "text": "leg, activity, cry, and consolability (FLACC",
            "probability": 3.4210462524885687e-07,
            "start_logit": -5.9147844314575195,
            "end_logit": 9.902244567871094
        },
        {
            "text": "Face, leg, activity, cry, and consolability (FLACC) scores for postoperative pain",
            "probability": 2.1396384318193038e-07,
            "start_logit": 7.052624225616455,
            "end_logit": -3.5344736576080322
        },
        {
            "text": "Face, leg, activity, cry, and consolability (FLAC",
            "probability": 1.7094011691038507e-07,
            "start_logit": 7.052624225616455,
            "end_logit": -3.758967399597168
        }
    ],
    "6441057657b1c7a315000052_002": [
        {
            "text": "FLACC and COMFORT",
            "probability": 0.8547113331284549,
            "start_logit": 7.419487953186035,
            "end_logit": 7.165234088897705
        },
        {
            "text": "FLACC",
            "probability": 0.10324146371638357,
            "start_logit": 7.419487953186035,
            "end_logit": 5.051540851593018
        },
        {
            "text": "COMFORT",
            "probability": 0.03143073475076113,
            "start_logit": 4.116510391235352,
            "end_logit": 7.165234088897705
        },
        {
            "text": "FLACC and COMFORT scales",
            "probability": 0.005466363243459506,
            "start_logit": 7.419487953186035,
            "end_logit": 2.113083839416504
        },
        {
            "text": "The FLACC and COMFORT",
            "probability": 0.004369053211493463,
            "start_logit": 2.143270492553711,
            "end_logit": 7.165234088897705
        },
        {
            "text": "The FLACC",
            "probability": 0.0005277424448770709,
            "start_logit": 2.143270492553711,
            "end_logit": 5.051540851593018
        },
        {
            "text": "COMFORT scales",
            "probability": 0.00020101735696847765,
            "start_logit": 4.116510391235352,
            "end_logit": 2.113083839416504
        },
        {
            "text": "The FLACC and COMFORT scales",
            "probability": 2.794257073509194e-05,
            "start_logit": 2.143270492553711,
            "end_logit": 2.113083839416504
        },
        {
            "text": "FL",
            "probability": 1.583120821598504e-05,
            "start_logit": 7.419487953186035,
            "end_logit": -3.731301784515381
        },
        {
            "text": "FLACC and COMFORT scales were utilized to assess pain",
            "probability": 3.1061796580161234e-06,
            "start_logit": 7.419487953186035,
            "end_logit": -5.359891414642334
        },
        {
            "text": "and COMFORT",
            "probability": 1.3941889684280567e-06,
            "start_logit": -5.9067182540893555,
            "end_logit": 7.165234088897705
        },
        {
            "text": "FLACC and COMFOR",
            "probability": 8.500670737246158e-07,
            "start_logit": 7.419487953186035,
            "end_logit": -6.655725002288818
        },
        {
            "text": "FLAC",
            "probability": 7.915981294214323e-07,
            "start_logit": 7.419487953186035,
            "end_logit": -6.726986408233643
        },
        {
            "text": "FLACC and CO",
            "probability": 7.42820378793401e-07,
            "start_logit": 7.419487953186035,
            "end_logit": -6.790585994720459
        },
        {
            "text": "FLACC and COMF",
            "probability": 6.851560197265709e-07,
            "start_logit": 7.419487953186035,
            "end_logit": -6.87139368057251
        },
        {
            "text": "FLACC and COMFORT scales were utilized",
            "probability": 3.8810271625896687e-07,
            "start_logit": 7.419487953186035,
            "end_logit": -7.439770221710205
        },
        {
            "text": "FLACC and COMFORT scales were",
            "probability": 3.3384577692558564e-07,
            "start_logit": 7.419487953186035,
            "end_logit": -7.59036111831665
        },
        {
            "text": "COMFORT scales were utilized to assess pain",
            "probability": 1.1422512506294556e-07,
            "start_logit": 4.116510391235352,
            "end_logit": -5.359891414642334
        },
        {
            "text": "The FL",
            "probability": 8.092485546517956e-08,
            "start_logit": 2.143270492553711,
            "end_logit": -3.731301784515381
        },
        {
            "text": "COMFOR",
            "probability": 3.125994903659317e-08,
            "start_logit": 4.116510391235352,
            "end_logit": -6.655725002288818
        }
    ],
    "6441057657b1c7a315000052_003": [
        {
            "text": "Wong-Baker Faces Pain Rating Scale",
            "probability": 0.77230305206705,
            "start_logit": 0.8784596920013428,
            "end_logit": -0.3856366276741028
        },
        {
            "text": "Wong-Baker Faces",
            "probability": 0.10720876025450889,
            "start_logit": 0.8784596920013428,
            "end_logit": -2.3602356910705566
        },
        {
            "text": "Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC)",
            "probability": 0.04991301927601331,
            "start_logit": 0.8784596920013428,
            "end_logit": -3.1247317790985107
        },
        {
            "text": "Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC",
            "probability": 0.02228088172705863,
            "start_logit": 0.8784596920013428,
            "end_logit": -3.9312846660614014
        },
        {
            "text": "Wong-Baker Faces Pain Rating Scale,",
            "probability": 0.013132773394545777,
            "start_logit": 0.8784596920013428,
            "end_logit": -4.459902763366699
        },
        {
            "text": "the Wong-Baker Faces Pain Rating Scale",
            "probability": 0.0064419053610129985,
            "start_logit": -3.908092975616455,
            "end_logit": -0.3856366276741028
        },
        {
            "text": "Faces Pain Rating Scale",
            "probability": 0.0038524746268234567,
            "start_logit": -4.422201633453369,
            "end_logit": -0.3856366276741028
        },
        {
            "text": "Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale",
            "probability": 0.00377657234261451,
            "start_logit": -4.442100524902344,
            "end_logit": -0.3856366276741028
        },
        {
            "text": "Wong-Baker Faces Pain",
            "probability": 0.003483243447294429,
            "start_logit": 0.8784596920013428,
            "end_logit": -5.787049770355225
        },
        {
            "text": "Postoperative pain was assessed using the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale",
            "probability": 0.003397479471865252,
            "start_logit": -4.5478835105896,
            "end_logit": -0.3856366276741028
        },
        {
            "text": "Face, Legs, Activity, Cry, and Consolability (FLACC) scale.",
            "probability": 0.0033360762469511287,
            "start_logit": -2.919990301132202,
            "end_logit": -2.031768321990967
        },
        {
            "text": "Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability",
            "probability": 0.0019002245139774993,
            "start_logit": 0.8784596920013428,
            "end_logit": -6.393041610717773
        },
        {
            "text": "pain was assessed using the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale",
            "probability": 0.0017953735465601754,
            "start_logit": -5.185704231262207,
            "end_logit": -0.3856366276741028
        },
        {
            "text": "Wong-Baker",
            "probability": 0.0015928086488611326,
            "start_logit": 0.8784596920013428,
            "end_logit": -6.569514751434326
        },
        {
            "text": "the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale",
            "probability": 0.0013162946742779548,
            "start_logit": -5.496096611022949,
            "end_logit": -0.3856366276741028
        },
        {
            "text": "Face, Legs, Activity, Cry, and Consolability (FLACC)",
            "probability": 0.0011183248353440133,
            "start_logit": -2.919990301132202,
            "end_logit": -3.1247317790985107
        },
        {
            "text": "the Wong-Baker Faces",
            "probability": 0.0008942457052094091,
            "start_logit": -3.908092975616455,
            "end_logit": -2.3602356910705566
        },
        {
            "text": "FLACC) scale.",
            "probability": 0.0008805975135694994,
            "start_logit": -4.2519402503967285,
            "end_logit": -2.031768321990967
        },
        {
            "text": "Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC) scale.",
            "probability": 0.0007427349760680777,
            "start_logit": -4.422201633453369,
            "end_logit": -2.031768321990967
        },
        {
            "text": "the Face, Legs, Activity, Cry, and Consolability (FLACC) scale.",
            "probability": 0.0006331573703940062,
            "start_logit": -4.581821918487549,
            "end_logit": -2.031768321990967
        }
    ],
    "6441057657b1c7a315000052_004": [
        {
            "text": "FLACC-r",
            "probability": 0.7362943066678045,
            "start_logit": 7.091574668884277,
            "end_logit": 6.057802200317383
        },
        {
            "text": "Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r",
            "probability": 0.13805854154937236,
            "start_logit": 5.4176225662231445,
            "end_logit": 6.057802200317383
        },
        {
            "text": "FLACC",
            "probability": 0.08592132248242276,
            "start_logit": 7.091574668884277,
            "end_logit": 3.90960431098938
        },
        {
            "text": "Face, Legs, Activity, Cry, Consolability-revised scale (FLACC",
            "probability": 0.01611063994722489,
            "start_logit": 5.4176225662231445,
            "end_logit": 3.90960431098938
        },
        {
            "text": "Face, Legs, Activity, Cry, Consolability-revised scale",
            "probability": 0.010160991336297961,
            "start_logit": 5.4176225662231445,
            "end_logit": 3.4486804008483887
        },
        {
            "text": "FLACC-r)",
            "probability": 0.010135529385546517,
            "start_logit": 7.091574668884277,
            "end_logit": 1.7722193002700806
        },
        {
            "text": "Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r)",
            "probability": 0.0019004579991010063,
            "start_logit": 5.4176225662231445,
            "end_logit": 1.7722193002700806
        },
        {
            "text": "FLACC-r).",
            "probability": 0.0006584034047238505,
            "start_logit": 7.091574668884277,
            "end_logit": -0.9617651700973511
        },
        {
            "text": "the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r",
            "probability": 0.0003552491331589524,
            "start_logit": -0.5449911952018738,
            "end_logit": 6.057802200317383
        },
        {
            "text": "Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r).",
            "probability": 0.00012345364208870172,
            "start_logit": 5.4176225662231445,
            "end_logit": -0.9617651700973511
        },
        {
            "text": "(FLACC-r",
            "probability": 0.00011115246005487406,
            "start_logit": -1.7069077491760254,
            "end_logit": 6.057802200317383
        },
        {
            "text": "the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC",
            "probability": 4.1455536264961015e-05,
            "start_logit": -0.5449911952018738,
            "end_logit": 3.90960431098938
        },
        {
            "text": "FL",
            "probability": 3.8255202420054336e-05,
            "start_logit": 7.091574668884277,
            "end_logit": -3.8073034286499023
        },
        {
            "text": "r",
            "probability": 2.8082952556210884e-05,
            "start_logit": -3.0826478004455566,
            "end_logit": 6.057802200317383
        },
        {
            "text": "the Face, Legs, Activity, Cry, Consolability-revised scale",
            "probability": 2.6146034310847654e-05,
            "start_logit": -0.5449911952018738,
            "end_logit": 3.4486804008483887
        },
        {
            "text": "(FLACC",
            "probability": 1.2970854559925735e-05,
            "start_logit": -1.7069077491760254,
            "end_logit": 3.90960431098938
        },
        {
            "text": "Face, Legs, Activity, Cry, Consolability-revised scale (FL",
            "probability": 7.173024977866042e-06,
            "start_logit": 5.4176225662231445,
            "end_logit": -3.8073034286499023
        },
        {
            "text": "mild) was evaluated by the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r",
            "probability": 5.612526307329428e-06,
            "start_logit": -4.692809581756592,
            "end_logit": 6.057802200317383
        },
        {
            "text": "FLACC-",
            "probability": 5.365645038289623e-06,
            "start_logit": 7.091574668884277,
            "end_logit": -5.771566390991211
        },
        {
            "text": "the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r)",
            "probability": 4.890215767955133e-06,
            "start_logit": -0.5449911952018738,
            "end_logit": 1.7722193002700806
        }
    ],
    "6441057657b1c7a315000052_005": [
        {
            "text": "FLACC",
            "probability": 0.9979788158861725,
            "start_logit": 6.199003219604492,
            "end_logit": 5.501306056976318
        },
        {
            "text": "FLACC scale",
            "probability": 0.0011310430157135322,
            "start_logit": 6.199003219604492,
            "end_logit": -1.2812857627868652
        },
        {
            "text": "FLACC scale (54%) and the COMFORT Behavioural scale",
            "probability": 0.0005734947269820163,
            "start_logit": 6.199003219604492,
            "end_logit": -1.960432529449463
        },
        {
            "text": "FLACC scale (54%) and the COMFORT Behavioural scale (48%), respectively.",
            "probability": 0.00020051227413504303,
            "start_logit": 6.199003219604492,
            "end_logit": -3.011305809020996
        },
        {
            "text": "FLACC scale (54%)",
            "probability": 2.86044321743763e-05,
            "start_logit": 6.199003219604492,
            "end_logit": -4.958619594573975
        },
        {
            "text": "FL",
            "probability": 1.3536011209541457e-05,
            "start_logit": 6.199003219604492,
            "end_logit": -5.706827640533447
        },
        {
            "text": "FLACC scale (54%",
            "probability": 1.2324114291950057e-05,
            "start_logit": 6.199003219604492,
            "end_logit": -5.800623416900635
        },
        {
            "text": "FLACC scale (54%) and the COMFORT Behavioural scale (48%),",
            "probability": 1.001919509677044e-05,
            "start_logit": 6.199003219604492,
            "end_logit": -6.007678508758545
        },
        {
            "text": "FLACC scale (54%) and the COMFORT Behavioural scale (48%)",
            "probability": 9.247635471505508e-06,
            "start_logit": 6.199003219604492,
            "end_logit": -6.087813377380371
        },
        {
            "text": "FLACC scale (54%) and the COMFORT Behavioural",
            "probability": 8.14055063532478e-06,
            "start_logit": 6.199003219604492,
            "end_logit": -6.215323448181152
        },
        {
            "text": "PICUs, using the preferred validated FLACC",
            "probability": 6.301905571547218e-06,
            "start_logit": -5.773632049560547,
            "end_logit": 5.501306056976318
        },
        {
            "text": "FLACC scale (54%) and the COMFORT Behavioural scale (48%",
            "probability": 5.43245265232882e-06,
            "start_logit": 6.199003219604492,
            "end_logit": -6.619790554046631
        },
        {
            "text": "FLAC",
            "probability": 4.381188317649367e-06,
            "start_logit": 6.199003219604492,
            "end_logit": -6.8348612785339355
        },
        {
            "text": "validated FLACC",
            "probability": 3.3422487436255947e-06,
            "start_logit": -6.407840251922607,
            "end_logit": 5.501306056976318
        },
        {
            "text": "81%) and sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC",
            "probability": 3.1925266402115414e-06,
            "start_logit": -6.453671455383301,
            "end_logit": 5.501306056976318
        },
        {
            "text": "the preferred validated FLACC",
            "probability": 3.0622632048750344e-06,
            "start_logit": -6.495329856872559,
            "end_logit": 5.501306056976318
        },
        {
            "text": "most of the PICUs, using the preferred validated FLACC",
            "probability": 2.903819569176294e-06,
            "start_logit": -6.548457145690918,
            "end_logit": 5.501306056976318
        },
        {
            "text": "sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC",
            "probability": 2.838212754844847e-06,
            "start_logit": -6.571309566497803,
            "end_logit": 5.501306056976318
        },
        {
            "text": "87%) was reported by most of the PICUs, using the preferred validated FLACC",
            "probability": 1.4650112417143338e-06,
            "start_logit": -7.232621192932129,
            "end_logit": 5.501306056976318
        },
        {
            "text": "using the preferred validated FLACC",
            "probability": 1.3425294217580788e-06,
            "start_logit": -7.3199286460876465,
            "end_logit": 5.501306056976318
        }
    ],
    "64257c9c690f196b5100004b_001": [
        {
            "text": "drug-specific liver injury phenotypes",
            "probability": 0.40456564971624953,
            "start_logit": 4.484716892242432,
            "end_logit": 5.0786919593811035
        },
        {
            "text": "DILI causality assessment tool",
            "probability": 0.2090560627155841,
            "start_logit": 3.038785457611084,
            "end_logit": 5.8644118309021
        },
        {
            "text": "liver injury phenotypes",
            "probability": 0.18696340286299737,
            "start_logit": 3.712815761566162,
            "end_logit": 5.0786919593811035
        },
        {
            "text": "DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes",
            "probability": 0.09528597063046937,
            "start_logit": 3.038785457611084,
            "end_logit": 5.0786919593811035
        },
        {
            "text": "drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development",
            "probability": 0.04340624764170799,
            "start_logit": 4.484716892242432,
            "end_logit": 2.8464813232421875
        },
        {
            "text": "uses drug-specific liver injury phenotypes",
            "probability": 0.026379398158374128,
            "start_logit": 1.7544862031936646,
            "end_logit": 5.0786919593811035
        },
        {
            "text": "liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development",
            "probability": 0.020059487923158006,
            "start_logit": 3.712815761566162,
            "end_logit": 2.8464813232421875
        },
        {
            "text": "uses drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development",
            "probability": 0.0028302716503605632,
            "start_logit": 1.7544862031936646,
            "end_logit": 2.8464813232421875
        },
        {
            "text": "We utilised a novel DILI causality assessment tool",
            "probability": 0.0028150026906972425,
            "start_logit": -1.268853783607483,
            "end_logit": 5.8644118309021
        },
        {
            "text": "drug-specific liver injury phenotypes,",
            "probability": 0.0019168769212554182,
            "start_logit": 4.484716892242432,
            "end_logit": -0.27342480421066284
        },
        {
            "text": "novel DILI causality assessment tool",
            "probability": 0.0015244827090629346,
            "start_logit": -1.8821618556976318,
            "end_logit": 5.8644118309021
        },
        {
            "text": "liver injury phenotypes,",
            "probability": 0.0008858533400421418,
            "start_logit": 3.712815761566162,
            "end_logit": -0.27342480421066284
        },
        {
            "text": "a novel DILI causality assessment tool",
            "probability": 0.0008665088788806602,
            "start_logit": -2.4470999240875244,
            "end_logit": 5.8644118309021
        },
        {
            "text": "causality assessment tool",
            "probability": 0.0007025758825883855,
            "start_logit": -2.6568188667297363,
            "end_logit": 5.8644118309021
        },
        {
            "text": "novel DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes",
            "probability": 0.0006948462185478662,
            "start_logit": -1.8821618556976318,
            "end_logit": 5.0786919593811035
        },
        {
            "text": "drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.",
            "probability": 0.0006023465125891467,
            "start_logit": 4.484716892242432,
            "end_logit": -1.4310444593429565
        },
        {
            "text": "DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes,",
            "probability": 0.0004514754976085456,
            "start_logit": 3.038785457611084,
            "end_logit": -0.27342480421066284
        },
        {
            "text": "a novel DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes",
            "probability": 0.0003949473577161588,
            "start_logit": -2.4470999240875244,
            "end_logit": 5.0786919593811035
        },
        {
            "text": "causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes",
            "probability": 0.00032022809596807033,
            "start_logit": -2.6568188667297363,
            "end_logit": 5.0786919593811035
        },
        {
            "text": "liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.",
            "probability": 0.00027836459614233745,
            "start_logit": 3.712815761566162,
            "end_logit": -1.4310444593429565
        }
    ],
    "64257c9c690f196b5100004b_002": [
        {
            "text": "phenotype-based drug-induced liver injury causality assessment tool",
            "probability": 0.8011136954230054,
            "start_logit": 6.645481109619141,
            "end_logit": 6.908705234527588
        },
        {
            "text": "A novel phenotype-based drug-induced liver injury causality assessment tool",
            "probability": 0.10935868354948253,
            "start_logit": 4.654111385345459,
            "end_logit": 6.908705234527588
        },
        {
            "text": "drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development",
            "probability": 0.06256995520728618,
            "start_logit": 2.4278085231781006,
            "end_logit": 8.57666015625
        },
        {
            "text": "drug-induced liver injury causality assessment tool",
            "probability": 0.011802723293228103,
            "start_logit": 2.4278085231781006,
            "end_logit": 6.908705234527588
        },
        {
            "text": "allows for signal confirmation in early drug development",
            "probability": 0.00581716840342255,
            "start_logit": 0.0523369237780571,
            "end_logit": 8.57666015625
        },
        {
            "text": "novel phenotype-based drug-induced liver injury causality assessment tool",
            "probability": 0.002521676867700843,
            "start_logit": 0.884402334690094,
            "end_logit": 6.908705234527588
        },
        {
            "text": "phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation",
            "probability": 0.002171555694618499,
            "start_logit": 6.645481109619141,
            "end_logit": 0.9981461763381958
        },
        {
            "text": "development",
            "probability": 0.0012446876508667825,
            "start_logit": -1.4895920753479004,
            "end_logit": 8.57666015625
        },
        {
            "text": "signal confirmation in early drug development",
            "probability": 0.0011469279450424333,
            "start_logit": -1.5713896751403809,
            "end_logit": 8.57666015625
        },
        {
            "text": "drug development",
            "probability": 0.000652876759696744,
            "start_logit": -2.134843587875366,
            "end_logit": 8.57666015625
        },
        {
            "text": "early drug development",
            "probability": 0.0004838961287621883,
            "start_logit": -2.434361696243286,
            "end_logit": 8.57666015625
        },
        {
            "text": "for signal confirmation in early drug development",
            "probability": 0.00031886329007792263,
            "start_logit": -2.8514695167541504,
            "end_logit": 8.57666015625
        },
        {
            "text": "A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation",
            "probability": 0.00029643541656402145,
            "start_logit": 4.654111385345459,
            "end_logit": 0.9981461763381958
        },
        {
            "text": "phenotype-based drug-induced liver injury causality assessment",
            "probability": 0.00024922545400154393,
            "start_logit": 6.645481109619141,
            "end_logit": -1.16669499874115
        },
        {
            "text": "tool (DILI-CAT) allows for signal confirmation in early drug development",
            "probability": 9.508139630499244e-05,
            "start_logit": -4.061498641967773,
            "end_logit": 8.57666015625
        },
        {
            "text": "causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development",
            "probability": 3.967967585214414e-05,
            "start_logit": -4.9353928565979,
            "end_logit": 8.57666015625
        },
        {
            "text": "A novel phenotype-based drug-induced liver injury causality assessment",
            "probability": 3.4021347671805494e-05,
            "start_logit": 4.654111385345459,
            "end_logit": -1.16669499874115
        },
        {
            "text": "drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation",
            "probability": 3.1993300234222754e-05,
            "start_logit": 2.4278085231781006,
            "end_logit": 0.9981461763381958
        },
        {
            "text": "(DILI-CAT) allows for signal confirmation in early drug development",
            "probability": 2.69373892633112e-05,
            "start_logit": -5.32271671295166,
            "end_logit": 8.57666015625
        },
        {
            "text": "assessment tool (DILI-CAT) allows for signal confirmation in early drug development",
            "probability": 2.3915806917795566e-05,
            "start_logit": -5.441692352294922,
            "end_logit": 8.57666015625
        }
    ],
    "64257c9c690f196b5100004b_003": [
        {
            "text": "early detection of drug's hepatotoxicity in clinical drug development",
            "probability": 0.9286679022418741,
            "start_logit": 5.488376140594482,
            "end_logit": 7.526790142059326
        },
        {
            "text": "computer-assisted scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development",
            "probability": 0.0535144831249488,
            "start_logit": 2.6345772743225098,
            "end_logit": 7.526790142059326
        },
        {
            "text": "computer-assisted scoring algorithm",
            "probability": 0.005830323485672138,
            "start_logit": 2.6345772743225098,
            "end_logit": 5.309910297393799
        },
        {
            "text": "early detection of drug's hepatotoxicity",
            "probability": 0.00418747291688899,
            "start_logit": 5.488376140594482,
            "end_logit": 2.125136375427246
        },
        {
            "text": "hepatotoxicity in clinical drug development",
            "probability": 0.004172804824877046,
            "start_logit": 0.08321337401866913,
            "end_logit": 7.526790142059326
        },
        {
            "text": "drug's hepatotoxicity in clinical drug development",
            "probability": 0.0011761021296311366,
            "start_logit": -1.1831693649291992,
            "end_logit": 7.526790142059326
        },
        {
            "text": "scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development",
            "probability": 0.0009240905952050616,
            "start_logit": -1.4243202209472656,
            "end_logit": 7.526790142059326
        },
        {
            "text": "a useful tool for early detection of drug's hepatotoxicity in clinical drug development",
            "probability": 0.00027770672016971663,
            "start_logit": -2.6265647411346436,
            "end_logit": 7.526790142059326
        },
        {
            "text": "computer-assisted scoring algorithm, is a useful tool for early detection of drug's hepatotoxicity",
            "probability": 0.00024130310545466773,
            "start_logit": 2.6345772743225098,
            "end_logit": 2.125136375427246
        },
        {
            "text": "early detection of drug's hepatotoxicity in clinical drug development.",
            "probability": 0.0002055116108128946,
            "start_logit": 5.488376140594482,
            "end_logit": -0.8892138004302979
        },
        {
            "text": "development",
            "probability": 0.00016302078221909431,
            "start_logit": -3.159252643585205,
            "end_logit": 7.526790142059326
        },
        {
            "text": "algorithm, is a useful tool for early detection of drug's hepatotoxicity in clinical drug development",
            "probability": 0.00012897988615681922,
            "start_logit": -3.3934738636016846,
            "end_logit": 7.526790142059326
        },
        {
            "text": "clinical drug development",
            "probability": 0.00010076287449001756,
            "start_logit": -3.6403603553771973,
            "end_logit": 7.526790142059326
        },
        {
            "text": "scoring algorithm",
            "probability": 0.00010067829838761933,
            "start_logit": -1.4243202209472656,
            "end_logit": 5.309910297393799
        },
        {
            "text": "DILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm",
            "probability": 7.474148660757587e-05,
            "start_logit": -1.722215175628662,
            "end_logit": 5.309910297393799
        },
        {
            "text": "hepatotoxicity in clinical drug development.",
            "probability": 7.256250176895324e-05,
            "start_logit": -3.968682050704956,
            "end_logit": 7.526790142059326
        },
        {
            "text": "detection of drug's hepatotoxicity in clinical drug development",
            "probability": 5.646676326150823e-05,
            "start_logit": -4.219478130340576,
            "end_logit": 7.526790142059326
        },
        {
            "text": "a clinically intuitive, data-driven, computer-assisted scoring algorithm",
            "probability": 5.565216988701142e-05,
            "start_logit": -2.017129421234131,
            "end_logit": 5.309910297393799
        },
        {
            "text": "is a useful tool for early detection of drug's hepatotoxicity in clinical drug development",
            "probability": 3.030126481518833e-05,
            "start_logit": -4.841940879821777,
            "end_logit": 7.526790142059326
        },
        {
            "text": "useful tool for early detection of drug's hepatotoxicity in clinical drug development",
            "probability": 1.913321687187575e-05,
            "start_logit": -5.301704406738281,
            "end_logit": 7.526790142059326
        }
    ],
    "6429e85e57b1c7a315000009_001": [
        {
            "text": "riboswitches",
            "probability": 0.8501398382672845,
            "start_logit": 3.244206428527832,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "riboswitches might be representatives of an ancient form of genetic control.",
            "probability": 0.14201238392160373,
            "start_logit": 3.244206428527832,
            "end_logit": -1.5460001230239868
        },
        {
            "text": "riboswitch",
            "probability": 0.003168814021402912,
            "start_logit": 3.244206428527832,
            "end_logit": -5.348556995391846
        },
        {
            "text": "These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches",
            "probability": 0.0024465316929737795,
            "start_logit": -2.606523036956787,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches",
            "probability": 0.0007975542647886139,
            "start_logit": -3.7273998260498047,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "riboswitches might be representatives of an ancient form of genetic control",
            "probability": 0.0005942129852291923,
            "start_logit": 3.244206428527832,
            "end_logit": -7.02243185043335
        },
        {
            "text": "rib",
            "probability": 0.00028135446795181336,
            "start_logit": 3.244206428527832,
            "end_logit": -7.770054340362549
        },
        {
            "text": "some riboswitches",
            "probability": 0.0001782223424801451,
            "start_logit": -5.225917816162109,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "eukaryotic gene regulation and that some riboswitches",
            "probability": 7.353712475229181e-05,
            "start_logit": -6.111159324645996,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches",
            "probability": 5.657313533983961e-05,
            "start_logit": -6.373415470123291,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches",
            "probability": 5.405966331577771e-05,
            "start_logit": -6.418861389160156,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "gene regulation and that some riboswitches",
            "probability": 3.4759840708003936e-05,
            "start_logit": -6.86048698425293,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches",
            "probability": 3.373846094277105e-05,
            "start_logit": -6.890311241149902,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "some riboswitches might be representatives of an ancient form of genetic control.",
            "probability": 2.9771313593870774e-05,
            "start_logit": -5.225917816162109,
            "end_logit": -1.5460001230239868
        },
        {
            "text": "that some riboswitches",
            "probability": 2.848173604292642e-05,
            "start_logit": -7.059686660766602,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches",
            "probability": 2.6658806025926085e-05,
            "start_logit": -7.125830173492432,
            "end_logit": 0.2434864640235901
        },
        {
            "text": "These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation",
            "probability": 1.4289652519111096e-05,
            "start_logit": -2.606523036956787,
            "end_logit": -4.899404525756836
        },
        {
            "text": "eukaryotic gene regulation and that some riboswitches might be representatives of an ancient form of genetic control.",
            "probability": 1.2284076010480983e-05,
            "start_logit": -6.111159324645996,
            "end_logit": -1.5460001230239868
        },
        {
            "text": "These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitch",
            "probability": 9.119210256400774e-06,
            "start_logit": -2.606523036956787,
            "end_logit": -5.348556995391846
        },
        {
            "text": "genetic control.",
            "probability": 7.81501677815173e-06,
            "start_logit": -6.563416004180908,
            "end_logit": -1.5460001230239868
        }
    ],
    "6429e85e57b1c7a315000009_002": [
        {
            "text": "riboswitches are typically located in noncoding regions of mRNA,",
            "probability": 0.6732243803360511,
            "start_logit": 1.6395316123962402,
            "end_logit": -0.0749208927154541
        },
        {
            "text": "riboswitches",
            "probability": 0.2730105871955911,
            "start_logit": 1.6395316123962402,
            "end_logit": -0.9774889945983887
        },
        {
            "text": "These riboswitches are typically located in noncoding regions of mRNA,",
            "probability": 0.01565528984965803,
            "start_logit": -2.1217381954193115,
            "end_logit": -0.0749208927154541
        },
        {
            "text": "mRNAs is widespread in prokaryotes. These riboswitches are typically located in noncoding regions of mRNA,",
            "probability": 0.009275985241161926,
            "start_logit": -2.645118236541748,
            "end_logit": -0.0749208927154541
        },
        {
            "text": "These riboswitches",
            "probability": 0.0063486409574752,
            "start_logit": -2.1217381954193115,
            "end_logit": -0.9774889945983887
        },
        {
            "text": "mRNAs is widespread in prokaryotes. These riboswitches",
            "probability": 0.0037616614185052885,
            "start_logit": -2.645118236541748,
            "end_logit": -0.9774889945983887
        },
        {
            "text": "riboswitches are typically located in noncoding regions of mRNA",
            "probability": 0.002819782829520247,
            "start_logit": 1.6395316123962402,
            "end_logit": -5.550339698791504
        },
        {
            "text": "riboswitch",
            "probability": 0.0026080556088225464,
            "start_logit": 1.6395316123962402,
            "end_logit": -5.628394603729248
        },
        {
            "text": "mRNAs is widespread in prokaryotes.",
            "probability": 0.0026038794673081188,
            "start_logit": -2.645118236541748,
            "end_logit": -1.345347285270691
        },
        {
            "text": "Genetic control by metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches",
            "probability": 0.0018944260768136557,
            "start_logit": -3.3310630321502686,
            "end_logit": -0.9774889945983887
        },
        {
            "text": "mRNAs",
            "probability": 0.001592691396330849,
            "start_logit": -2.645118236541748,
            "end_logit": -1.836924433708191
        },
        {
            "text": "metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches",
            "probability": 0.0014053011189874365,
            "start_logit": -3.629727363586426,
            "end_logit": -0.9774889945983887
        },
        {
            "text": "Genetic control by metabolite-binding mRNAs is widespread in prokaryotes.",
            "probability": 0.001311350654655209,
            "start_logit": -3.3310630321502686,
            "end_logit": -1.345347285270691
        },
        {
            "text": "riboswitches are typically located in noncoding regions of mRNA, where",
            "probability": 0.0011316610025792907,
            "start_logit": 1.6395316123962402,
            "end_logit": -6.463313102722168
        },
        {
            "text": "metabolite-binding mRNAs is widespread in prokaryotes.",
            "probability": 0.0009727708908396443,
            "start_logit": -3.629727363586426,
            "end_logit": -1.345347285270691
        },
        {
            "text": "Genetic control by metabolite-binding mRNAs",
            "probability": 0.0008021019910730895,
            "start_logit": -3.3310630321502686,
            "end_logit": -1.836924433708191
        },
        {
            "text": "riboswitches are typically located in noncoding regions",
            "probability": 0.0005954773462853363,
            "start_logit": 1.6395316123962402,
            "end_logit": -7.105391502380371
        },
        {
            "text": "metabolite-binding mRNAs",
            "probability": 0.000595005970089346,
            "start_logit": -3.629727363586426,
            "end_logit": -1.836924433708191
        },
        {
            "text": "mRNA,",
            "probability": 0.00019805871905322612,
            "start_logit": -6.491738796234131,
            "end_logit": -0.0749208927154541
        },
        {
            "text": "they selectively bind their target compound and subsequently modulate gene expression.",
            "probability": 0.00019289192919952087,
            "start_logit": -5.241694927215576,
            "end_logit": -1.351398229598999
        }
    ],
    "6429e85e57b1c7a315000009_003": [
        {
            "text": "Metabolite-sensing mRNAs, or \"riboswitches,",
            "probability": 0.3013943017395485,
            "start_logit": -0.04872199147939682,
            "end_logit": -3.084167718887329
        },
        {
            "text": "Metabolite-sensing mRNAs, or \"riboswitches",
            "probability": 0.16412939915672245,
            "start_logit": -0.04872199147939682,
            "end_logit": -3.691931962966919
        },
        {
            "text": "riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism.",
            "probability": 0.14948883661641788,
            "start_logit": -2.166112184524536,
            "end_logit": -1.6679751873016357
        },
        {
            "text": "riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism",
            "probability": 0.1200771527178419,
            "start_logit": -2.166112184524536,
            "end_logit": -1.887062430381775
        },
        {
            "text": "Metabolite-sensing mRNAs, or \"riboswitches,\"",
            "probability": 0.05920304444478739,
            "start_logit": -0.04872199147939682,
            "end_logit": -4.71161413192749
        },
        {
            "text": "Metabolite-sensing mRNAs, or \"riboswitch",
            "probability": 0.03844634671214473,
            "start_logit": -0.04872199147939682,
            "end_logit": -5.1433234214782715
        },
        {
            "text": "riboswitches,",
            "probability": 0.03627138676281287,
            "start_logit": -2.166112184524536,
            "end_logit": -3.084167718887329
        },
        {
            "text": "Metabolite-sensing mRNAs,",
            "probability": 0.02113451382624125,
            "start_logit": -0.04872199147939682,
            "end_logit": -5.741679668426514
        },
        {
            "text": "riboswitches",
            "probability": 0.01975220129113809,
            "start_logit": -2.166112184524536,
            "end_logit": -3.691931962966919
        },
        {
            "text": "Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes,",
            "probability": 0.013394828234286222,
            "start_logit": -1.1229124069213867,
            "end_logit": -5.123528003692627
        },
        {
            "text": "metabolism.",
            "probability": 0.012755883710590634,
            "start_logit": -4.627341270446777,
            "end_logit": -1.6679751873016357
        },
        {
            "text": "metabolism",
            "probability": 0.01024618447127177,
            "start_logit": -4.627341270446777,
            "end_logit": -1.887062430381775
        },
        {
            "text": "Metabolite-sensing mRNAs",
            "probability": 0.009070560638637131,
            "start_logit": -0.04872199147939682,
            "end_logit": -6.587553024291992
        },
        {
            "text": "direct expression of the genes involved in their metabolism.",
            "probability": 0.0071726431711450255,
            "start_logit": -5.203059673309326,
            "end_logit": -1.6679751873016357
        },
        {
            "text": "riboswitches,\"",
            "probability": 0.007124807968163081,
            "start_logit": -2.166112184524536,
            "end_logit": -4.71161413192749
        },
        {
            "text": "Riboswitches contain sensing \"aptamer\" modules,",
            "probability": 0.006450906341650411,
            "start_logit": -1.1229124069213867,
            "end_logit": -5.854176044464111
        },
        {
            "text": "Riboswitches",
            "probability": 0.006273825044527273,
            "start_logit": -1.1229124069213867,
            "end_logit": -5.882010459899902
        },
        {
            "text": "Riboswitches contain sensing \"aptamer\" modules",
            "probability": 0.006165611923513213,
            "start_logit": -1.1229124069213867,
            "end_logit": -5.899409294128418
        },
        {
            "text": "direct expression of the genes involved in their metabolism",
            "probability": 0.005761437368478233,
            "start_logit": -5.203059673309326,
            "end_logit": -1.887062430381775
        },
        {
            "text": "Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions,",
            "probability": 0.005686127860081833,
            "start_logit": -1.1229124069213867,
            "end_logit": -5.980367183685303
        }
    ],
    "6429e85e57b1c7a315000009_004": [
        {
            "text": "Riboswitches",
            "probability": 0.827653626499747,
            "start_logit": 8.551667213439941,
            "end_logit": 3.520573854446411
        },
        {
            "text": "Riboswitch",
            "probability": 0.16885700512774124,
            "start_logit": 8.551667213439941,
            "end_logit": 1.931031346321106
        },
        {
            "text": "R",
            "probability": 0.001972433527585659,
            "start_logit": 8.551667213439941,
            "end_logit": -2.5187528133392334
        },
        {
            "text": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs",
            "probability": 0.0006269106954790966,
            "start_logit": 8.551667213439941,
            "end_logit": -3.6649720668792725
        },
        {
            "text": "Riboswitches are a class of RNA motifs in the untranslated regions",
            "probability": 0.00024788916912342034,
            "start_logit": 8.551667213439941,
            "end_logit": -4.592794418334961
        },
        {
            "text": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs)",
            "probability": 0.00020344878138113282,
            "start_logit": 8.551667213439941,
            "end_logit": -4.7903618812561035
        },
        {
            "text": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs",
            "probability": 0.0001290835230671365,
            "start_logit": 8.551667213439941,
            "end_logit": -5.245316505432129
        },
        {
            "text": "Riboswitches are",
            "probability": 9.616497127288266e-05,
            "start_logit": 8.551667213439941,
            "end_logit": -5.539710998535156
        },
        {
            "text": "Riboswitches are a class of RNA motifs",
            "probability": 9.586111250292148e-05,
            "start_logit": 8.551667213439941,
            "end_logit": -5.54287576675415
        },
        {
            "text": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs) that",
            "probability": 5.765415337634316e-05,
            "start_logit": 8.551667213439941,
            "end_logit": -6.051313877105713
        },
        {
            "text": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNA",
            "probability": 4.944364136628881e-05,
            "start_logit": 8.551667213439941,
            "end_logit": -6.20494270324707
        },
        {
            "text": "The binding of specific small molecule or ion ligands, or other RNAs, influences the conformation the riboswitch adopts.",
            "probability": 8.939930779841651e-06,
            "start_logit": 0.17340265214443207,
            "end_logit": 0.46301624178886414
        },
        {
            "text": "messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression.",
            "probability": 1.2320029943956422e-06,
            "start_logit": -1.8152320384979248,
            "end_logit": 0.46976438164711
        },
        {
            "text": "The binding of specific small molecule or ion ligands, or other RNAs,",
            "probability": 9.822627055067385e-08,
            "start_logit": 0.17340265214443207,
            "end_logit": -4.047993183135986
        },
        {
            "text": "The binding of specific small molecule or ion ligands,",
            "probability": 5.123114189796788e-08,
            "start_logit": 0.17340265214443207,
            "end_logit": -4.698919296264648
        },
        {
            "text": "RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression.",
            "probability": 3.458117979796091e-08,
            "start_logit": -5.38831901550293,
            "end_logit": 0.46976438164711
        },
        {
            "text": "riboswitch adopts.",
            "probability": 3.4560543050667245e-08,
            "start_logit": -5.382167816162109,
            "end_logit": 0.46301624178886414
        },
        {
            "text": "bacterial messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression.",
            "probability": 3.452657644624047e-08,
            "start_logit": -5.389899253845215,
            "end_logit": 0.46976438164711
        },
        {
            "text": "can adopt different conformations to regulate gene expression.",
            "probability": 3.007499398513965e-08,
            "start_logit": -5.527934551239014,
            "end_logit": 0.46976438164711
        },
        {
            "text": "mRNAs) that can adopt different conformations to regulate gene expression.",
            "probability": 2.3662876719971972e-08,
            "start_logit": -5.767721176147461,
            "end_logit": 0.46976438164711
        }
    ],
    "6440393157b1c7a31500004a_001": [
        {
            "text": "2021",
            "probability": 0.9999122771933793,
            "start_logit": 9.676026344299316,
            "end_logit": 10.603686332702637
        },
        {
            "text": "202",
            "probability": 8.490710894390169e-05,
            "start_logit": 9.676026344299316,
            "end_logit": 1.2298213243484497
        },
        {
            "text": "the 2021",
            "probability": 1.2145940493573004e-06,
            "start_logit": -3.944986581802368,
            "end_logit": 10.603686332702637
        },
        {
            "text": "2021 FDA approval of CLS-TA",
            "probability": 9.775650161558332e-07,
            "start_logit": 9.676026344299316,
            "end_logit": -3.234426975250244
        },
        {
            "text": "after the 2021",
            "probability": 3.7292946630208743e-07,
            "start_logit": -5.125762462615967,
            "end_logit": 10.603686332702637
        },
        {
            "text": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021",
            "probability": 6.418723760016328e-08,
            "start_logit": -6.885347366333008,
            "end_logit": 10.603686332702637
        },
        {
            "text": "2021 FDA approval of CLS-TA,",
            "probability": 5.885553255364345e-08,
            "start_logit": 9.676026344299316,
            "end_logit": -6.044405937194824
        },
        {
            "text": "SCS\u00ae) has become a clinical reality after the 2021",
            "probability": 4.0479603707986214e-08,
            "start_logit": -7.346353530883789,
            "end_logit": 10.603686332702637
        },
        {
            "text": "suprachoroidal space (SCS\u00ae) has become a clinical reality after the 2021",
            "probability": 3.3059259930113815e-08,
            "start_logit": -7.548850059509277,
            "end_logit": 10.603686332702637
        },
        {
            "text": "2021 FDA approval of CLS-TA, a triamcinolone acetonide",
            "probability": 2.2048850933583716e-08,
            "start_logit": 9.676026344299316,
            "end_logit": -7.026231288909912
        },
        {
            "text": "2021 FDA approval of CLS-TA, a triamcinolone",
            "probability": 1.208082865455579e-08,
            "start_logit": 9.676026344299316,
            "end_logit": -7.627871990203857
        },
        {
            "text": "2021 FDA",
            "probability": 1.0138501133985958e-08,
            "start_logit": 9.676026344299316,
            "end_logit": -7.803151607513428
        },
        {
            "text": "2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension",
            "probability": 9.610659973857238e-09,
            "start_logit": 9.676026344299316,
            "end_logit": -7.856618881225586
        },
        {
            "text": "the 202",
            "probability": 1.0313671671365075e-10,
            "start_logit": -3.944986581802368,
            "end_logit": 1.2298213243484497
        },
        {
            "text": "after the 202",
            "probability": 3.1667140754167056e-11,
            "start_logit": -5.125762462615967,
            "end_logit": 1.2298213243484497
        },
        {
            "text": "Drug delivery to the suprachoroidal space (SCS\u00ae) has become a clinical reality after the 202",
            "probability": 5.450430902821254e-12,
            "start_logit": -6.885347366333008,
            "end_logit": 1.2298213243484497
        },
        {
            "text": "SCS\u00ae) has become a clinical reality after the 202",
            "probability": 3.437307652314432e-12,
            "start_logit": -7.346353530883789,
            "end_logit": 1.2298213243484497
        },
        {
            "text": "suprachoroidal space (SCS\u00ae) has become a clinical reality after the 202",
            "probability": 2.8072124410450464e-12,
            "start_logit": -7.548850059509277,
            "end_logit": 1.2298213243484497
        },
        {
            "text": "the 2021 FDA approval of CLS-TA",
            "probability": 1.187448817825766e-12,
            "start_logit": -3.944986581802368,
            "end_logit": -3.234426975250244
        },
        {
            "text": "CLS-TA",
            "probability": 9.839877935211994e-13,
            "start_logit": -4.132935523986816,
            "end_logit": -3.234426975250244
        }
    ],
    "6415b3b4690f196b51000009_001": [
        {
            "text": "yellow light",
            "probability": 0.6317901988025261,
            "start_logit": 8.489890098571777,
            "end_logit": 7.965588092803955
        },
        {
            "text": "yellow",
            "probability": 0.3681469109310437,
            "start_logit": 8.489890098571777,
            "end_logit": 7.425512790679932
        },
        {
            "text": "light",
            "probability": 5.108369891699033e-05,
            "start_logit": -0.932957112789154,
            "end_logit": 7.965588092803955
        },
        {
            "text": "yellow light.",
            "probability": 1.0971845340828115e-05,
            "start_logit": 8.489890098571777,
            "end_logit": -2.995392084121704
        },
        {
            "text": "millisecond-timescale pulses of yellow light",
            "probability": 3.154676875528877e-07,
            "start_logit": -6.0201215744018555,
            "end_logit": 7.965588092803955
        },
        {
            "text": "millisecond-timescale pulses of yellow",
            "probability": 1.8382440071289516e-07,
            "start_logit": -6.0201215744018555,
            "end_logit": 7.425512790679932
        },
        {
            "text": "enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light",
            "probability": 1.0627116348685082e-07,
            "start_logit": -7.108183860778809,
            "end_logit": 7.965588092803955
        },
        {
            "text": "silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light",
            "probability": 1.0509258318542811e-07,
            "start_logit": -7.119336128234863,
            "end_logit": 7.965588092803955
        },
        {
            "text": "enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow",
            "probability": 6.192467156484103e-08,
            "start_logit": -7.108183860778809,
            "end_logit": 7.425512790679932
        },
        {
            "text": "silenced reliably, and reversibly, by millisecond-timescale pulses of yellow",
            "probability": 6.123790767063163e-08,
            "start_logit": -7.119336128234863,
            "end_logit": 7.425512790679932
        },
        {
            "text": "light.",
            "probability": 8.871338064708287e-10,
            "start_logit": -0.932957112789154,
            "end_logit": -2.995392084121704
        },
        {
            "text": "millisecond-timescale pulses of yellow light.",
            "probability": 5.478500116683245e-12,
            "start_logit": -6.0201215744018555,
            "end_logit": -2.995392084121704
        },
        {
            "text": "Here we report",
            "probability": 2.5541038349338337e-12,
            "start_logit": -4.439352989196777,
            "end_logit": -5.339290618896484
        },
        {
            "text": "enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light.",
            "probability": 1.845534755331068e-12,
            "start_logit": -7.108183860778809,
            "end_logit": -2.995392084121704
        },
        {
            "text": "silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light.",
            "probability": 1.8250672000991797e-12,
            "start_logit": -7.119336128234863,
            "end_logit": -2.995392084121704
        },
        {
            "text": "Here we",
            "probability": 1.063667607071133e-12,
            "start_logit": -4.439352989196777,
            "end_logit": -6.215269088745117
        },
        {
            "text": "light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis",
            "probability": 1.0629734820035277e-12,
            "start_logit": -4.487133979797363,
            "end_logit": -6.168140888214111
        },
        {
            "text": "Here",
            "probability": 1.0283874151344735e-12,
            "start_logit": -4.439352989196777,
            "end_logit": -6.249000072479248
        },
        {
            "text": "we report",
            "probability": 9.671314544614265e-13,
            "start_logit": -5.410475254058838,
            "end_logit": -5.339290618896484
        },
        {
            "text": "report",
            "probability": 7.992226899439714e-13,
            "start_logit": -5.601170063018799,
            "end_logit": -5.339290618896484
        }
    ],
    "6429fad757b1c7a31500000e_001": [
        {
            "text": "TATA\" box",
            "probability": 0.9986701294917794,
            "start_logit": 7.655010223388672,
            "end_logit": 6.803775310516357
        },
        {
            "text": "TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site.",
            "probability": 0.0005274419300036578,
            "start_logit": 7.655010223388672,
            "end_logit": -0.7423657178878784
        },
        {
            "text": "\"TATA\" box",
            "probability": 0.00035823395235655203,
            "start_logit": -0.27798330783843994,
            "end_logit": 6.803775310516357
        },
        {
            "text": "the \"TATA\" box",
            "probability": 0.00024410553183737608,
            "start_logit": -0.6615689396858215,
            "end_logit": 6.803775310516357
        },
        {
            "text": "TATA\" box,",
            "probability": 9.116170409780802e-05,
            "start_logit": 7.655010223388672,
            "end_logit": -2.497769594192505
        },
        {
            "text": "A critical regulatory element in many promoters transcribed by RNA polymerase II is the \"TATA\" box",
            "probability": 4.166642722641777e-05,
            "start_logit": -2.429473876953125,
            "end_logit": 6.803775310516357
        },
        {
            "text": "box",
            "probability": 2.1664746622075544e-05,
            "start_logit": -3.0834832191467285,
            "end_logit": 6.803775310516357
        },
        {
            "text": "T",
            "probability": 1.6168189065196694e-05,
            "start_logit": 7.655010223388672,
            "end_logit": -4.227358818054199
        },
        {
            "text": "TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site",
            "probability": 8.028266421661539e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -4.927435874938965
        },
        {
            "text": "TATA\" box, which is located 25-30 nucleotides",
            "probability": 5.587073084712407e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -5.2899489402771
        },
        {
            "text": "TATA",
            "probability": 3.4860247113816427e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -5.7616424560546875
        },
        {
            "text": "TATA\" box, which is located 25-30 nucleotides upstream",
            "probability": 2.6276768294166987e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -6.044304370880127
        },
        {
            "text": "RNA polymerase II is the \"TATA\" box",
            "probability": 2.1447291370431395e-06,
            "start_logit": -5.396156311035156,
            "end_logit": 6.803775310516357
        },
        {
            "text": "TATA\"",
            "probability": 1.5460748977396588e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -6.574685096740723
        },
        {
            "text": "TATA\" box, which",
            "probability": 1.1809275651770667e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -6.844104290008545
        },
        {
            "text": "TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation",
            "probability": 1.1512283102383098e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -6.869575023651123
        },
        {
            "text": "TATA\" box, which is located 25-30 nucleotide",
            "probability": 1.128958309097919e-06,
            "start_logit": 7.655010223388672,
            "end_logit": -6.889109134674072
        },
        {
            "text": "TATA\" box, which is located 25-30 nucleotides upstream of",
            "probability": 9.111204813525405e-07,
            "start_logit": 7.655010223388672,
            "end_logit": -7.103484630584717
        },
        {
            "text": "critical regulatory element in many promoters transcribed by RNA polymerase II is the \"TATA\" box",
            "probability": 8.295090870122849e-07,
            "start_logit": -6.346090793609619,
            "end_logit": 6.803775310516357
        },
        {
            "text": "many promoters transcribed by RNA polymerase II is the \"TATA\" box",
            "probability": 8.064381773343476e-07,
            "start_logit": -6.374297618865967,
            "end_logit": 6.803775310516357
        }
    ],
    "6429fad757b1c7a31500000e_002": [
        {
            "text": "TATAWAWR",
            "probability": 0.5948340378312127,
            "start_logit": 2.7778923511505127,
            "end_logit": 0.36758774518966675
        },
        {
            "text": "TATA-like element and their promoters are generally AT-rich;",
            "probability": 0.18483317346762035,
            "start_logit": 3.94439697265625,
            "end_logit": -1.9677456617355347
        },
        {
            "text": "TATAWAWR).",
            "probability": 0.14907052646936048,
            "start_logit": 2.7778923511505127,
            "end_logit": -1.01627516746521
        },
        {
            "text": "TATA-like element",
            "probability": 0.032369440200060856,
            "start_logit": 3.94439697265625,
            "end_logit": -3.709984540939331
        },
        {
            "text": "TATAWAWR)",
            "probability": 0.014675079015024033,
            "start_logit": 2.7778923511505127,
            "end_logit": -3.3345439434051514
        },
        {
            "text": "TATA",
            "probability": 0.014464699547359216,
            "start_logit": 3.94439697265625,
            "end_logit": -4.515488147735596
        },
        {
            "text": "TATA-like element and their promoters",
            "probability": 0.0033674358575821964,
            "start_logit": 3.94439697265625,
            "end_logit": -5.973047733306885
        },
        {
            "text": "TATA-like element and their promoters are generally AT-rich",
            "probability": 0.0020182420050959974,
            "start_logit": 3.94439697265625,
            "end_logit": -6.4849724769592285
        },
        {
            "text": "T",
            "probability": 0.0014847178740698824,
            "start_logit": 3.94439697265625,
            "end_logit": -6.7919745445251465
        },
        {
            "text": "TATA-like element and their promoters are generally AT-rich; however",
            "probability": 0.0012638944857329985,
            "start_logit": 3.94439697265625,
            "end_logit": -6.953001499176025
        },
        {
            "text": "TATA-like element and their promoters are generally AT-rich; however, only approximately 10%",
            "probability": 0.0012121543416673162,
            "start_logit": 3.94439697265625,
            "end_logit": -6.994800090789795
        },
        {
            "text": "10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR",
            "probability": 7.477006798652557e-05,
            "start_logit": -6.203727722167969,
            "end_logit": 0.36758774518966675
        },
        {
            "text": "About 24% of human genes have a TATA-like element and their promoters are generally AT-rich;",
            "probability": 6.703476631523744e-05,
            "start_logit": -3.977600574493408,
            "end_logit": -1.9677456617355347
        },
        {
            "text": "TATA box (TATAWAWR",
            "probability": 6.670573705260462e-05,
            "start_logit": -6.317854404449463,
            "end_logit": 0.36758774518966675
        },
        {
            "text": "only approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR",
            "probability": 4.681743070314744e-05,
            "start_logit": -6.671889781951904,
            "end_logit": 0.36758774518966675
        },
        {
            "text": "however, only approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR",
            "probability": 4.138222986913302e-05,
            "start_logit": -6.795293807983398,
            "end_logit": 0.36758774518966675
        },
        {
            "text": "approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR",
            "probability": 4.008635610277309e-05,
            "start_logit": -6.827109336853027,
            "end_logit": 0.36758774518966675
        },
        {
            "text": "(TATAWAWR).",
            "probability": 3.399584280515332e-05,
            "start_logit": -6.991907119750977,
            "end_logit": 0.36758774518966675
        },
        {
            "text": "10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR).",
            "probability": 1.873802218773496e-05,
            "start_logit": -6.203727722167969,
            "end_logit": -1.01627516746521
        },
        {
            "text": "24% of human genes have a TATA-like element and their promoters are generally AT-rich;",
            "probability": 1.7068452191768726e-05,
            "start_logit": -5.345580101013184,
            "end_logit": -1.9677456617355347
        }
    ],
    "6429fad757b1c7a31500000e_003": [
        {
            "text": "TATA box",
            "probability": 0.9931908943223359,
            "start_logit": 9.271395683288574,
            "end_logit": 8.51681900024414
        },
        {
            "text": "TBP binding to the TATA box",
            "probability": 0.006537791057688836,
            "start_logit": 4.248072147369385,
            "end_logit": 8.51681900024414
        },
        {
            "text": "the TATA box",
            "probability": 0.00012516981156097164,
            "start_logit": 0.29238882660865784,
            "end_logit": 8.51681900024414
        },
        {
            "text": "TATA box induces a specific downstream unwinding site that is targeted by pluramycin.",
            "probability": 9.245831097082064e-05,
            "start_logit": 9.271395683288574,
            "end_logit": -0.7651013135910034
        },
        {
            "text": "TATA",
            "probability": 2.3785195375295617e-05,
            "start_logit": 9.271395683288574,
            "end_logit": -2.122795820236206
        },
        {
            "text": "T",
            "probability": 2.1227411377389837e-05,
            "start_logit": 9.271395683288574,
            "end_logit": -2.2365658283233643
        },
        {
            "text": "box",
            "probability": 6.389355136400718e-06,
            "start_logit": -2.6826491355895996,
            "end_logit": 8.51681900024414
        },
        {
            "text": "TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin.",
            "probability": 6.086172579003383e-07,
            "start_logit": 4.248072147369385,
            "end_logit": -0.7651013135910034
        },
        {
            "text": "TAT",
            "probability": 5.134869854353248e-07,
            "start_logit": 9.271395683288574,
            "end_logit": -5.958389759063721
        },
        {
            "text": "TATA box induces",
            "probability": 2.350403605653837e-07,
            "start_logit": 9.271395683288574,
            "end_logit": -6.739857196807861
        },
        {
            "text": "TATA box induces a specific downstream unwinding site that is targeted by pluramycin",
            "probability": 2.2161175184390915e-07,
            "start_logit": 9.271395683288574,
            "end_logit": -6.79868745803833
        },
        {
            "text": "TATA box induces a specific downstream unwinding site",
            "probability": 2.1615547461041794e-07,
            "start_logit": 9.271395683288574,
            "end_logit": -6.8236165046691895
        },
        {
            "text": "TBP binding to the TATA",
            "probability": 1.565687306628909e-07,
            "start_logit": 4.248072147369385,
            "end_logit": -2.122795820236206
        },
        {
            "text": "TBP binding to the T",
            "probability": 1.397318290716638e-07,
            "start_logit": 4.248072147369385,
            "end_logit": -2.2365658283233643
        },
        {
            "text": "TATA box induces a specific downstream unwinding site that",
            "probability": 1.1679371670511456e-07,
            "start_logit": 9.271395683288574,
            "end_logit": -7.439205169677734
        },
        {
            "text": "to the TATA box",
            "probability": 5.582418389226405e-08,
            "start_logit": -7.422830581665039,
            "end_logit": 8.51681900024414
        },
        {
            "text": "the TATA box induces a specific downstream unwinding site that is targeted by pluramycin.",
            "probability": 1.165233131679052e-08,
            "start_logit": 0.29238882660865784,
            "end_logit": -0.7651013135910034
        },
        {
            "text": "TBP binding to the TAT",
            "probability": 3.380085984285253e-09,
            "start_logit": 4.248072147369385,
            "end_logit": -5.958389759063721
        },
        {
            "text": "the TATA",
            "probability": 2.997599394120515e-09,
            "start_logit": 0.29238882660865784,
            "end_logit": -2.122795820236206
        },
        {
            "text": "the T",
            "probability": 2.6752471224054365e-09,
            "start_logit": 0.29238882660865784,
            "end_logit": -2.2365658283233643
        }
    ],
    "6429fad757b1c7a31500000e_004": [
        {
            "text": "TATA box",
            "probability": 0.4711913927515961,
            "start_logit": 3.586963653564453,
            "end_logit": 3.0533716678619385
        },
        {
            "text": "TFIID",
            "probability": 0.26781310812400316,
            "start_logit": 5.958614349365234,
            "end_logit": 0.11674598604440689
        },
        {
            "text": "TFIID multiprotein complex.",
            "probability": 0.11751159371012292,
            "start_logit": 5.958614349365234,
            "end_logit": -0.7070063948631287
        },
        {
            "text": "TATA-binding protein (TBP) is one of the major components of the human TFIID",
            "probability": 0.07702292640755168,
            "start_logit": 4.712428092956543,
            "end_logit": 0.11674598604440689
        },
        {
            "text": "TATA-binding protein (TBP) is one of the major components of the human TFIID multiprotein complex.",
            "probability": 0.033796280166309346,
            "start_logit": 4.712428092956543,
            "end_logit": -0.7070063948631287
        },
        {
            "text": "TFIID multiprotein complex. It is important in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence",
            "probability": 0.016859341697583543,
            "start_logit": 5.958614349365234,
            "end_logit": -2.6486384868621826
        },
        {
            "text": "TATA box) found in many eukaryotic promoters.",
            "probability": 0.010887212181318691,
            "start_logit": 3.586963653564453,
            "end_logit": -0.7143037915229797
        },
        {
            "text": "TATA box)",
            "probability": 0.0015757832230381022,
            "start_logit": 3.586963653564453,
            "end_logit": -2.6471402645111084
        },
        {
            "text": "TFIID multiprotein complex. It is important in directing the initiation of RNA transcription",
            "probability": 0.0013190709954561516,
            "start_logit": 5.958614349365234,
            "end_logit": -5.196615695953369
        },
        {
            "text": "T",
            "probability": 0.00038311339261225556,
            "start_logit": 5.958614349365234,
            "end_logit": -6.432967662811279
        },
        {
            "text": "TATA",
            "probability": 0.0003325432671118936,
            "start_logit": 4.712428092956543,
            "end_logit": -5.328342437744141
        },
        {
            "text": "TATA sequence (TATA box",
            "probability": 0.00031620755204123693,
            "start_logit": -3.7196571826934814,
            "end_logit": 3.0533716678619385
        },
        {
            "text": "(TATA box",
            "probability": 0.0001687578067298733,
            "start_logit": -4.347591400146484,
            "end_logit": 3.0533716678619385
        },
        {
            "text": "TATA-binding protein",
            "probability": 0.00014432373030731884,
            "start_logit": 4.712428092956543,
            "end_logit": -6.163053512573242
        },
        {
            "text": "TAT",
            "probability": 0.00014430989836778385,
            "start_logit": 4.712428092956543,
            "end_logit": -6.163149356842041
        },
        {
            "text": "It is important in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence (TATA box",
            "probability": 0.00014276550614614745,
            "start_logit": -4.514852523803711,
            "end_logit": 3.0533716678619385
        },
        {
            "text": "TATA-binding protein (TBP)",
            "probability": 0.00011482643012743275,
            "start_logit": 4.712428092956543,
            "end_logit": -6.391690731048584
        },
        {
            "text": "TATA-binding protein (TBP) is one of the major components of the human T",
            "probability": 0.00011018323506128813,
            "start_logit": 4.712428092956543,
            "end_logit": -6.432967662811279
        },
        {
            "text": "TATA box) found in many eukaryotic promoters",
            "probability": 8.832527467398372e-05,
            "start_logit": 3.586963653564453,
            "end_logit": -5.528621673583984
        },
        {
            "text": "The TATA-binding protein (TBP) is one of the major components of the human TFIID",
            "probability": 7.79346498411918e-05,
            "start_logit": -2.1835596561431885,
            "end_logit": 0.11674598604440689
        }
    ],
    "64402e7757b1c7a315000044_001": [
        {
            "text": "9",
            "probability": 0.9817438081275505,
            "start_logit": 7.344411849975586,
            "end_logit": 6.425304889678955
        },
        {
            "text": "9 subjects",
            "probability": 0.017187415926407303,
            "start_logit": 7.344411849975586,
            "end_logit": 2.3801519870758057
        },
        {
            "text": "9 subjects each cohort",
            "probability": 0.0005320115679408019,
            "start_logit": 7.344411849975586,
            "end_logit": -1.0951155424118042
        },
        {
            "text": "9 subjects each cohort)",
            "probability": 0.00041086484506934907,
            "start_logit": 7.344411849975586,
            "end_logit": -1.3535164594650269
        },
        {
            "text": "(9",
            "probability": 7.237576173382193e-05,
            "start_logit": -2.170802354812622,
            "end_logit": 6.425304889678955
        },
        {
            "text": "9 subjects each",
            "probability": 4.799801689505751e-05,
            "start_logit": 7.344411849975586,
            "end_logit": -3.5006210803985596
        },
        {
            "text": "Friedreich's ataxia patients (9",
            "probability": 1.2758835203086184e-06,
            "start_logit": -6.2090349197387695,
            "end_logit": 6.425304889678955
        },
        {
            "text": "(9 subjects",
            "probability": 1.2670844568730236e-06,
            "start_logit": -2.170802354812622,
            "end_logit": 2.3801519870758057
        },
        {
            "text": "2 doses of RT001 in Friedreich's ataxia patients (9",
            "probability": 8.715244581948697e-07,
            "start_logit": -6.590185165405273,
            "end_logit": 6.425304889678955
        },
        {
            "text": "RT001 in Friedreich's ataxia patients (9",
            "probability": 7.541185627997891e-07,
            "start_logit": -6.734879493713379,
            "end_logit": 6.425304889678955
        },
        {
            "text": "9 subjects each cohor",
            "probability": 4.5984861130997633e-07,
            "start_logit": 7.344411849975586,
            "end_logit": -8.148638725280762
        },
        {
            "text": "in Friedreich's ataxia patients (9",
            "probability": 3.712430799506519e-07,
            "start_logit": -7.443572044372559,
            "end_logit": 6.425304889678955
        },
        {
            "text": "comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9",
            "probability": 3.34583835045483e-07,
            "start_logit": -7.547541618347168,
            "end_logit": 6.425304889678955
        },
        {
            "text": "subjects",
            "probability": 6.466101726022703e-08,
            "start_logit": -5.146117687225342,
            "end_logit": 2.3801519870758057
        },
        {
            "text": "(9 subjects each cohort",
            "probability": 3.9220764278981705e-08,
            "start_logit": -2.170802354812622,
            "end_logit": -1.0951155424118042
        },
        {
            "text": "(9 subjects each cohort)",
            "probability": 3.028962941794221e-08,
            "start_logit": -2.170802354812622,
            "end_logit": -1.3535164594650269
        },
        {
            "text": "Friedreich's ataxia patients (9 subjects",
            "probability": 2.2336927980241336e-08,
            "start_logit": -6.2090349197387695,
            "end_logit": 2.3801519870758057
        },
        {
            "text": "2 doses of RT001 in Friedreich's ataxia patients (9 subjects",
            "probability": 1.525780272717122e-08,
            "start_logit": -6.590185165405273,
            "end_logit": 2.3801519870758057
        },
        {
            "text": "RT001 in Friedreich's ataxia patients (9 subjects",
            "probability": 1.3202374478312482e-08,
            "start_logit": -6.734879493713379,
            "end_logit": 2.3801519870758057
        },
        {
            "text": "in Friedreich's ataxia patients (9 subjects",
            "probability": 6.499362839967447e-09,
            "start_logit": -7.443572044372559,
            "end_logit": 2.3801519870758057
        }
    ],
    "64402e7757b1c7a315000044_002": [
        {
            "text": "Nineteen",
            "probability": 0.9739069447722675,
            "start_logit": 6.172880172729492,
            "end_logit": 5.404084205627441
        },
        {
            "text": "Nineteen patients enrolled in the trial, and 18",
            "probability": 0.02309471458921852,
            "start_logit": 6.172880172729492,
            "end_logit": 1.6623722314834595
        },
        {
            "text": "Nine",
            "probability": 0.0014159383252073856,
            "start_logit": 6.172880172729492,
            "end_logit": -1.129439115524292
        },
        {
            "text": "Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements.",
            "probability": 0.0006005390690246604,
            "start_logit": 6.172880172729492,
            "end_logit": -1.9871591329574585
        },
        {
            "text": "18",
            "probability": 0.0004720095347524793,
            "start_logit": 2.282520294189453,
            "end_logit": 1.6623722314834595
        },
        {
            "text": "Nineteen patients enrolled in the trial,",
            "probability": 0.00026610421283644386,
            "start_logit": 6.172880172729492,
            "end_logit": -2.8010988235473633
        },
        {
            "text": "Nineteen patients",
            "probability": 8.604303086210878e-05,
            "start_logit": 6.172880172729492,
            "end_logit": -3.9301393032073975
        },
        {
            "text": "Nineteen patients enrolled",
            "probability": 7.591835329351574e-05,
            "start_logit": 6.172880172729492,
            "end_logit": -4.055328369140625
        },
        {
            "text": "Nineteen patients enrolled in the trial",
            "probability": 4.128961647028234e-05,
            "start_logit": 6.172880172729492,
            "end_logit": -4.6643757820129395
        },
        {
            "text": "Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements",
            "probability": 1.3542998877560122e-05,
            "start_logit": 6.172880172729492,
            "end_logit": -5.779117107391357
        },
        {
            "text": "Nineteen patients enrolled in the trial, and",
            "probability": 1.2759523776399676e-05,
            "start_logit": 6.172880172729492,
            "end_logit": -5.838708877563477
        },
        {
            "text": "18 completed all safety and efficacy measurements.",
            "probability": 1.2273811199353242e-05,
            "start_logit": 2.282520294189453,
            "end_logit": -1.9871591329574585
        },
        {
            "text": "enrolled in the trial, and 18",
            "probability": 7.001664886319946e-07,
            "start_logit": -4.2309160232543945,
            "end_logit": 1.6623722314834595
        },
        {
            "text": "and 18",
            "probability": 5.465425759856886e-07,
            "start_logit": -4.478621959686279,
            "end_logit": 1.6623722314834595
        },
        {
            "text": "18 completed all safety and efficacy measurements",
            "probability": 2.76791669135185e-07,
            "start_logit": 2.282520294189453,
            "end_logit": -5.779117107391357
        },
        {
            "text": "patients enrolled in the trial, and 18",
            "probability": 1.9900703685360455e-07,
            "start_logit": -5.488893985748291,
            "end_logit": 1.6623722314834595
        },
        {
            "text": "the trial, and 18",
            "probability": 1.3944971430303484e-07,
            "start_logit": -5.84453010559082,
            "end_logit": 1.6623722314834595
        },
        {
            "text": "all safety and efficacy measurements.",
            "probability": 2.7786164304543725e-08,
            "start_logit": -3.808164596557617,
            "end_logit": -1.9871591329574585
        },
        {
            "text": "enrolled in the trial, and 18 completed all safety and efficacy measurements.",
            "probability": 1.8206647656153244e-08,
            "start_logit": -4.2309160232543945,
            "end_logit": -1.9871591329574585
        },
        {
            "text": "and 18 completed all safety and efficacy measurements.",
            "probability": 1.421191712488236e-08,
            "start_logit": -4.478621959686279,
            "end_logit": -1.9871591329574585
        }
    ],
    "64425ce357b1c7a315000059_001": [
        {
            "text": "1:8000",
            "probability": 0.910790106527367,
            "start_logit": 10.042779922485352,
            "end_logit": 10.13814640045166
        },
        {
            "text": "8000",
            "probability": 0.07461661185405964,
            "start_logit": 7.540830612182617,
            "end_logit": 10.13814640045166
        },
        {
            "text": "1:8000 incidence",
            "probability": 0.013172686979566063,
            "start_logit": 10.042779922485352,
            "end_logit": 5.901979446411133
        },
        {
            "text": "8000 incidence",
            "probability": 0.0010791742953564596,
            "start_logit": 7.540830612182617,
            "end_logit": 5.901979446411133
        },
        {
            "text": "approximate 1:8000",
            "probability": 0.00016755960181352183,
            "start_logit": 1.4420512914657593,
            "end_logit": 10.13814640045166
        },
        {
            "text": "1",
            "probability": 0.00011803143064616145,
            "start_logit": 10.042779922485352,
            "end_logit": 1.1870296001434326
        },
        {
            "text": "an approximate 1:8000",
            "probability": 2.114382726769824e-05,
            "start_logit": -0.6279398202896118,
            "end_logit": 10.13814640045166
        },
        {
            "text": "1:800",
            "probability": 1.1900163812374104e-05,
            "start_logit": 10.042779922485352,
            "end_logit": -1.1073691844940186
        },
        {
            "text": "1:8000 incidence.",
            "probability": 9.919817081735651e-06,
            "start_logit": 10.042779922485352,
            "end_logit": -1.2893868684768677
        },
        {
            "text": "with an approximate 1:8000",
            "probability": 4.424881817134882e-06,
            "start_logit": -2.192044258117676,
            "end_logit": 10.13814640045166
        },
        {
            "text": "1:",
            "probability": 3.0927654855492834e-06,
            "start_logit": 10.042779922485352,
            "end_logit": -2.4548556804656982
        },
        {
            "text": "approximate 1:8000 incidence",
            "probability": 2.4234015820899036e-06,
            "start_logit": 1.4420512914657593,
            "end_logit": 5.901979446411133
        },
        {
            "text": "800",
            "probability": 9.749226499321492e-07,
            "start_logit": 7.540830612182617,
            "end_logit": -1.1073691844940186
        },
        {
            "text": "8000 incidence.",
            "probability": 8.1268245619541e-07,
            "start_logit": 7.540830612182617,
            "end_logit": -1.2893868684768677
        },
        {
            "text": "an approximate 1:8000 incidence",
            "probability": 3.058015410480676e-07,
            "start_logit": -0.6279398202896118,
            "end_logit": 5.901979446411133
        },
        {
            "text": "FSHD) is in the top three list of all dystrophies with an approximate 1:8000",
            "probability": 2.9450988556045546e-07,
            "start_logit": -4.901730537414551,
            "end_logit": 10.13814640045166
        },
        {
            "text": "incidence",
            "probability": 2.498436397202556e-07,
            "start_logit": -0.8300408720970154,
            "end_logit": 5.901979446411133
        },
        {
            "text": "in the top three list of all dystrophies with an approximate 1:8000",
            "probability": 1.0136322367545654e-07,
            "start_logit": -5.968332767486572,
            "end_logit": 10.13814640045166
        },
        {
            "text": "top three list of all dystrophies with an approximate 1:8000",
            "probability": 9.718965440367464e-08,
            "start_logit": -6.010378837585449,
            "end_logit": 10.13814640045166
        },
        {
            "text": ":8000",
            "probability": 8.814109460191725e-08,
            "start_logit": -6.108104228973389,
            "end_logit": 10.13814640045166
        }
    ],
    "64425ce357b1c7a315000059_002": [
        {
            "text": "1 in 20000",
            "probability": 0.7460797209991166,
            "start_logit": 9.155120849609375,
            "end_logit": 7.881030559539795
        },
        {
            "text": "1 in 20000.",
            "probability": 0.1730512642893994,
            "start_logit": 9.155120849609375,
            "end_logit": 6.419785976409912
        },
        {
            "text": "20000",
            "probability": 0.053746484482147514,
            "start_logit": 6.524566650390625,
            "end_logit": 7.881030559539795
        },
        {
            "text": "20000.",
            "probability": 0.012466358257654917,
            "start_logit": 6.524566650390625,
            "end_logit": 6.419785976409912
        },
        {
            "text": "about 1 in 20000",
            "probability": 0.005855834235864457,
            "start_logit": 4.307726860046387,
            "end_logit": 7.881030559539795
        },
        {
            "text": "1 in 20000. Overall lifespan is not affected significantly.",
            "probability": 0.004869926862746304,
            "start_logit": 9.155120849609375,
            "end_logit": 2.8492770195007324
        },
        {
            "text": "about 1 in 20000.",
            "probability": 0.0013582456263902304,
            "start_logit": 4.307726860046387,
            "end_logit": 6.419785976409912
        },
        {
            "text": "1",
            "probability": 0.001198652130724736,
            "start_logit": 9.155120849609375,
            "end_logit": 1.4473958015441895
        },
        {
            "text": "It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000",
            "probability": 0.00043837575860540036,
            "start_logit": 1.7156095504760742,
            "end_logit": 7.881030559539795
        },
        {
            "text": "20000. Overall lifespan is not affected significantly.",
            "probability": 0.00035082236011893634,
            "start_logit": 6.524566650390625,
            "end_logit": 2.8492770195007324
        },
        {
            "text": "1 in",
            "probability": 0.00011692051676138653,
            "start_logit": 9.155120849609375,
            "end_logit": -0.8800628185272217
        },
        {
            "text": "It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000.",
            "probability": 0.00010168012495889688,
            "start_logit": 1.7156095504760742,
            "end_logit": 6.419785976409912
        },
        {
            "text": "1 in 2000",
            "probability": 0.00010002449117198663,
            "start_logit": 9.155120849609375,
            "end_logit": -1.036142110824585
        },
        {
            "text": "incidence of about 1 in 20000",
            "probability": 8.33843814585734e-05,
            "start_logit": 0.05599413067102432,
            "end_logit": 7.881030559539795
        },
        {
            "text": "4 per 100000 and an incidence of about 1 in 20000",
            "probability": 6.438511019960732e-05,
            "start_logit": -0.20258449018001556,
            "end_logit": 7.881030559539795
        },
        {
            "text": "about 1 in 20000. Overall lifespan is not affected significantly.",
            "probability": 3.8223106253091107e-05,
            "start_logit": 4.307726860046387,
            "end_logit": 2.8492770195007324
        },
        {
            "text": "around 4 per 100000 and an incidence of about 1 in 20000",
            "probability": 3.173744647757532e-05,
            "start_logit": -0.9099696278572083,
            "end_logit": 7.881030559539795
        },
        {
            "text": "incidence of about 1 in 20000.",
            "probability": 1.9340791911716854e-05,
            "start_logit": 0.05599413067102432,
            "end_logit": 6.419785976409912
        },
        {
            "text": "4 per 100000 and an incidence of about 1 in 20000.",
            "probability": 1.4933960015068613e-05,
            "start_logit": -0.20258449018001556,
            "end_logit": 6.419785976409912
        },
        {
            "text": "an incidence of about 1 in 20000",
            "probability": 1.3685068023746379e-05,
            "start_logit": -1.7511615753173828,
            "end_logit": 7.881030559539795
        }
    ],
    "63f581e933942b094c000007_001": [
        {
            "text": "spinal muscular atrophy",
            "probability": 0.9998870815574765,
            "start_logit": 9.377345085144043,
            "end_logit": 10.612930297851562
        },
        {
            "text": "atrophy-is",
            "probability": 0.00010333614409808343,
            "start_logit": 0.19993466138839722,
            "end_logit": 10.612930297851562
        },
        {
            "text": "spinal",
            "probability": 6.2722381620845695e-06,
            "start_logit": 9.377345085144043,
            "end_logit": -1.366334080696106
        },
        {
            "text": "atrophy",
            "probability": 9.572339294411628e-07,
            "start_logit": -4.481760025024414,
            "end_logit": 10.612930297851562
        },
        {
            "text": "spinal muscular at",
            "probability": 7.51889510760318e-07,
            "start_logit": 9.377345085144043,
            "end_logit": -3.487633228302002
        },
        {
            "text": "spinal muscular atrophy-is presented here as a case study.",
            "probability": 4.714377308787402e-07,
            "start_logit": 9.377345085144043,
            "end_logit": -3.9544355869293213
        },
        {
            "text": "\u22652 months of age with spinal muscular atrophy",
            "probability": 3.237189021028371e-07,
            "start_logit": -5.565932273864746,
            "end_logit": 10.612930297851562
        },
        {
            "text": "patients \u22652 months of age with spinal muscular atrophy",
            "probability": 1.5647545466306516e-07,
            "start_logit": -6.292908668518066,
            "end_logit": 10.612930297851562
        },
        {
            "text": "with spinal muscular atrophy",
            "probability": 1.3566187605979273e-07,
            "start_logit": -6.435642242431641,
            "end_logit": 10.612930297851562
        },
        {
            "text": "muscular atrophy",
            "probability": 1.179149425987483e-07,
            "start_logit": -6.5758442878723145,
            "end_logit": 10.612930297851562
        },
        {
            "text": "European Medicines Agency for the treatment of patients \u22652 months of age with spinal muscular atrophy",
            "probability": 8.10087967550708e-08,
            "start_logit": -6.951250076293945,
            "end_logit": 10.612930297851562
        },
        {
            "text": "treatment of patients \u22652 months of age with spinal muscular atrophy",
            "probability": 7.12333060874188e-08,
            "start_logit": -7.07984733581543,
            "end_logit": 10.612930297851562
        },
        {
            "text": "the treatment of patients \u22652 months of age with spinal muscular atrophy",
            "probability": 6.418531415985626e-08,
            "start_logit": -7.184033393859863,
            "end_logit": 10.612930297851562
        },
        {
            "text": "spinal muscular atrop",
            "probability": 4.269337917437016e-08,
            "start_logit": 9.377345085144043,
            "end_logit": -6.3561787605285645
        },
        {
            "text": "spinal muscular atrophy-",
            "probability": 3.56740859503816e-08,
            "start_logit": 9.377345085144043,
            "end_logit": -6.535798072814941
        },
        {
            "text": "spinal muscular atrophy-is presented here as a case study",
            "probability": 3.552397676998899e-08,
            "start_logit": 9.377345085144043,
            "end_logit": -6.540014743804932
        },
        {
            "text": "spinal muscular",
            "probability": 2.0203249083345583e-08,
            "start_logit": 9.377345085144043,
            "end_logit": -7.104379177093506
        },
        {
            "text": "spinal muscular atrophy-is presented here",
            "probability": 1.892630038090507e-08,
            "start_logit": 9.377345085144043,
            "end_logit": -7.169670104980469
        },
        {
            "text": "spinal muscular atrophy-is",
            "probability": 1.4028014072328733e-08,
            "start_logit": 9.377345085144043,
            "end_logit": -7.469166278839111
        },
        {
            "text": "spinal muscular atrophy-is presented",
            "probability": 1.2251494553892457e-08,
            "start_logit": 9.377345085144043,
            "end_logit": -7.604574680328369
        }
    ],
    "63f581e933942b094c000007_002": [
        {
            "text": "spinal muscular atrophy",
            "probability": 0.9999147074135231,
            "start_logit": 8.873814582824707,
            "end_logit": 9.413650512695312
        },
        {
            "text": "An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy",
            "probability": 2.8368190735224944e-05,
            "start_logit": -1.5963422060012817,
            "end_logit": 9.413650512695312
        },
        {
            "text": "Type 1 or 2 spinal muscular atrophy",
            "probability": 1.9927790083430487e-05,
            "start_logit": -1.9494954347610474,
            "end_logit": 9.413650512695312
        },
        {
            "text": "atrophy.",
            "probability": 1.6067503712525653e-05,
            "start_logit": -2.164811849594116,
            "end_logit": 9.413650512695312
        },
        {
            "text": "spinal",
            "probability": 1.4401330441380066e-05,
            "start_logit": 8.873814582824707,
            "end_logit": -1.7344541549682617
        },
        {
            "text": "spinal muscular atrophy.",
            "probability": 4.245729513576909e-06,
            "start_logit": 8.873814582824707,
            "end_logit": -2.9558610916137695
        },
        {
            "text": "patients with Type 1 or 2 spinal muscular atrophy",
            "probability": 4.418332798081694e-07,
            "start_logit": -5.7584333419799805,
            "end_logit": 9.413650512695312
        },
        {
            "text": "1 or 2 spinal muscular atrophy",
            "probability": 3.805640339131162e-07,
            "start_logit": -5.907711505889893,
            "end_logit": 9.413650512695312
        },
        {
            "text": "spinal muscular at",
            "probability": 2.470201113567244e-07,
            "start_logit": 8.873814582824707,
            "end_logit": -5.800060272216797
        },
        {
            "text": "or 2 spinal muscular atrophy",
            "probability": 2.3975072135668905e-07,
            "start_logit": -6.3697662353515625,
            "end_logit": 9.413650512695312
        },
        {
            "text": "risdiplam for patients with Type 1 or 2 spinal muscular atrophy",
            "probability": 2.2193457261750895e-07,
            "start_logit": -6.446983337402344,
            "end_logit": 9.413650512695312
        },
        {
            "text": "atrophy",
            "probability": 1.9153516286576292e-07,
            "start_logit": -6.594294548034668,
            "end_logit": 9.413650512695312
        },
        {
            "text": "2 spinal muscular atrophy",
            "probability": 1.4383348981112726e-07,
            "start_logit": -6.880709648132324,
            "end_logit": 9.413650512695312
        },
        {
            "text": "expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy",
            "probability": 1.0729112552957178e-07,
            "start_logit": -7.1738200187683105,
            "end_logit": 9.413650512695312
        },
        {
            "text": "for patients with Type 1 or 2 spinal muscular atrophy",
            "probability": 9.54644774074217e-08,
            "start_logit": -7.290611743927002,
            "end_logit": 9.413650512695312
        },
        {
            "text": "with Type 1 or 2 spinal muscular atrophy",
            "probability": 9.327301277373462e-08,
            "start_logit": -7.313835144042969,
            "end_logit": 9.413650512695312
        },
        {
            "text": "spinal muscular atrop",
            "probability": 8.476999544913414e-08,
            "start_logit": 8.873814582824707,
            "end_logit": -6.869588375091553
        },
        {
            "text": "spinal muscular",
            "probability": 3.407642198703407e-08,
            "start_logit": 8.873814582824707,
            "end_logit": -7.780924320220947
        },
        {
            "text": "An expanded access program of risdiplam for patients with Type 1 or 2 spinal",
            "probability": 4.085745371811157e-10,
            "start_logit": -1.5963422060012817,
            "end_logit": -1.7344541549682617
        },
        {
            "text": "Type 1 or 2 spinal",
            "probability": 2.8701116988296637e-10,
            "start_logit": -1.9494954347610474,
            "end_logit": -1.7344541549682617
        }
    ],
    "63f581e933942b094c000007_003": [
        {
            "text": "spinal muscular atrophy",
            "probability": 0.9997792149474206,
            "start_logit": 8.276803970336914,
            "end_logit": 9.580621719360352
        },
        {
            "text": "Type 1 or 2 spinal muscular atrophy",
            "probability": 8.823441252336143e-05,
            "start_logit": -1.0584887266159058,
            "end_logit": 9.580621719360352
        },
        {
            "text": "spinal muscular atrophy (SMA)",
            "probability": 7.17004010115696e-05,
            "start_logit": 8.276803970336914,
            "end_logit": 0.03782831132411957
        },
        {
            "text": "atrophy",
            "probability": 5.1466462361624544e-05,
            "start_logit": -1.59755539894104,
            "end_logit": 9.580621719360352
        },
        {
            "text": "spinal",
            "probability": 5.231113890894316e-06,
            "start_logit": 8.276803970336914,
            "end_logit": -2.5800437927246094
        },
        {
            "text": "spinal muscular atrophy (SMA) who had no satisfactory treatment options access to risdiplam prior to commercial availability.",
            "probability": 1.1601467085760872e-06,
            "start_logit": 8.276803970336914,
            "end_logit": -4.086121559143066
        },
        {
            "text": "spinal muscular atrophy (SMA",
            "probability": 1.1384682809276786e-06,
            "start_logit": 8.276803970336914,
            "end_logit": -4.104984283447266
        },
        {
            "text": "NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy",
            "probability": 6.273177153100956e-07,
            "start_logit": -6.004787921905518,
            "end_logit": 9.580621719360352
        },
        {
            "text": "EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy",
            "probability": 2.9154195642310786e-07,
            "start_logit": -6.77105712890625,
            "end_logit": 9.580621719360352
        },
        {
            "text": "1 or 2 spinal muscular atrophy",
            "probability": 2.627415796177785e-07,
            "start_logit": -6.875070095062256,
            "end_logit": 9.580621719360352
        },
        {
            "text": "or 2 spinal muscular atrophy",
            "probability": 2.2415097389320655e-07,
            "start_logit": -7.033921241760254,
            "end_logit": 9.580621719360352
        },
        {
            "text": "spinal muscular at",
            "probability": 1.7514559880950343e-07,
            "start_logit": 8.276803970336914,
            "end_logit": -5.976805686950684
        },
        {
            "text": "(EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy",
            "probability": 1.559138618124824e-07,
            "start_logit": -7.396937370300293,
            "end_logit": 9.580621719360352
        },
        {
            "text": "spinal muscular atrop",
            "probability": 6.841406713410535e-08,
            "start_logit": 8.276803970336914,
            "end_logit": -6.916844844818115
        },
        {
            "text": "spinal muscular atrophy (SMA) who had no satisfactory treatment options",
            "probability": 3.8151733667892944e-08,
            "start_logit": 8.276803970336914,
            "end_logit": -7.500852108001709
        },
        {
            "text": "Type 1 or 2 spinal muscular atrophy (SMA)",
            "probability": 6.32783985340002e-09,
            "start_logit": -1.0584887266159058,
            "end_logit": 0.03782831132411957
        },
        {
            "text": "atrophy (SMA)",
            "probability": 3.6909809033881573e-09,
            "start_logit": -1.59755539894104,
            "end_logit": 0.03782831132411957
        },
        {
            "text": "Type 1 or 2 spinal",
            "probability": 4.6166618999988865e-10,
            "start_logit": -1.0584887266159058,
            "end_logit": -2.5800437927246094
        },
        {
            "text": "Type 1 or 2 spinal muscular atrophy (SMA",
            "probability": 1.004742631596095e-10,
            "start_logit": -1.0584887266159058,
            "end_logit": -4.104984283447266
        },
        {
            "text": "(SMA)",
            "probability": 8.935426277922222e-11,
            "start_logit": -5.318593978881836,
            "end_logit": 0.03782831132411957
        }
    ],
    "63f581e933942b094c000007_004": [
        {
            "text": "SMA",
            "probability": 0.9995334119121835,
            "start_logit": 1.4365347623825073,
            "end_logit": 4.991489410400391
        },
        {
            "text": "motor neurons. Major advances and developments in SMA",
            "probability": 0.00022215115678565097,
            "start_logit": -6.975151062011719,
            "end_logit": 4.991489410400391
        },
        {
            "text": "Major advances and developments in SMA",
            "probability": 0.00015759945831999577,
            "start_logit": -7.31845235824585,
            "end_logit": 4.991489410400391
        },
        {
            "text": "SMA therapeutics are shifting the natural history of the disease.",
            "probability": 7.201689203032608e-05,
            "start_logit": 1.4365347623825073,
            "end_logit": -4.546653747558594
        },
        {
            "text": "SMA therapeutics are shifting the natural history of the disease. With three relatively new available therapies,",
            "probability": 7.3263149624596106e-06,
            "start_logit": 1.4365347623825073,
            "end_logit": -6.8320817947387695
        },
        {
            "text": "SMA therapeutics are shifting the natural history of the disease. With three relatively new available therapies",
            "probability": 4.798374879230316e-06,
            "start_logit": 1.4365347623825073,
            "end_logit": -7.255277156829834
        },
        {
            "text": "SMN1 produces SMN, a ubiquitously expressed protein,",
            "probability": 1.551226950007011e-06,
            "start_logit": -4.125824451446533,
            "end_logit": -2.8221490383148193
        },
        {
            "text": "SMN1 produces SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons.",
            "probability": 2.776019453165546e-07,
            "start_logit": -4.125824451446533,
            "end_logit": -4.542762279510498
        },
        {
            "text": "SMN1 produces SMN,",
            "probability": 2.3496977260497786e-07,
            "start_logit": -4.125824451446533,
            "end_logit": -4.709493637084961
        },
        {
            "text": "SMN, a ubiquitously expressed protein,",
            "probability": 1.764835210102606e-07,
            "start_logit": -6.299398422241211,
            "end_logit": -2.8221490383148193
        },
        {
            "text": "Evrysdi), patients survive longer and have improved outcomes.",
            "probability": 1.0330873926966938e-07,
            "start_logit": -5.1071906089782715,
            "end_logit": -4.549862384796143
        },
        {
            "text": "Evrysdi",
            "probability": 8.115673539856154e-08,
            "start_logit": -5.1071906089782715,
            "end_logit": -4.791202068328857
        },
        {
            "text": "Evrysdi)",
            "probability": 6.984474890592555e-08,
            "start_logit": -5.1071906089782715,
            "end_logit": -4.941309452056885
        },
        {
            "text": "Evrysdi),",
            "probability": 3.6458414810082353e-08,
            "start_logit": -5.1071906089782715,
            "end_logit": -5.59141206741333
        },
        {
            "text": "SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons.",
            "probability": 3.158285043238964e-08,
            "start_logit": -6.299398422241211,
            "end_logit": -4.542762279510498
        },
        {
            "text": "(Evrysdi), patients survive longer and have improved outcomes.",
            "probability": 3.1112854901652194e-08,
            "start_logit": -6.307291507720947,
            "end_logit": -4.549862384796143
        },
        {
            "text": "SMN1 produces SMN",
            "probability": 2.9437625411933597e-08,
            "start_logit": -4.125824451446533,
            "end_logit": -6.78667688369751
        },
        {
            "text": "SMN,",
            "probability": 2.6732576300404883e-08,
            "start_logit": -6.299398422241211,
            "end_logit": -4.709493637084961
        },
        {
            "text": "(Evrysdi",
            "probability": 2.4441472721452043e-08,
            "start_logit": -6.307291507720947,
            "end_logit": -4.791202068328857
        },
        {
            "text": "SMN1 produces SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons",
            "probability": 2.15326318667399e-08,
            "start_logit": -4.125824451446533,
            "end_logit": -7.099380970001221
        }
    ],
    "6431f7de57b1c7a31500001b_001": [
        {
            "text": "frataxin",
            "probability": 0.9985466131336039,
            "start_logit": 8.338162422180176,
            "end_logit": 6.152126312255859
        },
        {
            "text": "frataxin (FXN",
            "probability": 0.0007341362499054407,
            "start_logit": 8.338162422180176,
            "end_logit": -1.0632351636886597
        },
        {
            "text": "frataxin (FXN) gene",
            "probability": 0.000558059633475094,
            "start_logit": 8.338162422180176,
            "end_logit": -1.3374639749526978
        },
        {
            "text": "f",
            "probability": 5.8877552912270926e-05,
            "start_logit": 8.338162422180176,
            "end_logit": -3.586469888687134
        },
        {
            "text": "frataxin (FXN)",
            "probability": 5.325879412181269e-05,
            "start_logit": 8.338162422180176,
            "end_logit": -3.6867668628692627
        },
        {
            "text": "frataxin (FXN) gene,",
            "probability": 3.943081542962924e-05,
            "start_logit": 8.338162422180176,
            "end_logit": -3.987382173538208
        },
        {
            "text": "frataxin (FXN) gene, which leads to reduced expression of full-length frataxin",
            "probability": 2.873941072864892e-06,
            "start_logit": 8.338162422180176,
            "end_logit": -6.606245517730713
        },
        {
            "text": "frataxin (FXN) gene, which leads to reduced expression of full-length frataxin (1-210)",
            "probability": 2.454847908513641e-06,
            "start_logit": 8.338162422180176,
            "end_logit": -6.763864994049072
        },
        {
            "text": "frataxin (FXN) gene, which leads to reduced expression of full-length frataxin (1-210",
            "probability": 1.684051136853852e-06,
            "start_logit": 8.338162422180176,
            "end_logit": -7.140727519989014
        },
        {
            "text": "the frataxin",
            "probability": 8.450434848359351e-07,
            "start_logit": -5.644260883331299,
            "end_logit": 6.152126312255859
        },
        {
            "text": "an intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin",
            "probability": 4.0579729084587125e-07,
            "start_logit": -6.377795219421387,
            "end_logit": 6.152126312255859
        },
        {
            "text": "guanine-adenine-adenine (GAA) triplet expansion in the frataxin",
            "probability": 3.8520934829526315e-07,
            "start_logit": -6.429862022399902,
            "end_logit": 6.152126312255859
        },
        {
            "text": "intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin",
            "probability": 3.729786894470014e-07,
            "start_logit": -6.462127685546875,
            "end_logit": 6.152126312255859
        },
        {
            "text": "FXN",
            "probability": 2.3441566839642313e-07,
            "start_logit": 0.2888084053993225,
            "end_logit": -1.0632351636886597
        },
        {
            "text": "FXN) gene",
            "probability": 1.7819297440083756e-07,
            "start_logit": 0.2888084053993225,
            "end_logit": -1.3374639749526978
        },
        {
            "text": "GAA) triplet expansion in the frataxin",
            "probability": 1.202335905636687e-07,
            "start_logit": -7.594212532043457,
            "end_logit": 6.152126312255859
        },
        {
            "text": "FXN) gene, which leads to reduced expression of full-length frataxin (1-210) also known as isoform 1.",
            "probability": 3.859516899121632e-08,
            "start_logit": 0.2888084053993225,
            "end_logit": -2.867203950881958
        },
        {
            "text": "FXN)",
            "probability": 1.700596561423072e-08,
            "start_logit": 0.2888084053993225,
            "end_logit": -3.6867668628692627
        },
        {
            "text": "FXN) gene,",
            "probability": 1.2590579685369155e-08,
            "start_logit": 0.2888084053993225,
            "end_logit": -3.987382173538208
        },
        {
            "text": "FXN) gene, which leads to reduced expression of full-length frataxin",
            "probability": 9.176727312053199e-10,
            "start_logit": 0.2888084053993225,
            "end_logit": -6.606245517730713
        }
    ],
    "6431f7de57b1c7a31500001b_002": [
        {
            "text": "frataxin",
            "probability": 0.9981678071167136,
            "start_logit": 7.775629043579102,
            "end_logit": 6.46074914932251
        },
        {
            "text": "frataxin (FXN",
            "probability": 0.00135928152183464,
            "start_logit": 7.775629043579102,
            "end_logit": -0.13821598887443542
        },
        {
            "text": "frataxin (FXN) gene",
            "probability": 0.00031366122927982827,
            "start_logit": 7.775629043579102,
            "end_logit": -1.604614019393921
        },
        {
            "text": "frataxin (FXN) gene.",
            "probability": 9.216468800314386e-05,
            "start_logit": 7.775629043579102,
            "end_logit": -2.829350471496582
        },
        {
            "text": "f",
            "probability": 3.238875151232874e-05,
            "start_logit": 7.775629043579102,
            "end_logit": -3.8751163482666016
        },
        {
            "text": "frataxin (FXN)",
            "probability": 2.409262065970567e-05,
            "start_logit": 7.775629043579102,
            "end_logit": -4.171021938323975
        },
        {
            "text": "FXN",
            "probability": 3.38849593845425e-06,
            "start_logit": 1.7813036441802979,
            "end_logit": -0.13821598887443542
        },
        {
            "text": "FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin",
            "probability": 3.1169589684597045e-06,
            "start_logit": -4.901189804077148,
            "end_logit": 6.46074914932251
        },
        {
            "text": "frataxin (FX",
            "probability": 1.2027225828247184e-06,
            "start_logit": 7.775629043579102,
            "end_logit": -7.168339729309082
        },
        {
            "text": "FXN) gene",
            "probability": 7.819129329667753e-07,
            "start_logit": 1.7813036441802979,
            "end_logit": -1.604614019393921
        },
        {
            "text": "intron 1 of frataxin",
            "probability": 4.813570347167536e-07,
            "start_logit": -6.769193649291992,
            "end_logit": 6.46074914932251
        },
        {
            "text": "GAA hyper expansion in intron 1 of frataxin",
            "probability": 3.500297506803166e-07,
            "start_logit": -7.087784767150879,
            "end_logit": 6.46074914932251
        },
        {
            "text": "(FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin",
            "probability": 3.040522485682557e-07,
            "start_logit": -7.228603363037109,
            "end_logit": 6.46074914932251
        },
        {
            "text": "multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin",
            "probability": 2.781720655407474e-07,
            "start_logit": -7.317563056945801,
            "end_logit": 6.46074914932251
        },
        {
            "text": "FXN) gene.",
            "probability": 2.297534881118969e-07,
            "start_logit": 1.7813036441802979,
            "end_logit": -2.829350471496582
        },
        {
            "text": "by GAA hyper expansion in intron 1 of frataxin",
            "probability": 1.999958633202956e-07,
            "start_logit": -7.647506237030029,
            "end_logit": 6.46074914932251
        },
        {
            "text": "an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin",
            "probability": 1.9800261577465862e-07,
            "start_logit": -7.657522678375244,
            "end_logit": 6.46074914932251
        },
        {
            "text": "FXN)",
            "probability": 6.00594843237066e-08,
            "start_logit": 1.7813036441802979,
            "end_logit": -4.171021938323975
        },
        {
            "text": "(FXN",
            "probability": 9.560806583924092e-09,
            "start_logit": -4.089165687561035,
            "end_logit": -0.13821598887443542
        },
        {
            "text": "FX",
            "probability": 2.998216720762977e-09,
            "start_logit": 1.7813036441802979,
            "end_logit": -7.168339729309082
        }
    ],
    "6431f7de57b1c7a31500001b_003": [
        {
            "text": "frataxin",
            "probability": 0.999754087439059,
            "start_logit": 8.20471477508545,
            "end_logit": 6.239025592803955
        },
        {
            "text": "frataxin.",
            "probability": 0.00015605536780044334,
            "start_logit": 8.20471477508545,
            "end_logit": -2.5260281562805176
        },
        {
            "text": "f",
            "probability": 8.445065437401884e-05,
            "start_logit": 8.20471477508545,
            "end_logit": -3.1400716304779053
        },
        {
            "text": "mitochondrial protein frataxin",
            "probability": 2.120303355842973e-06,
            "start_logit": -4.858990669250488,
            "end_logit": 6.239025592803955
        },
        {
            "text": "decreased expression of the mitochondrial protein frataxin",
            "probability": 1.528694451075497e-06,
            "start_logit": -5.186135768890381,
            "end_logit": 6.239025592803955
        },
        {
            "text": "the mitochondrial protein frataxin",
            "probability": 1.0729824559250457e-06,
            "start_logit": -5.540107727050781,
            "end_logit": 6.239025592803955
        },
        {
            "text": "neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin",
            "probability": 2.560481794597436e-07,
            "start_logit": -6.972939491271973,
            "end_logit": 6.239025592803955
        },
        {
            "text": "a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin",
            "probability": 1.5211960408741375e-07,
            "start_logit": -7.493638038635254,
            "end_logit": 6.239025592803955
        },
        {
            "text": "by decreased expression of the mitochondrial protein frataxin",
            "probability": 1.3803387301572135e-07,
            "start_logit": -7.590806007385254,
            "end_logit": 6.239025592803955
        },
        {
            "text": "in most cases, by decreased expression of the mitochondrial protein frataxin",
            "probability": 1.367760329232624e-07,
            "start_logit": -7.5999603271484375,
            "end_logit": 6.239025592803955
        },
        {
            "text": "mitochondrial protein frataxin.",
            "probability": 3.309661087679812e-10,
            "start_logit": -4.858990669250488,
            "end_logit": -2.5260281562805176
        },
        {
            "text": "decreased expression of the mitochondrial protein frataxin.",
            "probability": 2.386196543873848e-10,
            "start_logit": -5.186135768890381,
            "end_logit": -2.5260281562805176
        },
        {
            "text": "Friedreich ataxia, the most common hereditary ataxia,",
            "probability": 2.2947860725422881e-10,
            "start_logit": -2.0347585678100586,
            "end_logit": -5.716466426849365
        },
        {
            "text": "mitochondrial protein f",
            "probability": 1.791050500539034e-10,
            "start_logit": -4.858990669250488,
            "end_logit": -3.1400716304779053
        },
        {
            "text": "the mitochondrial protein frataxin.",
            "probability": 1.674858586792352e-10,
            "start_logit": -5.540107727050781,
            "end_logit": -2.5260281562805176
        },
        {
            "text": "decreased expression of the mitochondrial protein f",
            "probability": 1.2913100166657396e-10,
            "start_logit": -5.186135768890381,
            "end_logit": -3.1400716304779053
        },
        {
            "text": "Friedreich ataxia,",
            "probability": 1.0987683889400672e-10,
            "start_logit": -2.0347585678100586,
            "end_logit": -6.452916145324707
        },
        {
            "text": "the mitochondrial protein f",
            "probability": 9.063635915390585e-11,
            "start_logit": -5.540107727050781,
            "end_logit": -3.1400716304779053
        },
        {
            "text": "Friedreich ataxia, the most common hereditary ataxia",
            "probability": 5.592995057369675e-11,
            "start_logit": -2.0347585678100586,
            "end_logit": -7.128176212310791
        },
        {
            "text": "Friedreich ataxia",
            "probability": 4.9585083846455206e-11,
            "start_logit": -2.0347585678100586,
            "end_logit": -7.248586177825928
        }
    ],
    "6431f7de57b1c7a31500001b_004": [
        {
            "text": "Frataxin",
            "probability": 0.9998401219837565,
            "start_logit": 3.36080265045166,
            "end_logit": 5.417847156524658
        },
        {
            "text": "Simultaneous Quantification of Mitochondrial Mature Frataxin",
            "probability": 4.5111641519496456e-05,
            "start_logit": -6.645407676696777,
            "end_logit": 5.417847156524658
        },
        {
            "text": "Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood.",
            "probability": 3.611492793730794e-05,
            "start_logit": 3.36080265045166,
            "end_logit": -4.810797214508057
        },
        {
            "text": "Mitochondrial Mature Frataxin",
            "probability": 2.60802952686661e-05,
            "start_logit": -7.193367958068848,
            "end_logit": 5.417847156524658
        },
        {
            "text": "Frataxin and Extra-Mitochondrial Frataxin",
            "probability": 2.0339848859520943e-05,
            "start_logit": 3.36080265045166,
            "end_logit": -5.384921550750732
        },
        {
            "text": "Quantification of Mitochondrial Mature Frataxin",
            "probability": 1.3489629650053794e-05,
            "start_logit": -7.852626800537109,
            "end_logit": 5.417847156524658
        },
        {
            "text": "Frataxin and Extra-Mitochondrial Frataxin Isoform E",
            "probability": 1.0991010320251386e-05,
            "start_logit": 3.36080265045166,
            "end_logit": -6.000425815582275
        },
        {
            "text": "Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood",
            "probability": 3.2567134952122233e-06,
            "start_logit": 3.36080265045166,
            "end_logit": -7.216784954071045
        },
        {
            "text": "Fr",
            "probability": 2.2926322339679484e-06,
            "start_logit": 3.36080265045166,
            "end_logit": -7.567802906036377
        },
        {
            "text": "Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia",
            "probability": 2.1897343445145522e-06,
            "start_logit": 3.36080265045166,
            "end_logit": -7.613723278045654
        },
        {
            "text": "Frataxin Isoform E in Friedreich's Ataxia Blood.",
            "probability": 3.6022479297205988e-09,
            "start_logit": -5.852100849151611,
            "end_logit": -4.810797214508057
        },
        {
            "text": "Friedreich's Ataxia Blood.",
            "probability": 3.063083222169245e-09,
            "start_logit": -6.014236927032471,
            "end_logit": -4.810797214508057
        },
        {
            "text": "Frataxin Isoform E",
            "probability": 1.096287503062219e-09,
            "start_logit": -5.852100849151611,
            "end_logit": -6.000425815582275
        },
        {
            "text": "Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin",
            "probability": 9.177106920763823e-10,
            "start_logit": -6.645407676696777,
            "end_logit": -5.384921550750732
        },
        {
            "text": "Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood.",
            "probability": 6.29950936170335e-10,
            "start_logit": -7.5957722663879395,
            "end_logit": -4.810797214508057
        },
        {
            "text": "Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood.",
            "probability": 5.415495082318765e-10,
            "start_logit": -7.746979713439941,
            "end_logit": -4.810797214508057
        },
        {
            "text": "Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin",
            "probability": 5.305540879114328e-10,
            "start_logit": -7.193367958068848,
            "end_logit": -5.384921550750732
        },
        {
            "text": "Ataxia Blood.",
            "probability": 4.3774659219348376e-10,
            "start_logit": -7.959774017333984,
            "end_logit": -4.810797214508057
        },
        {
            "text": "in Friedreich's Ataxia Blood.",
            "probability": 4.0869725815790583e-10,
            "start_logit": -8.02843952178955,
            "end_logit": -4.810797214508057
        },
        {
            "text": "Extra-Mitochondrial Frataxin",
            "probability": 3.547869970240746e-10,
            "start_logit": -7.5957722663879395,
            "end_logit": -5.384921550750732
        }
    ],
    "6431f7de57b1c7a31500001b_005": [
        {
            "text": "frataxin",
            "probability": 0.9999413999560475,
            "start_logit": 9.310748100280762,
            "end_logit": 9.693062782287598
        },
        {
            "text": "frataxin proteoforms in whole blood from healthy controls and FRDA patients.",
            "probability": 2.706362002392521e-05,
            "start_logit": 9.310748100280762,
            "end_logit": -0.8241987824440002
        },
        {
            "text": "f",
            "probability": 2.009841757040593e-05,
            "start_logit": 9.310748100280762,
            "end_logit": -1.1217480897903442
        },
        {
            "text": "We now report a quantitative assay for frataxin",
            "probability": 5.747258091620363e-06,
            "start_logit": -2.755980968475342,
            "end_logit": 9.693062782287598
        },
        {
            "text": "frataxin proteoforms in whole blood from healthy controls and FRDA",
            "probability": 3.82687940557444e-06,
            "start_logit": 9.310748100280762,
            "end_logit": -2.780339479446411
        },
        {
            "text": "now report a quantitative assay for frataxin",
            "probability": 3.9220880613542167e-07,
            "start_logit": -5.440664768218994,
            "end_logit": 9.693062782287598
        },
        {
            "text": "a quantitative assay for frataxin",
            "probability": 2.972697337349469e-07,
            "start_logit": -5.7178192138671875,
            "end_logit": 9.693062782287598
        },
        {
            "text": "frataxin proteoforms",
            "probability": 2.404235323321094e-07,
            "start_logit": 9.310748100280762,
            "end_logit": -5.5477423667907715
        },
        {
            "text": "report a quantitative assay for frataxin",
            "probability": 2.1085109669314127e-07,
            "start_logit": -6.061306953430176,
            "end_logit": 9.693062782287598
        },
        {
            "text": "frataxin proteoforms in whole blood",
            "probability": 2.0096693693929472e-07,
            "start_logit": 9.310748100280762,
            "end_logit": -5.727004051208496
        },
        {
            "text": "frataxin proteoforms in whole blood from healthy controls",
            "probability": 1.5842603500736555e-07,
            "start_logit": 9.310748100280762,
            "end_logit": -5.9648566246032715
        },
        {
            "text": "frataxin proteoforms in whole blood from healthy controls and FRDA patients",
            "probability": 1.2526902788795393e-07,
            "start_logit": 9.310748100280762,
            "end_logit": -6.199680805206299
        },
        {
            "text": "quantitative assay for frataxin",
            "probability": 9.289679387790504e-08,
            "start_logit": -6.880970001220703,
            "end_logit": 9.693062782287598
        },
        {
            "text": "assay for frataxin",
            "probability": 7.931238144727316e-08,
            "start_logit": -7.039064884185791,
            "end_logit": 9.693062782287598
        },
        {
            "text": "frataxin proteoforms in whole blood from",
            "probability": 6.512024195693583e-08,
            "start_logit": 9.310748100280762,
            "end_logit": -6.853909015655518
        },
        {
            "text": "FRDA patients.",
            "probability": 7.282367514065405e-10,
            "start_logit": -1.2123266458511353,
            "end_logit": -0.8241987824440002
        },
        {
            "text": "We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and FRDA patients.",
            "probability": 1.5555072445033269e-10,
            "start_logit": -2.755980968475342,
            "end_logit": -0.8241987824440002
        },
        {
            "text": "We now report a quantitative assay for f",
            "probability": 1.1551756234451106e-10,
            "start_logit": -2.755980968475342,
            "end_logit": -1.1217480897903442
        },
        {
            "text": "FRDA",
            "probability": 1.0297492441426631e-10,
            "start_logit": -1.2123266458511353,
            "end_logit": -2.780339479446411
        },
        {
            "text": "We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and FRDA",
            "probability": 2.1995352557969677e-11,
            "start_logit": -2.755980968475342,
            "end_logit": -2.780339479446411
        }
    ],
    "6431f7de57b1c7a31500001b_006": [
        {
            "text": "frataxin",
            "probability": 0.9996220818580291,
            "start_logit": 8.462174415588379,
            "end_logit": 6.387610912322998
        },
        {
            "text": "f",
            "probability": 0.00022021364660769274,
            "start_logit": 8.462174415588379,
            "end_logit": -2.032923460006714
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA",
            "probability": 0.00013651197011882956,
            "start_logit": 8.462174415588379,
            "end_logit": -2.5111093521118164
        },
        {
            "text": "frataxin in whole blood from healthy controls",
            "probability": 5.3984603083162835e-06,
            "start_logit": 8.462174415588379,
            "end_logit": -5.741407871246338
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA patients",
            "probability": 4.564781180841185e-06,
            "start_logit": 8.462174415588379,
            "end_logit": -5.909151077270508
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001",
            "probability": 4.204581734968295e-06,
            "start_logit": 8.462174415588379,
            "end_logit": -5.991346836090088
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous",
            "probability": 3.945748431716577e-06,
            "start_logit": 8.462174415588379,
            "end_logit": -6.054883003234863
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001)",
            "probability": 2.3225364844234983e-06,
            "start_logit": 8.462174415588379,
            "end_logit": -6.584861755371094
        },
        {
            "text": "The mean levels of mature frataxin",
            "probability": 4.78722213025306e-07,
            "start_logit": -6.089592933654785,
            "end_logit": 6.387610912322998
        },
        {
            "text": "mature frataxin",
            "probability": 2.6798647566021785e-07,
            "start_logit": -6.669776916503906,
            "end_logit": 6.387610912322998
        },
        {
            "text": "FRDA",
            "probability": 7.82438942853446e-09,
            "start_logit": -1.304747462272644,
            "end_logit": -2.5111093521118164
        },
        {
            "text": "homozygous FRDA",
            "probability": 3.2816213865589365e-10,
            "start_logit": -4.476240634918213,
            "end_logit": -2.5111093521118164
        },
        {
            "text": "FRDA patients",
            "probability": 2.6163731710747833e-10,
            "start_logit": -1.304747462272644,
            "end_logit": -5.909151077270508
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001) at 7.5 \u00b1 1.5",
            "probability": 2.468233920323095e-10,
            "start_logit": -1.304747462272644,
            "end_logit": -5.967437267303467
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001",
            "probability": 2.4099194268354665e-10,
            "start_logit": -1.304747462272644,
            "end_logit": -5.991346836090088
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001) at 7.5 \u00b1 1.5 ng/mL",
            "probability": 1.9691617703252824e-10,
            "start_logit": -1.304747462272644,
            "end_logit": -6.193332195281982
        },
        {
            "text": "2.1 \u00b1 1.2 ng/mL, respectively.",
            "probability": 1.9054927612866127e-10,
            "start_logit": -5.4587907791137695,
            "end_logit": -2.0721561908721924
        },
        {
            "text": "7.5 \u00b1 1.5 ng/mL and 2.1 \u00b1 1.2 ng/mL, respectively.",
            "probability": 1.755641511609926e-10,
            "start_logit": -5.54069709777832,
            "end_logit": -2.0721561908721924
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001)",
            "probability": 1.3311968100885408e-10,
            "start_logit": -1.304747462272644,
            "end_logit": -6.584861755371094
        },
        {
            "text": "1.5 ng/mL and 2.1 \u00b1 1.2 ng/mL, respectively.",
            "probability": 1.1026168969531138e-10,
            "start_logit": -6.005845069885254,
            "end_logit": -2.0721561908721924
        }
    ],
    "6431f7de57b1c7a31500001b_007": [
        {
            "text": "frataxin",
            "probability": 0.9996514253695962,
            "start_logit": 8.304195404052734,
            "end_logit": 6.4340643882751465
        },
        {
            "text": "f",
            "probability": 0.0001828677730634018,
            "start_logit": 8.304195404052734,
            "end_logit": -2.1723341941833496
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA",
            "probability": 0.00013897260096776216,
            "start_logit": 8.304195404052734,
            "end_logit": -2.4468207359313965
        },
        {
            "text": "frataxin in whole blood from healthy controls",
            "probability": 6.443449477101654e-06,
            "start_logit": 8.304195404052734,
            "end_logit": -5.518033504486084
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001",
            "probability": 4.957018972609508e-06,
            "start_logit": 8.304195404052734,
            "end_logit": -5.780292987823486
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA patients",
            "probability": 4.8051834151958804e-06,
            "start_logit": 8.304195404052734,
            "end_logit": -5.811402320861816
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous",
            "probability": 4.327645956447362e-06,
            "start_logit": 8.304195404052734,
            "end_logit": -5.916073799133301
        },
        {
            "text": "frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p < 0.0001)",
            "probability": 2.9544041621976277e-06,
            "start_logit": 8.304195404052734,
            "end_logit": -6.297800540924072
        },
        {
            "text": "frataxin in whole blood",
            "probability": 2.022938102139611e-06,
            "start_logit": 8.304195404052734,
            "end_logit": -6.676546573638916
        },
        {
            "text": "he mean levels of total frataxin",
            "probability": 8.26537840622345e-07,
            "start_logit": -5.701476097106934,
            "end_logit": 6.4340643882751465
        },
        {
            "text": "total frataxin",
            "probability": 3.835171479380586e-07,
            "start_logit": -6.469337463378906,
            "end_logit": 6.4340643882751465
        },
        {
            "text": "FRDA",
            "probability": 1.0171741752281455e-08,
            "start_logit": -1.218223214149475,
            "end_logit": -2.4468207359313965
        },
        {
            "text": "6.8 \u00b1 4.0 ng/mL, respectively.",
            "probability": 8.621607679862745e-10,
            "start_logit": -4.257089614868164,
            "end_logit": -1.875881314277649
        },
        {
            "text": "homozygous FRDA",
            "probability": 6.415921397523299e-10,
            "start_logit": -3.9816391468048096,
            "end_logit": -2.4468207359313965
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001) at 34.2 \u00b1 4.3",
            "probability": 5.013543798934551e-10,
            "start_logit": -1.218223214149475,
            "end_logit": -5.456876277923584
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001",
            "probability": 3.628162421903571e-10,
            "start_logit": -1.218223214149475,
            "end_logit": -5.780292987823486
        },
        {
            "text": "FRDA patients",
            "probability": 3.5170302945583116e-10,
            "start_logit": -1.218223214149475,
            "end_logit": -5.811402320861816
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001) at 34.2 \u00b1 4.3 ng/mL",
            "probability": 2.7078907596819854e-10,
            "start_logit": -1.218223214149475,
            "end_logit": -6.072849273681641
        },
        {
            "text": "FRDA patients were significantly different (p < 0.0001)",
            "probability": 2.162400067385285e-10,
            "start_logit": -1.218223214149475,
            "end_logit": -6.297800540924072
        },
        {
            "text": "34.2 \u00b1 4.3 ng/mL and 6.8 \u00b1 4.0 ng/mL, respectively.",
            "probability": 1.8290068004105684e-10,
            "start_logit": -5.80758810043335,
            "end_logit": -1.875881314277649
        }
    ],
    "643f9eeb57b1c7a31500003c_001": [
        {
            "text": "1:5,000 live male births",
            "probability": 0.8444512150232197,
            "start_logit": 9.099217414855957,
            "end_logit": 7.027109622955322
        },
        {
            "text": "1:5,000",
            "probability": 0.14975108470818005,
            "start_logit": 9.099217414855957,
            "end_logit": 5.297397136688232
        },
        {
            "text": "5,000 live male births",
            "probability": 0.002974248075663997,
            "start_logit": 3.45052170753479,
            "end_logit": 7.027109622955322
        },
        {
            "text": "1",
            "probability": 0.0012193522930520127,
            "start_logit": 9.099217414855957,
            "end_logit": 0.48674246668815613
        },
        {
            "text": "1:5,000 live male births.",
            "probability": 0.0007546174714682635,
            "start_logit": 9.099217414855957,
            "end_logit": 0.006878337822854519
        },
        {
            "text": "5,000",
            "probability": 0.0005274394394821892,
            "start_logit": 3.45052170753479,
            "end_logit": 5.297397136688232
        },
        {
            "text": "overall incidence of 1:5,000 live male births",
            "probability": 0.00016922605621638278,
            "start_logit": 0.5840106010437012,
            "end_logit": 7.027109622955322
        },
        {
            "text": "1:5,000 live male",
            "probability": 6.315832919657474e-05,
            "start_logit": 9.099217414855957,
            "end_logit": -2.4736878871917725
        },
        {
            "text": "overall incidence of 1:5,000",
            "probability": 3.0009768508171258e-05,
            "start_logit": 0.5840106010437012,
            "end_logit": 5.297397136688232
        },
        {
            "text": "1:",
            "probability": 1.6612888794227397e-05,
            "start_logit": 9.099217414855957,
            "end_logit": -3.8091537952423096
        },
        {
            "text": "1:5",
            "probability": 9.627728458159243e-06,
            "start_logit": 9.099217414855957,
            "end_logit": -4.354685306549072
        },
        {
            "text": "incidence of 1:5,000 live male births",
            "probability": 6.725222596302876e-06,
            "start_logit": -2.641359806060791,
            "end_logit": 7.027109622955322
        },
        {
            "text": "births",
            "probability": 4.8060890003951565e-06,
            "start_logit": -2.9773411750793457,
            "end_logit": 7.027109622955322
        },
        {
            "text": "an overall incidence of 1:5,000 live male births",
            "probability": 4.58245658166534e-06,
            "start_logit": -3.024989604949951,
            "end_logit": 7.027109622955322
        },
        {
            "text": "1:5,",
            "probability": 4.028374043166073e-06,
            "start_logit": 9.099217414855957,
            "end_logit": -5.2259697914123535
        },
        {
            "text": "X-linked muscular disease with an overall incidence of 1:5,000 live male births",
            "probability": 3.828501899410451e-06,
            "start_logit": -3.2047512531280518,
            "end_logit": 7.027109622955322
        },
        {
            "text": "with an overall incidence of 1:5,000 live male births",
            "probability": 2.967687204908702e-06,
            "start_logit": -3.459441900253296,
            "end_logit": 7.027109622955322
        },
        {
            "text": "5,000 live male births.",
            "probability": 2.657843961199344e-06,
            "start_logit": 3.45052170753479,
            "end_logit": 0.006878337822854519
        },
        {
            "text": "000 live male births",
            "probability": 2.61942250801848e-06,
            "start_logit": -3.58427095413208,
            "end_logit": 7.027109622955322
        },
        {
            "text": "incidence of 1:5,000",
            "probability": 1.1926199652310597e-06,
            "start_logit": -2.641359806060791,
            "end_logit": 5.297397136688232
        }
    ],
    "643f9eeb57b1c7a31500003c_002": [
        {
            "text": "19.7",
            "probability": 0.8834507730512673,
            "start_logit": 8.438521385192871,
            "end_logit": 7.530220985412598
        },
        {
            "text": "The cumulative incidence of disease was 19.7",
            "probability": 0.07329975420415798,
            "start_logit": 5.949243068695068,
            "end_logit": 7.530220985412598
        },
        {
            "text": "19.7 per 100,000 male live births",
            "probability": 0.027985410474634806,
            "start_logit": 8.438521385192871,
            "end_logit": 4.078068733215332
        },
        {
            "text": "7",
            "probability": 0.0034826030157781634,
            "start_logit": 2.9024658203125,
            "end_logit": 7.530220985412598
        },
        {
            "text": "19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD.",
            "probability": 0.0030321857451666837,
            "start_logit": 8.438521385192871,
            "end_logit": 1.8556691408157349
        },
        {
            "text": "19.7 per 100,000 male live births and 1 in 5076",
            "probability": 0.0028478413406825462,
            "start_logit": 8.438521385192871,
            "end_logit": 1.792946696281433
        },
        {
            "text": "The cumulative incidence of disease was 19.7 per 100,000 male live births",
            "probability": 0.002321944551600001,
            "start_logit": 5.949243068695068,
            "end_logit": 4.078068733215332
        },
        {
            "text": "19",
            "probability": 0.0018606210479129549,
            "start_logit": 8.438521385192871,
            "end_logit": 1.367295742034912
        },
        {
            "text": "19.7 per 100,000",
            "probability": 0.0002573753756152223,
            "start_logit": 8.438521385192871,
            "end_logit": -0.6108342409133911
        },
        {
            "text": "cumulative incidence of disease was 19.7",
            "probability": 0.00023911810900101828,
            "start_logit": 0.22388814389705658,
            "end_logit": 7.530220985412598
        },
        {
            "text": "The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076",
            "probability": 0.00023628489175860022,
            "start_logit": 5.949243068695068,
            "end_logit": 1.792946696281433
        },
        {
            "text": ".7",
            "probability": 0.00021558614453530338,
            "start_logit": 0.12029110640287399,
            "end_logit": 7.530220985412598
        },
        {
            "text": "The cumulative incidence of disease was 19",
            "probability": 0.00015437539887826668,
            "start_logit": 5.949243068695068,
            "end_logit": 1.367295742034912
        },
        {
            "text": "1 in 5076 live born males were diagnosed with DMD.",
            "probability": 0.00015014093995538723,
            "start_logit": 5.433056831359863,
            "end_logit": 1.8556691408157349
        },
        {
            "text": "1 in 5076",
            "probability": 0.00014101298919944071,
            "start_logit": 5.433056831359863,
            "end_logit": 1.792946696281433
        },
        {
            "text": "7 per 100,000 male live births",
            "probability": 0.0001103197573534719,
            "start_logit": 2.9024658203125,
            "end_logit": 4.078068733215332
        },
        {
            "text": "19.7 per",
            "probability": 9.871370861789743e-05,
            "start_logit": 8.438521385192871,
            "end_logit": -1.5691460371017456
        },
        {
            "text": "19.7 per 100,000 male live births and",
            "probability": 6.0518116727712523e-05,
            "start_logit": 8.438521385192871,
            "end_logit": -2.058427095413208
        },
        {
            "text": "19.",
            "probability": 3.172048385370505e-05,
            "start_logit": 8.438521385192871,
            "end_logit": -2.704407215118408
        },
        {
            "text": "19.7 per 100,000 male live births and 1 in 5076 live born males",
            "probability": 2.370065330371528e-05,
            "start_logit": 8.438521385192871,
            "end_logit": -2.9958672523498535
        }
    ],
    "6415c252690f196b51000011_001": [
        {
            "text": "Cancer",
            "probability": 0.5697079764477438,
            "start_logit": 0.9633548855781555,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "Non-muscle Invasive Bladder Cancer",
            "probability": 0.2869561808787542,
            "start_logit": 0.2775605022907257,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer",
            "probability": 0.08203551440243899,
            "start_logit": -0.9746167659759521,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "Treatment of Non-muscle Invasive Bladder Cancer",
            "probability": 0.04496074024391541,
            "start_logit": -1.5759793519973755,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "Bladder Cancer",
            "probability": 0.009177267318644385,
            "start_logit": -3.165039539337158,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "the Treatment of Non-muscle Invasive Bladder Cancer",
            "probability": 0.004004944375482357,
            "start_logit": -3.994239330291748,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "for the Treatment of Non-muscle Invasive Bladder Cancer",
            "probability": 0.0013042581065547028,
            "start_logit": -5.1161346435546875,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "muscle Invasive Bladder Cancer",
            "probability": 0.0005482356542826433,
            "start_logit": -5.982819080352783,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "of Non-muscle Invasive Bladder Cancer",
            "probability": 0.0005451769877991844,
            "start_logit": -5.9884138107299805,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "Invasive Bladder Cancer",
            "probability": 0.00040726885566353364,
            "start_logit": -6.280050754547119,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "-muscle Invasive Bladder Cancer",
            "probability": 0.00023790708104607776,
            "start_logit": -6.817644119262695,
            "end_logit": 7.7853827476501465
        },
        {
            "text": "Cancer: History and Current Status.",
            "probability": 6.259246378179648e-05,
            "start_logit": 0.9633548855781555,
            "end_logit": -1.3308515548706055
        },
        {
            "text": "Non-muscle Invasive Bladder Cancer: History and Current Status.",
            "probability": 3.15271948105918e-05,
            "start_logit": 0.2775605022907257,
            "end_logit": -1.3308515548706055
        },
        {
            "text": "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status.",
            "probability": 9.013047344136481e-06,
            "start_logit": -0.9746167659759521,
            "end_logit": -1.3308515548706055
        },
        {
            "text": "Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status.",
            "probability": 4.939729864530282e-06,
            "start_logit": -1.5759793519973755,
            "end_logit": -1.3308515548706055
        },
        {
            "text": "Non-muscle Invasive Bladder",
            "probability": 3.472231539190083e-06,
            "start_logit": 0.2775605022907257,
            "end_logit": -3.5369045734405518
        },
        {
            "text": "Bladder Cancer: History and Current Status.",
            "probability": 1.0082845879037859e-06,
            "start_logit": -3.165039539337158,
            "end_logit": -1.3308515548706055
        },
        {
            "text": "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder",
            "probability": 9.926473776223876e-07,
            "start_logit": -0.9746167659759521,
            "end_logit": -3.5369045734405518
        },
        {
            "text": "Treatment of Non-muscle Invasive Bladder",
            "probability": 5.440346321246092e-07,
            "start_logit": -1.5759793519973755,
            "end_logit": -3.5369045734405518
        },
        {
            "text": "the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status.",
            "probability": 4.4001373709655687e-07,
            "start_logit": -3.994239330291748,
            "end_logit": -1.3308515548706055
        }
    ],
    "6415c252690f196b51000011_002": [
        {
            "text": "bladder cancer",
            "probability": 0.9922772385158208,
            "start_logit": 9.70593547821045,
            "end_logit": 10.324115753173828
        },
        {
            "text": "bladder",
            "probability": 0.007211899639680274,
            "start_logit": 9.70593547821045,
            "end_logit": 5.399845600128174
        },
        {
            "text": "non-muscle invasive bladder cancer",
            "probability": 0.0003613011079458993,
            "start_logit": 1.7878893613815308,
            "end_logit": 10.324115753173828
        },
        {
            "text": "cancer",
            "probability": 0.0001416809113529975,
            "start_logit": 0.8517550826072693,
            "end_logit": 10.324115753173828
        },
        {
            "text": "non-muscle invasive bladder",
            "probability": 2.625946891726037e-06,
            "start_logit": 1.7878893613815308,
            "end_logit": 5.399845600128174
        },
        {
            "text": "bladder cancer,",
            "probability": 1.3334397659399935e-06,
            "start_logit": 9.70593547821045,
            "end_logit": -3.195880174636841
        },
        {
            "text": "bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines.",
            "probability": 1.2935812651606105e-06,
            "start_logit": 9.70593547821045,
            "end_logit": -3.2262275218963623
        },
        {
            "text": "bladder cancer, especially for intermediate and high-risk groups,",
            "probability": 8.800517997103618e-07,
            "start_logit": 9.70593547821045,
            "end_logit": -3.6114165782928467
        },
        {
            "text": "In the past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer",
            "probability": 6.663780498267248e-07,
            "start_logit": -4.507720470428467,
            "end_logit": 10.324115753173828
        },
        {
            "text": "bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer",
            "probability": 3.3807807764487756e-07,
            "start_logit": -5.186300754547119,
            "end_logit": 10.324115753173828
        },
        {
            "text": "the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer",
            "probability": 2.0268943745700143e-07,
            "start_logit": -5.697902679443359,
            "end_logit": 10.324115753173828
        },
        {
            "text": "muscle invasive bladder cancer",
            "probability": 1.3496002497329493e-07,
            "start_logit": -6.1045989990234375,
            "end_logit": 10.324115753173828
        },
        {
            "text": "BCG) treatment for non-muscle invasive bladder cancer",
            "probability": 1.3361915855605894e-07,
            "start_logit": -6.114583969116211,
            "end_logit": 10.324115753173828
        },
        {
            "text": "the past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer",
            "probability": 5.174550513268801e-08,
            "start_logit": -7.063240051269531,
            "end_logit": 10.324115753173828
        },
        {
            "text": "(BCG) treatment for non-muscle invasive bladder cancer",
            "probability": 4.9269248045297213e-08,
            "start_logit": -7.112277507781982,
            "end_logit": 10.324115753173828
        },
        {
            "text": "past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer",
            "probability": 4.624296677707603e-08,
            "start_logit": -7.175668239593506,
            "end_logit": 10.324115753173828
        },
        {
            "text": "for non-muscle invasive bladder cancer",
            "probability": 4.432241034289041e-08,
            "start_logit": -7.218087196350098,
            "end_logit": 10.324115753173828
        },
        {
            "text": "bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer,",
            "probability": 4.404536023500591e-08,
            "start_logit": -7.224357604980469,
            "end_logit": 10.324115753173828
        },
        {
            "text": "bladder cancer, especially for intermediate and high-risk groups",
            "probability": 2.430965250829168e-08,
            "start_logit": 9.70593547821045,
            "end_logit": -7.200523853302002
        },
        {
            "text": "bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines",
            "probability": 1.1145585665714731e-08,
            "start_logit": 9.70593547821045,
            "end_logit": -7.980353832244873
        }
    ],
    "63eeed0af36125a426000007_001": [
        {
            "text": "Multiple Myeloma",
            "probability": 0.9994095387409436,
            "start_logit": 8.825867652893066,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Multiple Myeloma.",
            "probability": 0.0004887565845602002,
            "start_logit": 8.825867652893066,
            "end_logit": 1.775915265083313
        },
        {
            "text": "Myeloma.",
            "probability": 6.464502392308027e-05,
            "start_logit": -0.8201411366462708,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Multiple",
            "probability": 2.4192141722537512e-05,
            "start_logit": 8.825867652893066,
            "end_logit": -1.2299214601516724
        },
        {
            "text": "Teclistamab in Relapsed or Refractory Multiple Myeloma",
            "probability": 6.617426746338918e-06,
            "start_logit": -3.0993456840515137,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Relapsed or Refractory Multiple Myeloma",
            "probability": 4.567955957001282e-06,
            "start_logit": -3.4699864387512207,
            "end_logit": 9.398970603942871
        },
        {
            "text": "in Relapsed or Refractory Multiple Myeloma",
            "probability": 4.890019503177365e-07,
            "start_logit": -5.704441070556641,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Multiple Myelo",
            "probability": 3.5405536810718584e-07,
            "start_logit": 8.825867652893066,
            "end_logit": -5.454251289367676
        },
        {
            "text": "Refractory Multiple Myeloma",
            "probability": 1.9769357804989432e-07,
            "start_logit": -6.610089302062988,
            "end_logit": 9.398970603942871
        },
        {
            "text": "or Refractory Multiple Myeloma",
            "probability": 1.7328028746830213e-07,
            "start_logit": -6.741897106170654,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Myeloma",
            "probability": 1.6005446993131015e-07,
            "start_logit": -6.821293354034424,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Relapsed or Refractory Multiple Myeloma.",
            "probability": 1.404997298908205e-07,
            "start_logit": -6.951601982116699,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Refractory Multiple Myeloma.",
            "probability": 8.925682590289992e-08,
            "start_logit": -7.405289649963379,
            "end_logit": 9.398970603942871
        },
        {
            "text": "Multiple My",
            "probability": 7.441815195843009e-08,
            "start_logit": 8.825867652893066,
            "end_logit": -7.014004707336426
        },
        {
            "text": "Teclistamab in Relapsed or Refractory Multiple Myeloma.",
            "probability": 3.236221758692151e-09,
            "start_logit": -3.0993456840515137,
            "end_logit": 1.775915265083313
        },
        {
            "text": "in Relapsed or Refractory Multiple Myeloma.",
            "probability": 2.3914412842373864e-10,
            "start_logit": -5.704441070556641,
            "end_logit": 1.775915265083313
        },
        {
            "text": "Teclistamab in Relapsed or Refractory Multiple",
            "probability": 1.6018430831430973e-10,
            "start_logit": -3.0993456840515137,
            "end_logit": -1.2299214601516724
        },
        {
            "text": "Relapsed or Refractory Multiple",
            "probability": 1.1057392751454352e-10,
            "start_logit": -3.4699864387512207,
            "end_logit": -1.2299214601516724
        },
        {
            "text": "or Refractory Multiple Myeloma.",
            "probability": 8.474191829438798e-11,
            "start_logit": -6.741897106170654,
            "end_logit": 1.775915265083313
        },
        {
            "text": ".",
            "probability": 3.491949167147384e-11,
            "start_logit": -7.628462314605713,
            "end_logit": 1.775915265083313
        }
    ],
    "63eeed0af36125a426000007_002": [
        {
            "text": "multiple myeloma",
            "probability": 0.9997643305941385,
            "start_logit": 9.138642311096191,
            "end_logit": 9.925308227539062
        },
        {
            "text": "myeloma.",
            "probability": 0.0002055438923544879,
            "start_logit": 0.6490270495414734,
            "end_logit": 9.925308227539062
        },
        {
            "text": "multiple",
            "probability": 2.5124245816529735e-05,
            "start_logit": 9.138642311096191,
            "end_logit": -0.6661332845687866
        },
        {
            "text": "multiple myeloma.",
            "probability": 1.3305361383190515e-06,
            "start_logit": 9.138642311096191,
            "end_logit": -3.604384660720825
        },
        {
            "text": "myeloma",
            "probability": 8.661339435971031e-07,
            "start_logit": -4.820348262786865,
            "end_logit": 9.925308227539062
        },
        {
            "text": "multiple myelo",
            "probability": 8.128505503619341e-07,
            "start_logit": 9.138642311096191,
            "end_logit": -4.097174644470215
        },
        {
            "text": "relapsed or refractory multiple myeloma",
            "probability": 5.169532840097953e-07,
            "start_logit": -5.336435317993164,
            "end_logit": 9.925308227539062
        },
        {
            "text": "teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma",
            "probability": 3.595586310224704e-07,
            "start_logit": -5.69951057434082,
            "end_logit": 9.925308227539062
        },
        {
            "text": "patients with relapsed or refractory multiple myeloma",
            "probability": 3.54808859191898e-07,
            "start_logit": -5.712808609008789,
            "end_logit": 9.925308227539062
        },
        {
            "text": "in patients with relapsed or refractory multiple myeloma",
            "probability": 1.449739348149995e-07,
            "start_logit": -6.6078338623046875,
            "end_logit": 9.925308227539062
        },
        {
            "text": "or refractory multiple myeloma",
            "probability": 1.1961291244203065e-07,
            "start_logit": -6.800127029418945,
            "end_logit": 9.925308227539062
        },
        {
            "text": "promising efficacy in patients with relapsed or refractory multiple myeloma",
            "probability": 9.190788373242909e-08,
            "start_logit": -7.063601016998291,
            "end_logit": 9.925308227539062
        },
        {
            "text": "showed promising efficacy in patients with relapsed or refractory multiple myeloma",
            "probability": 8.856021196684493e-08,
            "start_logit": -7.100705146789551,
            "end_logit": 9.925308227539062
        },
        {
            "text": "refractory multiple myeloma",
            "probability": 8.656087330393523e-08,
            "start_logit": -7.123539924621582,
            "end_logit": 9.925308227539062
        },
        {
            "text": "with relapsed or refractory multiple myeloma",
            "probability": 8.17627691084022e-08,
            "start_logit": -7.18056583404541,
            "end_logit": 9.925308227539062
        },
        {
            "text": "multiple my",
            "probability": 7.523562667719966e-08,
            "start_logit": 9.138642311096191,
            "end_logit": -6.477097034454346
        },
        {
            "text": "the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma",
            "probability": 7.178112859559987e-08,
            "start_logit": -7.310766220092773,
            "end_logit": 9.925308227539062
        },
        {
            "text": "relapsed or refractory multiple",
            "probability": 1.2991122993361729e-11,
            "start_logit": -5.336435317993164,
            "end_logit": -0.6661332845687866
        },
        {
            "text": "teclistamab showed promising efficacy in patients with relapsed or refractory multiple",
            "probability": 9.03576888554822e-12,
            "start_logit": -5.69951057434082,
            "end_logit": -0.6661332845687866
        },
        {
            "text": "patients with relapsed or refractory multiple",
            "probability": 8.91640632039968e-12,
            "start_logit": -5.712808609008789,
            "end_logit": -0.6661332845687866
        }
    ],
    "63eeed0af36125a426000007_003": [
        {
            "text": "multiple myeloma",
            "probability": 0.999774026368285,
            "start_logit": 9.451493263244629,
            "end_logit": 10.071370124816895
        },
        {
            "text": "myeloma.",
            "probability": 0.00017644660075469943,
            "start_logit": 0.8092269897460938,
            "end_logit": 10.071370124816895
        },
        {
            "text": "multiple",
            "probability": 4.3810404160951934e-05,
            "start_logit": 9.451493263244629,
            "end_logit": 0.03595689311623573
        },
        {
            "text": "multiple myeloma.",
            "probability": 2.5398599641868293e-06,
            "start_logit": 9.451493263244629,
            "end_logit": -2.811805486679077
        },
        {
            "text": "multiple myelo",
            "probability": 9.890960353678737e-07,
            "start_logit": 9.451493263244629,
            "end_logit": -3.754878282546997
        },
        {
            "text": "myeloma",
            "probability": 9.689470307558317e-07,
            "start_logit": -4.395336627960205,
            "end_logit": 10.071370124816895
        },
        {
            "text": "patients with triple-class-exposed relapsed or refractory multiple myeloma",
            "probability": 5.153619363649713e-07,
            "start_logit": -5.026677131652832,
            "end_logit": 10.071370124816895
        },
        {
            "text": "relapsed or refractory multiple myeloma",
            "probability": 1.521533244884174e-07,
            "start_logit": -6.246657848358154,
            "end_logit": 10.071370124816895
        },
        {
            "text": "triple-class-exposed relapsed or refractory multiple myeloma",
            "probability": 1.4886318309092992e-07,
            "start_logit": -6.268518924713135,
            "end_logit": 10.071370124816895
        },
        {
            "text": "in patients with triple-class-exposed relapsed or refractory multiple myeloma",
            "probability": 9.951834585079941e-08,
            "start_logit": -6.671204566955566,
            "end_logit": 10.071370124816895
        },
        {
            "text": "multiple my",
            "probability": 8.757121730727616e-08,
            "start_logit": 9.451493263244629,
            "end_logit": -6.179217338562012
        },
        {
            "text": "a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma",
            "probability": 8.462229984834864e-08,
            "start_logit": -6.833348751068115,
            "end_logit": 10.071370124816895
        },
        {
            "text": "with triple-class-exposed relapsed or refractory multiple myeloma",
            "probability": 6.818898879590636e-08,
            "start_logit": -7.0492634773254395,
            "end_logit": 10.071370124816895
        },
        {
            "text": "or refractory multiple myeloma",
            "probability": 6.239764221239644e-08,
            "start_logit": -7.13801908493042,
            "end_logit": 10.071370124816895
        },
        {
            "text": "patients with triple-class-exposed relapsed or refractory multiple",
            "probability": 2.2583317955694804e-11,
            "start_logit": -5.026677131652832,
            "end_logit": 0.03595689311623573
        },
        {
            "text": "relapsed or refractory multiple",
            "probability": 6.667405298059349e-12,
            "start_logit": -6.246657848358154,
            "end_logit": 0.03595689311623573
        },
        {
            "text": "triple-class-exposed relapsed or refractory multiple",
            "probability": 6.5232302939394585e-12,
            "start_logit": -6.268518924713135,
            "end_logit": 0.03595689311623573
        },
        {
            "text": "in patients with triple-class-exposed relapsed or refractory multiple",
            "probability": 4.360924407078818e-12,
            "start_logit": -6.671204566955566,
            "end_logit": 0.03595689311623573
        },
        {
            "text": "a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple",
            "probability": 3.70817510718142e-12,
            "start_logit": -6.833348751068115,
            "end_logit": 0.03595689311623573
        },
        {
            "text": "with triple-class-exposed relapsed or refractory multiple",
            "probability": 2.9880623817834823e-12,
            "start_logit": -7.0492634773254395,
            "end_logit": 0.03595689311623573
        }
    ],
    "63eeed0af36125a426000007_004": [
        {
            "text": "Multiple Myeloma",
            "probability": 0.9998893367965547,
            "start_logit": 9.6742525100708,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Myeloma.",
            "probability": 5.431262324824047e-05,
            "start_logit": -0.14639070630073547,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Multiple",
            "probability": 4.838343566598724e-05,
            "start_logit": 9.6742525100708,
            "end_logit": -0.392140656709671
        },
        {
            "text": "Multiple Myeloma.",
            "probability": 6.478904880444182e-06,
            "start_logit": 9.6742525100708,
            "end_logit": -2.4027466773986816
        },
        {
            "text": "Myeloma",
            "probability": 4.0705098932091894e-07,
            "start_logit": -5.039964199066162,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Multiple Myelo",
            "probability": 3.8396619575780923e-07,
            "start_logit": 9.6742525100708,
            "end_logit": -5.228498935699463
        },
        {
            "text": "Teclistamab for Multiple Myeloma",
            "probability": 2.0642706228478604e-07,
            "start_logit": -5.7189555168151855,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Multiple My",
            "probability": 1.4546663669658305e-07,
            "start_logit": 9.6742525100708,
            "end_logit": -6.199106693267822
        },
        {
            "text": "Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma",
            "probability": 1.222063996096359e-07,
            "start_logit": -6.243191242218018,
            "end_logit": 9.54410171508789
        },
        {
            "text": "for Multiple Myeloma",
            "probability": 7.434418627595332e-08,
            "start_logit": -6.74019718170166,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma",
            "probability": 4.581879153970217e-08,
            "start_logit": -7.224208354949951,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Therapeutic Dosing Range of Teclistamab for Multiple Myeloma",
            "probability": 4.2636226937072726e-08,
            "start_logit": -7.29619836807251,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Dosing Range of Teclistamab for Multiple Myeloma",
            "probability": 3.178190999227875e-08,
            "start_logit": -7.590005397796631,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.",
            "probability": 2.8515935160668463e-08,
            "start_logit": -7.698439598083496,
            "end_logit": 9.54410171508789
        },
        {
            "text": "Teclistamab for Multiple",
            "probability": 9.988755875498303e-12,
            "start_logit": -5.7189555168151855,
            "end_logit": -0.392140656709671
        },
        {
            "text": "Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple",
            "probability": 5.91341987147104e-12,
            "start_logit": -6.243191242218018,
            "end_logit": -0.392140656709671
        },
        {
            "text": "for Multiple",
            "probability": 3.5974252564257903e-12,
            "start_logit": -6.74019718170166,
            "end_logit": -0.392140656709671
        },
        {
            "text": "Efficacious Therapeutic Dosing Range of Teclistamab for Multiple",
            "probability": 2.217115905903017e-12,
            "start_logit": -7.224208354949951,
            "end_logit": -0.392140656709671
        },
        {
            "text": "Therapeutic Dosing Range of Teclistamab for Multiple",
            "probability": 2.0631154540155095e-12,
            "start_logit": -7.29619836807251,
            "end_logit": -0.392140656709671
        },
        {
            "text": "Dosing Range of Teclistamab for Multiple",
            "probability": 1.5378881850867183e-12,
            "start_logit": -7.590005397796631,
            "end_logit": -0.392140656709671
        }
    ],
    "63eeed0af36125a426000007_005": [
        {
            "text": "multiple myeloma",
            "probability": 0.9997711780841795,
            "start_logit": 9.206430435180664,
            "end_logit": 10.035438537597656
        },
        {
            "text": "myeloma",
            "probability": 0.00021131684602335193,
            "start_logit": 0.744507372379303,
            "end_logit": 10.035438537597656
        },
        {
            "text": "multiple",
            "probability": 1.443665645917013e-05,
            "start_logit": 9.206430435180664,
            "end_logit": -1.1100726127624512
        },
        {
            "text": "multiple myeloma cells in preclinical studies.",
            "probability": 2.1579751782605896e-06,
            "start_logit": 9.206430435180664,
            "end_logit": -3.0106728076934814
        },
        {
            "text": "potent T-cell-mediated cytotoxicity of multiple myeloma",
            "probability": 1.969437587055545e-07,
            "start_logit": -6.2336883544921875,
            "end_logit": 10.035438537597656
        },
        {
            "text": "T-cell-mediated cytotoxicity of multiple myeloma",
            "probability": 1.6822623158577382e-07,
            "start_logit": -6.391296863555908,
            "end_logit": 10.035438537597656
        },
        {
            "text": "CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma",
            "probability": 1.2410537155485662e-07,
            "start_logit": -6.6954755783081055,
            "end_logit": 10.035438537597656
        },
        {
            "text": "multiple myelo",
            "probability": 1.2110700266366536e-07,
            "start_logit": 9.206430435180664,
            "end_logit": -5.890923976898193
        },
        {
            "text": "multiple myeloma cells",
            "probability": 1.1175556844675083e-07,
            "start_logit": 9.206430435180664,
            "end_logit": -5.97128438949585
        },
        {
            "text": "displayed potent T-cell-mediated cytotoxicity of multiple myeloma",
            "probability": 9.14797209486719e-08,
            "start_logit": -7.000489234924316,
            "end_logit": 10.035438537597656
        },
        {
            "text": "multiple my",
            "probability": 6.035560419533765e-08,
            "start_logit": 9.206430435180664,
            "end_logit": -6.587344646453857
        },
        {
            "text": "multiple myeloma cells in preclinical studies",
            "probability": 3.597598500658488e-08,
            "start_logit": 9.206430435180664,
            "end_logit": -7.1047468185424805
        },
        {
            "text": "myeloma cells in preclinical studies.",
            "probability": 4.5612087892006863e-10,
            "start_logit": 0.744507372379303,
            "end_logit": -3.0106728076934814
        },
        {
            "text": "myeloma cells",
            "probability": 2.3621239306946485e-11,
            "start_logit": 0.744507372379303,
            "end_logit": -5.97128438949585
        },
        {
            "text": "potent T-cell-mediated cytotoxicity of multiple",
            "probability": 2.8438601237316244e-12,
            "start_logit": -6.2336883544921875,
            "end_logit": -1.1100726127624512
        },
        {
            "text": "T-cell-mediated cytotoxicity of multiple",
            "probability": 2.429180162483264e-12,
            "start_logit": -6.391296863555908,
            "end_logit": -1.1100726127624512
        },
        {
            "text": "CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple",
            "probability": 1.792076680294412e-12,
            "start_logit": -6.6954755783081055,
            "end_logit": -1.1100726127624512
        },
        {
            "text": "displayed potent T-cell-mediated cytotoxicity of multiple",
            "probability": 1.3209635697314802e-12,
            "start_logit": -7.000489234924316,
            "end_logit": -1.1100726127624512
        },
        {
            "text": "potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.",
            "probability": 4.250970143131542e-13,
            "start_logit": -6.2336883544921875,
            "end_logit": -3.0106728076934814
        },
        {
            "text": "T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.",
            "probability": 3.631111198765233e-13,
            "start_logit": -6.391296863555908,
            "end_logit": -3.0106728076934814
        }
    ],
    "63f03ea0f36125a426000020_001": [
        {
            "text": "rCDI",
            "probability": 0.9226532262093486,
            "start_logit": -1.5826785564422607,
            "end_logit": 1.881696343421936
        },
        {
            "text": "ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI",
            "probability": 0.015459916054946803,
            "start_logit": -5.6716814041137695,
            "end_logit": 1.881696343421936
        },
        {
            "text": "SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI",
            "probability": 0.013877600757589117,
            "start_logit": -5.779655933380127,
            "end_logit": 1.881696343421936
        },
        {
            "text": "rCDI.",
            "probability": 0.012169603208604501,
            "start_logit": -5.9109907150268555,
            "end_logit": 1.881696343421936
        },
        {
            "text": "reducing rCDI",
            "probability": 0.006960745058505432,
            "start_logit": -6.4696455001831055,
            "end_logit": 1.881696343421936
        },
        {
            "text": "oral microbiome therapeutic, was superior to placebo in reducing rCDI",
            "probability": 0.006335712351450752,
            "start_logit": -6.563729763031006,
            "end_logit": 1.881696343421936
        },
        {
            "text": "investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI",
            "probability": 0.005357043935296777,
            "start_logit": -6.73151969909668,
            "end_logit": 1.881696343421936
        },
        {
            "text": "placebo in reducing rCDI",
            "probability": 0.004167590304781583,
            "start_logit": -6.982594013214111,
            "end_logit": 1.881696343421936
        },
        {
            "text": "an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI",
            "probability": 0.0031889712328002588,
            "start_logit": -7.2502336502075195,
            "end_logit": 1.881696343421936
        },
        {
            "text": "microbiome therapeutic, was superior to placebo in reducing rCDI",
            "probability": 0.002940001317621113,
            "start_logit": -7.331521987915039,
            "end_logit": 1.881696343421936
        },
        {
            "text": "in reducing rCDI",
            "probability": 0.002803562198968872,
            "start_logit": -7.3790411949157715,
            "end_logit": 1.881696343421936
        },
        {
            "text": "superior to placebo in reducing rCDI",
            "probability": 0.002361473319918313,
            "start_logit": -7.5506463050842285,
            "end_logit": 1.881696343421936
        },
        {
            "text": "was superior to placebo in reducing rCDI",
            "probability": 0.0015825427569649943,
            "start_logit": -7.950899124145508,
            "end_logit": 1.881696343421936
        },
        {
            "text": "rCD",
            "probability": 3.4825374685206106e-05,
            "start_logit": -1.5826785564422607,
            "end_logit": -8.302966117858887
        },
        {
            "text": "r",
            "probability": 2.9804628937254773e-05,
            "start_logit": -1.5826785564422607,
            "end_logit": -8.458648681640625
        },
        {
            "text": "SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI.",
            "probability": 2.9261714040800377e-05,
            "start_logit": -5.779655933380127,
            "end_logit": -4.280055046081543
        },
        {
            "text": "reducing rCDI.",
            "probability": 1.4677128631295564e-05,
            "start_logit": -6.4696455001831055,
            "end_logit": -4.280055046081543
        },
        {
            "text": "oral microbiome therapeutic, was superior to placebo in reducing rCDI.",
            "probability": 1.3359211459627429e-05,
            "start_logit": -6.563729763031006,
            "end_logit": -4.280055046081543
        },
        {
            "text": "investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI.",
            "probability": 1.1295633191705297e-05,
            "start_logit": -6.73151969909668,
            "end_logit": -4.280055046081543
        },
        {
            "text": "placebo in reducing rCDI.",
            "probability": 8.787602256898814e-06,
            "start_logit": -6.982594013214111,
            "end_logit": -4.280055046081543
        }
    ],
    "63f03ea0f36125a426000020_002": [
        {
            "text": "Clostridioides difficile",
            "probability": 0.9998593405057421,
            "start_logit": 10.298348426818848,
            "end_logit": 10.355696678161621
        },
        {
            "text": "C",
            "probability": 6.732170622329905e-05,
            "start_logit": 10.298348426818848,
            "end_logit": 0.7498095035552979
        },
        {
            "text": "difficile",
            "probability": 3.3878174698582975e-05,
            "start_logit": 0.005749531090259552,
            "end_logit": 10.355696678161621
        },
        {
            "text": "Clostridioides difficile Infection.",
            "probability": 1.4841287783257291e-05,
            "start_logit": 10.298348426818848,
            "end_logit": -0.7622601985931396
        },
        {
            "text": "SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile",
            "probability": 1.4138380242256738e-05,
            "start_logit": -0.8681283593177795,
            "end_logit": 10.355696678161621
        },
        {
            "text": "Clostridioides difficile Infection",
            "probability": 5.431523465384457e-06,
            "start_logit": 10.298348426818848,
            "end_logit": -1.7674535512924194
        },
        {
            "text": "Clostridioides diffici",
            "probability": 2.198134192175722e-06,
            "start_logit": 10.298348426818848,
            "end_logit": -2.6720643043518066
        },
        {
            "text": "Oral Microbiome Therapy for Recurrent Clostridioides difficile",
            "probability": 1.6973537514641646e-06,
            "start_logit": -2.9879510402679443,
            "end_logit": 10.355696678161621
        },
        {
            "text": "Clostridioides difficile Infect",
            "probability": 7.552034378587984e-07,
            "start_logit": 10.298348426818848,
            "end_logit": -3.74044132232666
        },
        {
            "text": "Clos",
            "probability": 1.6176530355601043e-07,
            "start_logit": 10.298348426818848,
            "end_logit": -5.2812819480896
        },
        {
            "text": "Recurrent Clostridioides difficile",
            "probability": 9.336556321853363e-08,
            "start_logit": -5.888254165649414,
            "end_logit": 10.355696678161621
        },
        {
            "text": "an Oral Microbiome Therapy for Recurrent Clostridioides difficile",
            "probability": 7.907564349495039e-08,
            "start_logit": -6.0543718338012695,
            "end_logit": 10.355696678161621
        },
        {
            "text": "Clostridioides",
            "probability": 1.9014757949559377e-08,
            "start_logit": 10.298348426818848,
            "end_logit": -7.422213077545166
        },
        {
            "text": "Clostridioides di",
            "probability": 1.5171913037672916e-08,
            "start_logit": 10.298348426818848,
            "end_logit": -7.647982597351074
        },
        {
            "text": "Clostridioides diff",
            "probability": 1.5057484077446816e-08,
            "start_logit": 10.298348426818848,
            "end_logit": -7.655553340911865
        },
        {
            "text": "Clostri",
            "probability": 1.250083159308648e-08,
            "start_logit": 10.298348426818848,
            "end_logit": -7.841633319854736
        },
        {
            "text": "SER-109, an Oral Microbiome Therapy for Recurrent C",
            "probability": 9.519537824801043e-10,
            "start_logit": -0.8681283593177795,
            "end_logit": 0.7498095035552979
        },
        {
            "text": "difficile Infection.",
            "probability": 5.028664732169377e-10,
            "start_logit": 0.005749531090259552,
            "end_logit": -0.7622601985931396
        },
        {
            "text": "SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.",
            "probability": 2.098612889472188e-10,
            "start_logit": -0.8681283593177795,
            "end_logit": -0.7622601985931396
        },
        {
            "text": "Oral Microbiome Therapy for Recurrent C",
            "probability": 1.142848258588917e-10,
            "start_logit": -2.9879510402679443,
            "end_logit": 0.7498095035552979
        }
    ],
    "63f03ea0f36125a426000020_003": [
        {
            "text": "C. difficile",
            "probability": 0.9998978843955789,
            "start_logit": 9.621851921081543,
            "end_logit": 10.395586967468262
        },
        {
            "text": "difficile",
            "probability": 8.511928695364646e-05,
            "start_logit": 0.25049713253974915,
            "end_logit": 10.395586967468262
        },
        {
            "text": "C",
            "probability": 7.69128253795982e-06,
            "start_logit": 9.621851921081543,
            "end_logit": -1.379733920097351
        },
        {
            "text": "C. diffici",
            "probability": 4.270901767007957e-06,
            "start_logit": 9.621851921081543,
            "end_logit": -1.9679964780807495
        },
        {
            "text": "C. difficile infection.",
            "probability": 3.494492812388522e-06,
            "start_logit": 9.621851921081543,
            "end_logit": -2.168633222579956
        },
        {
            "text": "C. difficile infection",
            "probability": 7.747445825749456e-07,
            "start_logit": 9.621851921081543,
            "end_logit": -3.6750433444976807
        },
        {
            "text": "treatment of recurrent C. difficile",
            "probability": 1.0123573216592237e-07,
            "start_logit": -6.483860015869141,
            "end_logit": 10.395586967468262
        },
        {
            "text": "microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile",
            "probability": 9.092115577279131e-08,
            "start_logit": -6.5913190841674805,
            "end_logit": 10.395586967468262
        },
        {
            "text": "Firmicutes spores for the treatment of recurrent C. difficile",
            "probability": 9.035162033062844e-08,
            "start_logit": -6.597602844238281,
            "end_logit": 10.395586967468262
        },
        {
            "text": "the treatment of recurrent C. difficile",
            "probability": 7.671922854267218e-08,
            "start_logit": -6.761159420013428,
            "end_logit": 10.395586967468262
        },
        {
            "text": "recurrent C. difficile",
            "probability": 7.096224782364076e-08,
            "start_logit": -6.839163780212402,
            "end_logit": 10.395586967468262
        },
        {
            "text": "investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile",
            "probability": 6.317251810409989e-08,
            "start_logit": -6.955442428588867,
            "end_logit": 10.395586967468262
        },
        {
            "text": "for the treatment of recurrent C. difficile",
            "probability": 5.960401214721344e-08,
            "start_logit": -7.013588905334473,
            "end_logit": 10.395586967468262
        },
        {
            "text": "C. di",
            "probability": 5.571657124338184e-08,
            "start_logit": 9.621851921081543,
            "end_logit": -6.3072991371154785
        },
        {
            "text": "purified Firmicutes spores for the treatment of recurrent C. difficile",
            "probability": 5.3576839889769884e-08,
            "start_logit": -7.120194911956787,
            "end_logit": 10.395586967468262
        },
        {
            "text": ". difficile",
            "probability": 4.927304246695641e-08,
            "start_logit": -7.203934669494629,
            "end_logit": 10.395586967468262
        },
        {
            "text": "C. diff",
            "probability": 3.375211493653848e-08,
            "start_logit": 9.621851921081543,
            "end_logit": -6.808533668518066
        },
        {
            "text": "C.",
            "probability": 1.9282641016711142e-08,
            "start_logit": 9.621851921081543,
            "end_logit": -7.368371486663818
        },
        {
            "text": "difficile infection.",
            "probability": 2.974791137146532e-10,
            "start_logit": 0.25049713253974915,
            "end_logit": -2.168633222579956
        },
        {
            "text": "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C",
            "probability": 3.056389013733631e-11,
            "start_logit": -2.813926935195923,
            "end_logit": -1.379733920097351
        }
    ],
    "63f03ea0f36125a426000020_004": [
        {
            "text": "Clostridioides difficile",
            "probability": 0.9993391380938766,
            "start_logit": 9.865972518920898,
            "end_logit": 10.553300857543945
        },
        {
            "text": "Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus",
            "probability": 0.0005870540688234475,
            "start_logit": 9.865972518920898,
            "end_logit": 3.1135683059692383
        },
        {
            "text": "difficile",
            "probability": 4.068717306453055e-05,
            "start_logit": -0.24296407401561737,
            "end_logit": 10.553300857543945
        },
        {
            "text": "SARS",
            "probability": 2.4718644059840206e-05,
            "start_logit": 6.861556053161621,
            "end_logit": 2.950425624847412
        },
        {
            "text": "C",
            "probability": 4.616982111059564e-06,
            "start_logit": 9.865972518920898,
            "end_logit": -1.7318073511123657
        },
        {
            "text": "Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea",
            "probability": 1.8097114377434475e-06,
            "start_logit": 9.865972518920898,
            "end_logit": -2.6683812141418457
        },
        {
            "text": "Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus,",
            "probability": 3.7731493171591053e-07,
            "start_logit": 9.865972518920898,
            "end_logit": -4.2362236976623535
        },
        {
            "text": "SARS-CoV-2",
            "probability": 2.868642490386428e-07,
            "start_logit": 6.861556053161621,
            "end_logit": -1.5058783292770386
        },
        {
            "text": "SARS-CoV-2.",
            "probability": 2.253343408749523e-07,
            "start_logit": 6.861556053161621,
            "end_logit": -1.7473021745681763
        },
        {
            "text": "Clostridioides difficile recurrence,",
            "probability": 1.8494649229065491e-07,
            "start_logit": 9.865972518920898,
            "end_logit": -4.94923734664917
        },
        {
            "text": "SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile",
            "probability": 1.4710506307809266e-07,
            "start_logit": -5.865485191345215,
            "end_logit": 10.553300857543945
        },
        {
            "text": "SARS-CoV",
            "probability": 1.2454278841922673e-07,
            "start_logit": 6.861556053161621,
            "end_logit": -2.340238094329834
        },
        {
            "text": "Clostridioides diffici",
            "probability": 1.1694893091895996e-07,
            "start_logit": 9.865972518920898,
            "end_logit": -5.407566547393799
        },
        {
            "text": "a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile",
            "probability": 1.1576967473989213e-07,
            "start_logit": -6.105029582977295,
            "end_logit": 10.553300857543945
        },
        {
            "text": "to reduce risk of Clostridioides difficile",
            "probability": 8.500640589140697e-08,
            "start_logit": -6.413905620574951,
            "end_logit": 10.553300857543945
        },
        {
            "text": "porcine epidemic diarrhea virus",
            "probability": 7.759452575247978e-08,
            "start_logit": 0.9345971941947937,
            "end_logit": 3.1135683059692383
        },
        {
            "text": "porcine epidemic diarrhea virus, a model coronavirus for SARS",
            "probability": 6.591421996269771e-08,
            "start_logit": 0.9345971941947937,
            "end_logit": 2.950425624847412
        },
        {
            "text": "reduce risk of Clostridioides difficile",
            "probability": 6.496524591561498e-08,
            "start_logit": -6.682779788970947,
            "end_logit": 10.553300857543945
        },
        {
            "text": "microbiome therapeutic developed to reduce risk of Clostridioides difficile",
            "probability": 5.415508157594818e-08,
            "start_logit": -6.864780426025391,
            "end_logit": 10.553300857543945
        },
        {
            "text": "Clostridioides difficile recurrence",
            "probability": 4.8864676829221125e-08,
            "start_logit": 9.865972518920898,
            "end_logit": -6.280249118804932
        }
    ],
    "64179113690f196b5100002e_001": [
        {
            "text": "Xp21 chromosome locus",
            "probability": 0.8993247687322459,
            "start_logit": 9.1245756149292,
            "end_logit": 5.873420715332031
        },
        {
            "text": "Xp21",
            "probability": 0.07692819998816647,
            "start_logit": 9.1245756149292,
            "end_logit": 3.41464900970459
        },
        {
            "text": "Xp21 chromosome locus.",
            "probability": 0.017556050777371057,
            "start_logit": 9.1245756149292,
            "end_logit": 1.9371751546859741
        },
        {
            "text": "X",
            "probability": 0.0030012094098208265,
            "start_logit": 9.1245756149292,
            "end_logit": 0.1707918345928192
        },
        {
            "text": "Xp21 chromosome",
            "probability": 0.0029703847997806006,
            "start_logit": 9.1245756149292,
            "end_logit": 0.1604679971933365
        },
        {
            "text": "the Xp21 chromosome locus",
            "probability": 0.000115475359672996,
            "start_logit": 0.1642332822084427,
            "end_logit": 5.873420715332031
        },
        {
            "text": "Xp21 chromosome lo",
            "probability": 4.825261888930391e-05,
            "start_logit": 9.1245756149292,
            "end_logit": -3.959528684616089
        },
        {
            "text": "Xp",
            "probability": 1.6560438914616438e-05,
            "start_logit": 9.1245756149292,
            "end_logit": -5.028962135314941
        },
        {
            "text": "mapping on the Xp21 chromosome locus",
            "probability": 1.1694670090687687e-05,
            "start_logit": -2.1256906986236572,
            "end_logit": 5.873420715332031
        },
        {
            "text": "the Xp21",
            "probability": 9.877757036706838e-06,
            "start_logit": 0.1642332822084427,
            "end_logit": 3.41464900970459
        },
        {
            "text": "The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus",
            "probability": 7.284935989036407e-06,
            "start_logit": -2.599015235900879,
            "end_logit": 5.873420715332031
        },
        {
            "text": "on the Xp21 chromosome locus",
            "probability": 3.1720232537205902e-06,
            "start_logit": -3.4304542541503906,
            "end_logit": 5.873420715332031
        },
        {
            "text": "the Xp21 chromosome locus.",
            "probability": 2.2542371214929645e-06,
            "start_logit": 0.1642332822084427,
            "end_logit": 1.9371751546859741
        },
        {
            "text": "mapping on the Xp21",
            "probability": 1.000361549921797e-06,
            "start_logit": -2.1256906986236572,
            "end_logit": 3.41464900970459
        },
        {
            "text": "dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus",
            "probability": 8.601284109344231e-07,
            "start_logit": -4.73549747467041,
            "end_logit": 5.873420715332031
        },
        {
            "text": "locus.",
            "probability": 7.408140481461655e-07,
            "start_logit": -4.884829521179199,
            "end_logit": 5.873420715332031
        },
        {
            "text": "locus",
            "probability": 6.897784519549565e-07,
            "start_logit": -4.9562087059021,
            "end_logit": 5.873420715332031
        },
        {
            "text": "The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21",
            "probability": 6.231530945773781e-07,
            "start_logit": -2.599015235900879,
            "end_logit": 3.41464900970459
        },
        {
            "text": "chromosome locus",
            "probability": 5.146539304911322e-07,
            "start_logit": -5.24908447265625,
            "end_logit": 5.873420715332031
        },
        {
            "text": "the X",
            "probability": 3.8536216070372943e-07,
            "start_logit": 0.1642332822084427,
            "end_logit": 0.1707918345928192
        }
    ],
    "64179113690f196b5100002e_002": [
        {
            "text": "Xp21",
            "probability": 0.9983849841905522,
            "start_logit": 9.686431884765625,
            "end_logit": 8.523249626159668
        },
        {
            "text": "X",
            "probability": 0.0015182342802712138,
            "start_logit": 9.686431884765625,
            "end_logit": 2.034658670425415
        },
        {
            "text": "Xp21.",
            "probability": 8.511860929114718e-05,
            "start_logit": 9.686431884765625,
            "end_logit": -0.8465989232063293
        },
        {
            "text": "Xp",
            "probability": 7.933563827810319e-06,
            "start_logit": 9.686431884765625,
            "end_logit": -3.2195422649383545
        },
        {
            "text": "at Xp21",
            "probability": 1.972270377865061e-06,
            "start_logit": -3.448276996612549,
            "end_logit": 8.523249626159668
        },
        {
            "text": "X-linked recessive disorders caused by mutations of the DMD gene located at Xp21",
            "probability": 4.964570572150043e-07,
            "start_logit": -4.827720642089844,
            "end_logit": 8.523249626159668
        },
        {
            "text": "DMD gene located at Xp21",
            "probability": 4.243125037954943e-07,
            "start_logit": -4.984747409820557,
            "end_logit": 8.523249626159668
        },
        {
            "text": "located at Xp21",
            "probability": 3.4522723905477097e-07,
            "start_logit": -5.191014766693115,
            "end_logit": 8.523249626159668
        },
        {
            "text": "the DMD gene located at Xp21",
            "probability": 3.379107841681888e-07,
            "start_logit": -5.212435722351074,
            "end_logit": 8.523249626159668
        },
        {
            "text": "mutations of the DMD gene located at Xp21",
            "probability": 9.233650878132527e-08,
            "start_logit": -6.509778022766113,
            "end_logit": 8.523249626159668
        },
        {
            "text": "BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21",
            "probability": 5.488336342628384e-08,
            "start_logit": -7.030007362365723,
            "end_logit": 8.523249626159668
        },
        {
            "text": "at X",
            "probability": 2.9992122728747785e-09,
            "start_logit": -3.448276996612549,
            "end_logit": 2.034658670425415
        },
        {
            "text": "X-linked recessive disorders caused by mutations of the DMD gene located at X",
            "probability": 7.549573910684217e-10,
            "start_logit": -4.827720642089844,
            "end_logit": 2.034658670425415
        },
        {
            "text": "DMD gene located at X",
            "probability": 6.452478743280816e-10,
            "start_logit": -4.984747409820557,
            "end_logit": 2.034658670425415
        },
        {
            "text": "located at X",
            "probability": 5.249836857685569e-10,
            "start_logit": -5.191014766693115,
            "end_logit": 2.034658670425415
        },
        {
            "text": "the DMD gene located at X",
            "probability": 5.138576243846582e-10,
            "start_logit": -5.212435722351074,
            "end_logit": 2.034658670425415
        },
        {
            "text": "at Xp21.",
            "probability": 1.6814847415409273e-10,
            "start_logit": -3.448276996612549,
            "end_logit": -0.8465989232063293
        },
        {
            "text": "mutations of the DMD gene located at X",
            "probability": 1.404152257618646e-10,
            "start_logit": -6.509778022766113,
            "end_logit": 2.034658670425415
        },
        {
            "text": "Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at X",
            "probability": 1.2794038569528225e-10,
            "start_logit": -6.602817535400391,
            "end_logit": 2.034658670425415
        },
        {
            "text": "BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at X",
            "probability": 8.346059394906114e-11,
            "start_logit": -7.030007362365723,
            "end_logit": 2.034658670425415
        }
    ],
    "64179113690f196b5100002e_003": [
        {
            "text": "Xp21",
            "probability": 0.8174487898292814,
            "start_logit": 8.812579154968262,
            "end_logit": 6.2694010734558105
        },
        {
            "text": "Xp21)",
            "probability": 0.09023020293817159,
            "start_logit": 8.812579154968262,
            "end_logit": 4.065577030181885
        },
        {
            "text": "X chromosome (Xp21",
            "probability": 0.04675508761970479,
            "start_logit": 5.9513139724731445,
            "end_logit": 6.2694010734558105
        },
        {
            "text": "Xp21).",
            "probability": 0.03222467941486838,
            "start_logit": 8.812579154968262,
            "end_logit": 3.035945415496826
        },
        {
            "text": "X chromosome (Xp21)",
            "probability": 0.005160838326274858,
            "start_logit": 5.9513139724731445,
            "end_logit": 4.065577030181885
        },
        {
            "text": "X",
            "probability": 0.0025816805133355553,
            "start_logit": 8.812579154968262,
            "end_logit": 0.5116533637046814
        },
        {
            "text": "X chromosome",
            "probability": 0.0019172394284227908,
            "start_logit": 5.9513139724731445,
            "end_logit": 3.075364351272583
        },
        {
            "text": "X chromosome (Xp21).",
            "probability": 0.0018431340633261266,
            "start_logit": 5.9513139724731445,
            "end_logit": 3.035945415496826
        },
        {
            "text": "(Xp21",
            "probability": 0.0012573566143778297,
            "start_logit": 2.335402488708496,
            "end_logit": 6.2694010734558105
        },
        {
            "text": "X chromosome (X",
            "probability": 0.00014766270390136256,
            "start_logit": 5.9513139724731445,
            "end_logit": 0.5116533637046814
        },
        {
            "text": "(Xp21)",
            "probability": 0.00013878733921015101,
            "start_logit": 2.335402488708496,
            "end_logit": 4.065577030181885
        },
        {
            "text": "the X chromosome (Xp21",
            "probability": 0.00011021514279343008,
            "start_logit": -0.09893008321523666,
            "end_logit": 6.2694010734558105
        },
        {
            "text": "(Xp21).",
            "probability": 4.95663022719157e-05,
            "start_logit": 2.335402488708496,
            "end_logit": 3.035945415496826
        },
        {
            "text": "Xp",
            "probability": 3.699348493426103e-05,
            "start_logit": 8.812579154968262,
            "end_logit": -3.7338006496429443
        },
        {
            "text": "dystrophin gene, located on the X chromosome (Xp21",
            "probability": 3.200033092329448e-05,
            "start_logit": -1.3356181383132935,
            "end_logit": 6.2694010734558105
        },
        {
            "text": "on the X chromosome (Xp21",
            "probability": 2.183974798963865e-05,
            "start_logit": -1.71763277053833,
            "end_logit": 6.2694010734558105
        },
        {
            "text": "X chromosome (",
            "probability": 2.046436463477672e-05,
            "start_logit": 5.9513139724731445,
            "end_logit": -1.4645922183990479
        },
        {
            "text": "the X chromosome (Xp21)",
            "probability": 1.2165575170999575e-05,
            "start_logit": -0.09893008321523666,
            "end_logit": 4.065577030181885
        },
        {
            "text": "located on the X chromosome (Xp21",
            "probability": 6.7767775412799484e-06,
            "start_logit": -2.8878626823425293,
            "end_logit": 6.2694010734558105
        },
        {
            "text": "the X chromosome",
            "probability": 4.519482865512943e-06,
            "start_logit": -0.09893008321523666,
            "end_logit": 3.075364351272583
        }
    ],
    "6415c9e9690f196b51000018_001": [
        {
            "text": "mTNBC",
            "probability": 0.9997581544191289,
            "start_logit": 7.568415641784668,
            "end_logit": 7.622077465057373
        },
        {
            "text": "mTNBC,",
            "probability": 0.0001972945321467284,
            "start_logit": 7.568415641784668,
            "end_logit": -0.9084935188293457
        },
        {
            "text": "The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC",
            "probability": 2.0146267240912478e-05,
            "start_logit": -3.2438340187072754,
            "end_logit": 7.622077465057373
        },
        {
            "text": "m",
            "probability": 1.542804794179315e-05,
            "start_logit": 7.568415641784668,
            "end_logit": -3.4570040702819824
        },
        {
            "text": "PD-L1-positive mTNBC",
            "probability": 2.4590854190361764e-06,
            "start_logit": -5.3470635414123535,
            "end_logit": 7.622077465057373
        },
        {
            "text": "positive mTNBC",
            "probability": 1.1904516647313508e-06,
            "start_logit": -6.0725202560424805,
            "end_logit": 7.622077465057373
        },
        {
            "text": "mTNBC, as the FDA recently approved atezolizumab (Tecentriq) and pembrolizumab",
            "probability": 9.335135452389982e-07,
            "start_logit": 7.568415641784668,
            "end_logit": -6.261991024017334
        },
        {
            "text": "chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC",
            "probability": 8.105677300375954e-07,
            "start_logit": -6.456873416900635,
            "end_logit": 7.622077465057373
        },
        {
            "text": "mTNBC, as the FDA recently approved atezolizumab",
            "probability": 7.75195198252012e-07,
            "start_logit": 7.568415641784668,
            "end_logit": -6.447831630706787
        },
        {
            "text": "-positive mTNBC",
            "probability": 5.739843181625684e-07,
            "start_logit": -6.802006244659424,
            "end_logit": 7.622077465057373
        },
        {
            "text": "for PD-L1-positive mTNBC",
            "probability": 4.602385455127079e-07,
            "start_logit": -7.022863388061523,
            "end_logit": 7.622077465057373
        },
        {
            "text": "combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC",
            "probability": 4.5754906586555964e-07,
            "start_logit": -7.028724193572998,
            "end_logit": 7.622077465057373
        },
        {
            "text": "mTNBC, as the FDA recently approved atezolizumab (Tecentriq)",
            "probability": 4.373335501581429e-07,
            "start_logit": 7.568415641784668,
            "end_logit": -7.02025032043457
        },
        {
            "text": "immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC",
            "probability": 3.6620701552592235e-07,
            "start_logit": -7.251409530639648,
            "end_logit": 7.622077465057373
        },
        {
            "text": "mT",
            "probability": 2.6616782209615983e-07,
            "start_logit": 7.568415641784668,
            "end_logit": -7.516819477081299
        },
        {
            "text": "mTNBC, as the FDA recently approved atezolizumab (Tecentriq",
            "probability": 2.414328570450756e-07,
            "start_logit": 7.568415641784668,
            "end_logit": -7.614355087280273
        },
        {
            "text": "The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC,",
            "probability": 3.975709877663526e-09,
            "start_logit": -3.2438340187072754,
            "end_logit": -0.9084935188293457
        },
        {
            "text": "PD-L1-positive mTNBC,",
            "probability": 4.852814704366876e-10,
            "start_logit": -5.3470635414123535,
            "end_logit": -0.9084935188293457
        },
        {
            "text": "The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive m",
            "probability": 3.1089276488228616e-10,
            "start_logit": -3.2438340187072754,
            "end_logit": -3.4570040702819824
        },
        {
            "text": "positive mTNBC,",
            "probability": 2.3492642015300966e-10,
            "start_logit": -6.0725202560424805,
            "end_logit": -0.9084935188293457
        }
    ]
}
